{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Imports"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "import json\n",
    "import google.auth\n",
    "import xmltodict\n",
    "import data_repo_client\n",
    "import pandas as pd\n",
    "import re\n",
    "\n",
    "# Function to refresh TDR API client\n",
    "def refresh_tdr_api_client():\n",
    "    creds, project = google.auth.default()\n",
    "    auth_req = google.auth.transport.requests.Request()\n",
    "    creds.refresh(auth_req)\n",
    "    config = data_repo_client.Configuration()\n",
    "    config.host = \"https://data.terra.bio\"\n",
    "    config.access_token = creds.token\n",
    "    api_client = data_repo_client.ApiClient(configuration=config)\n",
    "    api_client.client_side_validation = False\n",
    "    return api_client\n",
    "\n",
    "# Display options\n",
    "pd.set_option('display.max_rows', None)\n",
    "pd.set_option('display.max_columns', None)\n",
    "pd.set_option(\"display.max_colwidth\", None)\n",
    "pd.set_option('display.width', 1000)\n",
    "pd.set_option('display.colheader_justify', 'center')\n",
    "pd.set_option('display.precision', 3)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Putting it all together"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {
    "code_folding": [
     4,
     7
    ]
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Snapshot PHS_ID: \n",
      "Source Workspace: AnVIL_CCDG_WASHU_PAGE\n",
      "PHS ID for dbGaP: TBD\n",
      "Snapshot PHS_ID: \n",
      "Source Workspace: AnVIL_CCDG_Broad_NP_Epilepsy_JPNFKA_GRU_WES\n",
      "PHS ID for dbGaP: \n",
      "Snapshot PHS_ID: phs001642\n",
      "Source Workspace: anvil_ccdg_broad_ai_ibd_daly_bernstein_gsa\n",
      "PHS ID for dbGaP: phs001642\n",
      "Snapshot PHS_ID: phs000298\n",
      "Source Workspace: AnVIL_CCDG_NHGRI_Broad_ASD_Daly_phs000298_WES_vcf\n",
      "PHS ID for dbGaP: phs000298\n",
      "Snapshot PHS_ID: phs002206\n",
      "Source Workspace: AnVIL_CMH_GAFK_GS-linked-read\n",
      "PHS ID for dbGaP: phs002206\n",
      "Snapshot PHS_ID: phs002206\n",
      "Source Workspace: AnVIL_CMH_GAFK_SCATAC\n",
      "PHS ID for dbGaP: phs002206\n",
      "Snapshot PHS_ID: phs002206\n",
      "Source Workspace: AnVIL_CMH_GAFK_scRNA\n",
      "PHS ID for dbGaP: phs002206\n",
      "Snapshot PHS_ID: phs002206\n",
      "Source Workspace: AnVIL_CMH_GAFK_WGBS\n",
      "PHS ID for dbGaP: phs002206\n",
      "Snapshot PHS_ID: phs002206\n",
      "Source Workspace: AnVIL_CMH_GAFK_GS-long-read\n",
      "PHS ID for dbGaP: phs002206\n",
      "Snapshot PHS_ID: phs002032\n",
      "Source Workspace: AnVIL_NIMH_Broad_ConvergentNeuro_McCarroll_Eggan_Finkel_SMA_DS_WGS\n",
      "PHS ID for dbGaP: phs002032\n",
      "Snapshot PHS_ID: phs002032\n",
      "Source Workspace: AnVIL_NIMH_Broad_ConvergentNeuro_McCarroll_Eggan_CIRM_GRU_VillageData\n",
      "PHS ID for dbGaP: phs002032\n",
      "Snapshot PHS_ID: phs002032\n",
      "Source Workspace: AnVIL_NIMH_CIRM_FCDI_ConvergentNeuro_McCarroll_Eggan_GRU_Arrays\n",
      "PHS ID for dbGaP: phs002032\n",
      "Snapshot PHS_ID: phs002032\n",
      "Source Workspace: AnVIL_NIMH_Broad_ConvergentNeuro_McCarroll_Eggan_CIRM_GRU_WGS\n",
      "PHS ID for dbGaP: phs002032\n",
      "Snapshot PHS_ID: \n",
      "Source Workspace: AnVIL_CSER_NCGENES2_GRU\n",
      "PHS ID for dbGaP: phs002110\n",
      "Snapshot PHS_ID: phs002111\n",
      "Source Workspace: AnVIL_CSER_CHARM_GRU\n",
      "PHS ID for dbGaP: phs002111\n",
      "Snapshot PHS_ID: phs002307\n",
      "Source Workspace: AnVIL_CSER_SouthSeq_GRU\n",
      "PHS ID for dbGaP: phs002307\n",
      "Snapshot PHS_ID: phs001616\n",
      "Source Workspace: AnVIL_eMERGE_GRU_eMERGEseq\n",
      "PHS ID for dbGaP: phs001616\n",
      "Snapshot PHS_ID: phs001616\n",
      "Source Workspace: AnVIL_eMERGE_GRU-IRB_eMERGEseq\n",
      "PHS ID for dbGaP: phs001616\n",
      "Snapshot PHS_ID: phs001616\n",
      "Source Workspace: AnVIL_eMERGE_GRU-IRB-NPU_eMERGEseq\n",
      "PHS ID for dbGaP: phs001616\n",
      "Snapshot PHS_ID: phs001616\n",
      "Source Workspace: AnVIL_eMERGE_GRU-IRB-PUB-NPU_eMERGEseq\n",
      "PHS ID for dbGaP: phs001616\n",
      "Snapshot PHS_ID: phs001616\n",
      "Source Workspace: AnVIL_eMERGE_GRU-NPU_eMERGEseq\n",
      "PHS ID for dbGaP: phs001616\n",
      "Snapshot PHS_ID: phs001616\n",
      "Source Workspace: AnVIL_eMERGE_HMB_eMERGEseq\n",
      "PHS ID for dbGaP: phs001616\n",
      "Snapshot PHS_ID: phs001616\n",
      "Source Workspace: AnVIL_eMERGE_HMB-GSO_eMERGEseq\n",
      "PHS ID for dbGaP: phs001616\n",
      "Snapshot PHS_ID: phs001616\n",
      "Source Workspace: AnVIL_eMERGE_HMB-IRB-PUB_eMERGEseq\n",
      "PHS ID for dbGaP: phs001616\n",
      "Snapshot PHS_ID: phs001616\n",
      "Source Workspace: AnVIL_eMERGE_HMB-NPU_eMERGEseq\n",
      "PHS ID for dbGaP: phs001616\n",
      "Snapshot PHS_ID: phs001616\n",
      "Source Workspace: AnVIL_eMERGE_PGRNseq\n",
      "PHS ID for dbGaP: phs001616\n",
      "Snapshot PHS_ID: \n",
      "Source Workspace: AnVIL_eMERGE_PRS_Arrays\n",
      "PHS ID for dbGaP: Registration Pending\n",
      "Snapshot PHS_ID: \n",
      "Source Workspace: AnVIL_HPRC\n",
      "PHS ID for dbGaP: None\n",
      "Snapshot PHS_ID: phs000220\n",
      "Source Workspace: AnVIL_PAGE_MEC_GRU_WGS\n",
      "PHS ID for dbGaP: phs000220\n",
      "Snapshot PHS_ID: phs000227\n",
      "Source Workspace: AnVIL_PAGE_WHI_HMB-IRB_WGS\n",
      "PHS ID for dbGaP: phs000227\n",
      "Snapshot PHS_ID: phs000925\n",
      "Source Workspace: AnVIL_PAGE_BioMe_GRU_WGS\n",
      "PHS ID for dbGaP: phs000925\n",
      "Snapshot PHS_ID: phs001033\n",
      "Source Workspace: AnVIL_PAGE_Stanford_Global_Reference_Panel_GRU_WGS\n",
      "PHS ID for dbGaP: phs001033\n",
      "Snapshot PHS_ID: \n",
      "Source Workspace: AnVIL_PAGE_SoL_HMB_WGS\n",
      "PHS ID for dbGaP: TBD\n",
      "Snapshot PHS_ID: \n",
      "Source Workspace: AnVIL_T2T\n",
      "PHS ID for dbGaP: None\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: center;\">\n",
       "      <th></th>\n",
       "      <th>snapshot_id</th>\n",
       "      <th>studyName</th>\n",
       "      <th>studyType</th>\n",
       "      <th>studyDescription</th>\n",
       "      <th>dataTypes</th>\n",
       "      <th>phenotypeIndication</th>\n",
       "      <th>species</th>\n",
       "      <th>piName</th>\n",
       "      <th>piEmail</th>\n",
       "      <th>piInstitution</th>\n",
       "      <th>dataCustodianEmail</th>\n",
       "      <th>dbGaPPhsID</th>\n",
       "      <th>dbGaPStudyRegistrationName</th>\n",
       "      <th>embargoReleaseDate</th>\n",
       "      <th>nihICsSupportingStudy</th>\n",
       "      <th>nihProgramOfficerName</th>\n",
       "      <th>nihGenomicProgramAdministratorName</th>\n",
       "      <th>consortium</th>\n",
       "      <th>consentGroups.consentCode</th>\n",
       "      <th>numberOfParticipants</th>\n",
       "      <th>dataLocation</th>\n",
       "      <th>url</th>\n",
       "      <th>consentGroups.fileTypes.fileType</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>fc513b58-cfb7-4871-8694-8dc372fc2e10</td>\n",
       "      <td></td>\n",
       "      <td>TBD</td>\n",
       "      <td></td>\n",
       "      <td>[]</td>\n",
       "      <td>Unspecified</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>TBD</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>CCDG</td>\n",
       "      <td>TBD</td>\n",
       "      <td>None</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/fc513b58-cfb7-4871-8694-8dc372fc2e10</td>\n",
       "      <td>[TBD]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>a1dcd80f-6390-489a-a34a-168f26690a36</td>\n",
       "      <td>NA</td>\n",
       "      <td>Case Set</td>\n",
       "      <td>AnVIL_CCDG_Broad_NP_Epilepsy_JPNFKA_GRU_WES</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>epilepsy</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>NA</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>ccusick@broadinstitute.org</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>CCDG</td>\n",
       "      <td>GRU</td>\n",
       "      <td>None</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/a1dcd80f-6390-489a-a34a-168f26690a36</td>\n",
       "      <td>[Exome]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>e91ccc70-2772-46d8-b586-cf3e270a05b5</td>\n",
       "      <td>Center for Common Disease Genomics [CCDG] - Autoimmune: Inflammatory Bowel Disease (IBD) Exomes and Genomes</td>\n",
       "      <td>TBD</td>\n",
       "      <td>\\nThe National Human Genome Research Institute (NHGRI) has funded a collaborative large-scale genome sequencing effort to comprehensively identify rare risk and protective variants contributing to multiple common disease phenotypes. Called the Centers for Common Disease Genomics (CCDG), this initiative will explore a range of diseases with the ultimate goal of: undertaking variant discovery for enough different examples of disease architectures and study designs to better understand the general principles of the genomic architecture underlying common, complex inherited diseases; understanding how best to design rare variant studies for common disease; developing resources, informatics tools, and innovative approaches and technologies for multiple disease research communities and the wider biomedical research community. The initial focus of the CCDGs will be in cardiovascular disease (early-onset coronary artery disease, atrial fibrillation, hemorrhagic stroke), neuropsychiatric disease (epilepsy, autism), and autoimmune/inflammatory disease (type 1 diabetes, inflammatory bowel disease). The Broad Institute is one of four selected CCDG project centers. The overarching aim of the Inflammatory Bowel Disease (IBD) program is to define the full allelic spectrum of protein-altering variation in genes associated to IBD, and assess their role in both Crohn's Disease (CD) and Ulcerative Colitis (UC) risk. The whole genome sequencing data generated here is comprised of samples from US-based diverse populations including African American, Puerto-Rican, Caribean and Cuban origins. \\n</td>\n",
       "      <td>[Genotyping Array data]</td>\n",
       "      <td>inflammatory bowel disease</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Mark Daly, PhD</td>\n",
       "      <td>None</td>\n",
       "      <td>The Broad Institute, Cambridge, MA, USA</td>\n",
       "      <td>curley@broadinstitute.org</td>\n",
       "      <td>phs001642</td>\n",
       "      <td>Center for Common Disease Genomics [CCDG] - Autoimmune: Inflammatory Bowel Disease (IBD) Exomes and Genomes</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Felsenfeld, Adam</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>CCDG</td>\n",
       "      <td>TBD</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/e91ccc70-2772-46d8-b586-cf3e270a05b5</td>\n",
       "      <td>[Genotyping Array]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>6fdea8c7-69d9-466e-9fa2-aca30722ff68</td>\n",
       "      <td>Autism Sequencing Consortium (ASC)</td>\n",
       "      <td>Unspecified</td>\n",
       "      <td>\\nThe ARRA Autism Sequencing Collaboration was created in 2010 bringing together expert large-scale sequencing center (at the Baylor College of Medicine, PI Richard Gibbs and the Board Institute of MIT and Harvard, PI Mark J. Daly) and a collaborative network of research labs focused on the genetics of autism (brought together by the Autism Genome Project and the Autism Consortium). These groups worked together to utilize dramatic new advances in DNA sequencing technology to reveal the genetic architecture of autism through comprehensive examination of the exotic sequence of all genes. The Autism Sequencing Consortium (ASC) was founded by Joseph D. Buxbaum and colleagues as an international group of scientists who share autism spectrum disorder (ASD) samples and genetic data. The PIs are Drs. Joseph D. Buxbaum (Icahn School of Medicine at Mount Sinai), Mark J. Daly (Broad Institute of MIT and Harvard), Bernie Devlin (University of Pittsburgh School of Medicine), Kathryn Roeder (Carnegie Mellon University, Matthew State and Stephan Sanders (University of California, San Francisco). The rationale for the ASC is described in [Buxbaum et al. 2012](https://www.ncbi.nlm.nih.gov/pubmed/23259942), and this paper should be cited when referencing the data set. All shared data and analysis is hosted at a single site, which enables joint analysis of large-scale data from many groups. The ASC was first supported by a cooperative agreement grant to four lead sites funded by the National Institute of Mental Health (U01MH100233, U01MH100209, U01MH100229, U01MH100239), with additional support from the National Human Genome Research Institute. The NIMH recently renewed their support with a second grant (U01MH111661, U01MH111660, U01MH111658 and U01MH111662) to expand the project from 29,000 genomes to more than 50,000 exomes over the next 5 years. NHGRI provides ongoing sequencing support for the ASD through the Broad Center for Common Disease Genomics (UM1HG008895, Mark Daly, PI).\\n</td>\n",
       "      <td>[SNP/CNV Genotypes (NGS), WXS]</td>\n",
       "      <td>Autistic Disorder</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Daly, Mark</td>\n",
       "      <td>mjdaly@broadinstitute.org</td>\n",
       "      <td>MASSACHUSETTS INSTITUTE OF TECHNOLOGYBROAD INSTITUTE, INC.MASSACHUSETTS GENERAL HOSPITAL</td>\n",
       "      <td>None</td>\n",
       "      <td>phs000298</td>\n",
       "      <td>Autism Sequencing Consortium (ASC)</td>\n",
       "      <td>none</td>\n",
       "      <td>National Institute of Mental Health</td>\n",
       "      <td>Senthil, Geetha</td>\n",
       "      <td>Farber, Gregory</td>\n",
       "      <td>CCDG</td>\n",
       "      <td>None</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/6fdea8c7-69d9-466e-9fa2-aca30722ff68</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>02d25240-823f-4b1d-8562-95385716a453</td>\n",
       "      <td>Genomic Answers for Kids (GA4K)</td>\n",
       "      <td>Case only / Trio / Family</td>\n",
       "      <td>\\nIdentification of complex genetic variants including defects in gene regulatory circuits and uncharacterized genes present challenges for rare disease diagnosis. In Genomic Answers for Kids program we apply the joint interpretation of patient genome sequence with genomic endophenotypes to expand the clinically actionable genome among pediatric cases of suspected genetic disease. Our objective is to examine the role of novel and under-interpreted sequence variation by combining complete DNA sequences, personal epigenetic variations and massively parallel functional screens.\\n\\nTo achieve this we perform augmented whole genome sequence (WGS) interpretation including reanalysis of clinical exomes as well as generating WGS for patients with negative exome results all be subject to family-based semi-automated recall pipeline to discover missed diagnostic variation. We use linked-read and long-read sequencing technologies to focus on putative structural variants missed in short-read genome and exome analysis by the optimized integration of linked and long read technologies that also improve identification of transmission patterns of all variants, as well as resolving genomic regions resistant to standard alignment. We also include tissue DNA sequencing to investigate somatic mosaicism.\\n\\nTo further assist on WGS interpretation for uncommon variation we capture snapshots of patient transcriptomes and epigenomes in individual cells using single-cell RNA (scRNA) and sc open chromatin (scATAC) as well as bulk whole genome bisulphite genome sequencing for methylome interpretation. Alternative splicing is functionally assessed in available patient tissues using RNA-seq, including full length cDNA sequences by IsoSeq (PacBio) methodology.\\n\\nOur overarching goal is an increase rate of diagnostic genomic findings up to two-fold among rare disease, resulting in the majority (&gt;50%) of patient cases resolved by the integrated system developed in our program.\\n</td>\n",
       "      <td>[]</td>\n",
       "      <td>pediatric disease</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Tomi Pastinen MD, PhD</td>\n",
       "      <td>None</td>\n",
       "      <td>Children's Mercy Hospital, Kansas City, MO, USA</td>\n",
       "      <td>tpastinen@cmh.edu</td>\n",
       "      <td>phs002206</td>\n",
       "      <td>Genomic Answers for Kids (GA4K)</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>None</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>CMH</td>\n",
       "      <td>DS-PEDD-IRB</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/02d25240-823f-4b1d-8562-95385716a453</td>\n",
       "      <td>[Whole Genome]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>99b46287-4790-492c-8a12-bea33f0f927c</td>\n",
       "      <td>Genomic Answers for Kids (GA4K)</td>\n",
       "      <td>TBD</td>\n",
       "      <td>\\nIdentification of complex genetic variants including defects in gene regulatory circuits and uncharacterized genes present challenges for rare disease diagnosis. In Genomic Answers for Kids program we apply the joint interpretation of patient genome sequence with genomic endophenotypes to expand the clinically actionable genome among pediatric cases of suspected genetic disease. Our objective is to examine the role of novel and under-interpreted sequence variation by combining complete DNA sequences, personal epigenetic variations and massively parallel functional screens.\\n\\nTo achieve this we perform augmented whole genome sequence (WGS) interpretation including reanalysis of clinical exomes as well as generating WGS for patients with negative exome results all be subject to family-based semi-automated recall pipeline to discover missed diagnostic variation. We use linked-read and long-read sequencing technologies to focus on putative structural variants missed in short-read genome and exome analysis by the optimized integration of linked and long read technologies that also improve identification of transmission patterns of all variants, as well as resolving genomic regions resistant to standard alignment. We also include tissue DNA sequencing to investigate somatic mosaicism.\\n\\nTo further assist on WGS interpretation for uncommon variation we capture snapshots of patient transcriptomes and epigenomes in individual cells using single-cell RNA (scRNA) and sc open chromatin (scATAC) as well as bulk whole genome bisulphite genome sequencing for methylome interpretation. Alternative splicing is functionally assessed in available patient tissues using RNA-seq, including full length cDNA sequences by IsoSeq (PacBio) methodology.\\n\\nOur overarching goal is an increase rate of diagnostic genomic findings up to two-fold among rare disease, resulting in the majority (&gt;50%) of patient cases resolved by the integrated system developed in our program.\\n</td>\n",
       "      <td>[]</td>\n",
       "      <td>pediatric disease</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Tomi Pastinen MD, PhD</td>\n",
       "      <td>None</td>\n",
       "      <td>Children's Mercy Hospital, Kansas City, MO, USA</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs002206</td>\n",
       "      <td>Genomic Answers for Kids (GA4K)</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>None</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>CMH</td>\n",
       "      <td>DS-PEDD-IRB</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/99b46287-4790-492c-8a12-bea33f0f927c</td>\n",
       "      <td>[TBD]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>c6ef5822-3929-4ae7-b5bc-dc27528bf226</td>\n",
       "      <td>Genomic Answers for Kids (GA4K)</td>\n",
       "      <td>TBD</td>\n",
       "      <td>\\nIdentification of complex genetic variants including defects in gene regulatory circuits and uncharacterized genes present challenges for rare disease diagnosis. In Genomic Answers for Kids program we apply the joint interpretation of patient genome sequence with genomic endophenotypes to expand the clinically actionable genome among pediatric cases of suspected genetic disease. Our objective is to examine the role of novel and under-interpreted sequence variation by combining complete DNA sequences, personal epigenetic variations and massively parallel functional screens.\\n\\nTo achieve this we perform augmented whole genome sequence (WGS) interpretation including reanalysis of clinical exomes as well as generating WGS for patients with negative exome results all be subject to family-based semi-automated recall pipeline to discover missed diagnostic variation. We use linked-read and long-read sequencing technologies to focus on putative structural variants missed in short-read genome and exome analysis by the optimized integration of linked and long read technologies that also improve identification of transmission patterns of all variants, as well as resolving genomic regions resistant to standard alignment. We also include tissue DNA sequencing to investigate somatic mosaicism.\\n\\nTo further assist on WGS interpretation for uncommon variation we capture snapshots of patient transcriptomes and epigenomes in individual cells using single-cell RNA (scRNA) and sc open chromatin (scATAC) as well as bulk whole genome bisulphite genome sequencing for methylome interpretation. Alternative splicing is functionally assessed in available patient tissues using RNA-seq, including full length cDNA sequences by IsoSeq (PacBio) methodology.\\n\\nOur overarching goal is an increase rate of diagnostic genomic findings up to two-fold among rare disease, resulting in the majority (&gt;50%) of patient cases resolved by the integrated system developed in our program.\\n</td>\n",
       "      <td>[]</td>\n",
       "      <td>pediatric disease</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Tomi Pastinen MD, PhD</td>\n",
       "      <td>None</td>\n",
       "      <td>Children's Mercy Hospital, Kansas City, MO, USA</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs002206</td>\n",
       "      <td>Genomic Answers for Kids (GA4K)</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>None</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>CMH</td>\n",
       "      <td>DS-PEDD-IRB</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/c6ef5822-3929-4ae7-b5bc-dc27528bf226</td>\n",
       "      <td>[TBD]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>08d19a7e-b868-4766-9f7e-d879d972cbd7</td>\n",
       "      <td>Genomic Answers for Kids (GA4K)</td>\n",
       "      <td>TBD</td>\n",
       "      <td>\\nIdentification of complex genetic variants including defects in gene regulatory circuits and uncharacterized genes present challenges for rare disease diagnosis. In Genomic Answers for Kids program we apply the joint interpretation of patient genome sequence with genomic endophenotypes to expand the clinically actionable genome among pediatric cases of suspected genetic disease. Our objective is to examine the role of novel and under-interpreted sequence variation by combining complete DNA sequences, personal epigenetic variations and massively parallel functional screens.\\n\\nTo achieve this we perform augmented whole genome sequence (WGS) interpretation including reanalysis of clinical exomes as well as generating WGS for patients with negative exome results all be subject to family-based semi-automated recall pipeline to discover missed diagnostic variation. We use linked-read and long-read sequencing technologies to focus on putative structural variants missed in short-read genome and exome analysis by the optimized integration of linked and long read technologies that also improve identification of transmission patterns of all variants, as well as resolving genomic regions resistant to standard alignment. We also include tissue DNA sequencing to investigate somatic mosaicism.\\n\\nTo further assist on WGS interpretation for uncommon variation we capture snapshots of patient transcriptomes and epigenomes in individual cells using single-cell RNA (scRNA) and sc open chromatin (scATAC) as well as bulk whole genome bisulphite genome sequencing for methylome interpretation. Alternative splicing is functionally assessed in available patient tissues using RNA-seq, including full length cDNA sequences by IsoSeq (PacBio) methodology.\\n\\nOur overarching goal is an increase rate of diagnostic genomic findings up to two-fold among rare disease, resulting in the majority (&gt;50%) of patient cases resolved by the integrated system developed in our program.\\n</td>\n",
       "      <td>[]</td>\n",
       "      <td>pediatric disease</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Tomi Pastinen MD, PhD</td>\n",
       "      <td>None</td>\n",
       "      <td>Children's Mercy Hospital, Kansas City, MO, USA</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs002206</td>\n",
       "      <td>Genomic Answers for Kids (GA4K)</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>None</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>CMH</td>\n",
       "      <td>DS-PEDD-IRB</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/08d19a7e-b868-4766-9f7e-d879d972cbd7</td>\n",
       "      <td>[TBD]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>1974a21b-c409-4736-a3d7-e195fa96c4eb</td>\n",
       "      <td>Genomic Answers for Kids (GA4K)</td>\n",
       "      <td>Case only / Trio / Family</td>\n",
       "      <td>\\nIdentification of complex genetic variants including defects in gene regulatory circuits and uncharacterized genes present challenges for rare disease diagnosis. In Genomic Answers for Kids program we apply the joint interpretation of patient genome sequence with genomic endophenotypes to expand the clinically actionable genome among pediatric cases of suspected genetic disease. Our objective is to examine the role of novel and under-interpreted sequence variation by combining complete DNA sequences, personal epigenetic variations and massively parallel functional screens.\\n\\nTo achieve this we perform augmented whole genome sequence (WGS) interpretation including reanalysis of clinical exomes as well as generating WGS for patients with negative exome results all be subject to family-based semi-automated recall pipeline to discover missed diagnostic variation. We use linked-read and long-read sequencing technologies to focus on putative structural variants missed in short-read genome and exome analysis by the optimized integration of linked and long read technologies that also improve identification of transmission patterns of all variants, as well as resolving genomic regions resistant to standard alignment. We also include tissue DNA sequencing to investigate somatic mosaicism.\\n\\nTo further assist on WGS interpretation for uncommon variation we capture snapshots of patient transcriptomes and epigenomes in individual cells using single-cell RNA (scRNA) and sc open chromatin (scATAC) as well as bulk whole genome bisulphite genome sequencing for methylome interpretation. Alternative splicing is functionally assessed in available patient tissues using RNA-seq, including full length cDNA sequences by IsoSeq (PacBio) methodology.\\n\\nOur overarching goal is an increase rate of diagnostic genomic findings up to two-fold among rare disease, resulting in the majority (&gt;50%) of patient cases resolved by the integrated system developed in our program.\\n</td>\n",
       "      <td>[]</td>\n",
       "      <td>Genetic Diseases, Inborn</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Tomi Pastinen MD, PhD</td>\n",
       "      <td>None</td>\n",
       "      <td>Children's Mercy Hospital, Kansas City, MO, USA</td>\n",
       "      <td>tpastinen@cmh.edu</td>\n",
       "      <td>phs002206</td>\n",
       "      <td>Genomic Answers for Kids (GA4K)</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>None</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>CMH</td>\n",
       "      <td>None</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/1974a21b-c409-4736-a3d7-e195fa96c4eb</td>\n",
       "      <td>[Whole Long-read Genome]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>8fd5b447-77b6-4c33-b66a-a5cc63587220</td>\n",
       "      <td>Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes</td>\n",
       "      <td>Prospective Longitudinal Cohort</td>\n",
       "      <td>\\nThe goal of this collaborative, interdisciplinary project is to develop powerful, generalizable approaches for discovering how risk variants for psychiatric disorders shape neurobiological processes at multiple levels of analysis, and to identify the processes whose dysregulation underlies disease.\\n\\nInduced pluripotent stem cells (iPSCs) were used towards the development of these new experimental and inferential systems bridging gaps between human genetics and experimental biology. The largest publicly available collection of iPSCs (2607 lines) has been generated from 2184 donors by the California Institute for Regenerative Medicine (CIRM). We wish to share the available SNP data for 2166 CIRM lines and whole genome sequence data generated at the Broad Institute for 299 of the CIRM iPSC donors. These data can be used to identify (for experiments) lines with specific genotypes of interest and lines from donors with high or low polygenic risk scores for phenotypes of interest. The data can also be used to identify acquired mutations in the iPSC lines. The CIRM iPSC lines are available through Fujifilm Cellular Dynamics iPSC Repository [[https://www.fujifilmcdi.com/cirm-ipsc-products/](https://www.fujifilmcdi.com/cirm-ipsc-products/)].\\n\\nAdditional project data registered with the study includes WGS data from an iPSC line derived from an SMA patient (n=1), as well as single-cell RNA sequence data and supplemental processed genomic datasets in support of project publications.\\n\\n**Molecular Datasets**\\n\\n  - **Whole Genome Genotyping**: Illumina HumanCore chip - **Whole Genome Sequencing**: Illumina Novaseq - **Single-Cell RNA-Seq**: 10X Genomics, Illumina Novaseq - **Supplemental \"cell village\" pooled genomic sequence data**: Illumina Nextseq  \\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>spinal muscular atrophy</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Steve McCarroll</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs002032</td>\n",
       "      <td>Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes</td>\n",
       "      <td>none</td>\n",
       "      <td>National Institute of Mental Health</td>\n",
       "      <td>Pevsner, Jonathan</td>\n",
       "      <td>Farber, Gregory</td>\n",
       "      <td>Convergent Neuroscience</td>\n",
       "      <td>DS-SMA-MDS</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/8fd5b447-77b6-4c33-b66a-a5cc63587220</td>\n",
       "      <td>[Whole Genome]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>aa2bfacc-c28c-4192-960c-b1389cf68516</td>\n",
       "      <td>Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes</td>\n",
       "      <td>TBD</td>\n",
       "      <td>\\nThe goal of this collaborative, interdisciplinary project is to develop powerful, generalizable approaches for discovering how risk variants for psychiatric disorders shape neurobiological processes at multiple levels of analysis, and to identify the processes whose dysregulation underlies disease.\\n\\nInduced pluripotent stem cells (iPSCs) were used towards the development of these new experimental and inferential systems bridging gaps between human genetics and experimental biology. The largest publicly available collection of iPSCs (2607 lines) has been generated from 2184 donors by the California Institute for Regenerative Medicine (CIRM). We wish to share the available SNP data for 2166 CIRM lines and whole genome sequence data generated at the Broad Institute for 299 of the CIRM iPSC donors. These data can be used to identify (for experiments) lines with specific genotypes of interest and lines from donors with high or low polygenic risk scores for phenotypes of interest. The data can also be used to identify acquired mutations in the iPSC lines. The CIRM iPSC lines are available through Fujifilm Cellular Dynamics iPSC Repository [[https://www.fujifilmcdi.com/cirm-ipsc-products/](https://www.fujifilmcdi.com/cirm-ipsc-products/)].\\n\\nAdditional project data registered with the study includes WGS data from an iPSC line derived from an SMA patient (n=1), as well as single-cell RNA sequence data and supplemental processed genomic datasets in support of project publications.\\n\\n**Molecular Datasets**\\n\\n  - **Whole Genome Genotyping**: Illumina HumanCore chip - **Whole Genome Sequencing**: Illumina Novaseq - **Single-Cell RNA-Seq**: 10X Genomics, Illumina Novaseq - **Supplemental \"cell village\" pooled genomic sequence data**: Illumina Nextseq  \\n</td>\n",
       "      <td>[]</td>\n",
       "      <td>Unspecified</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs002032</td>\n",
       "      <td>Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes</td>\n",
       "      <td>none</td>\n",
       "      <td>National Institute of Mental Health</td>\n",
       "      <td>Pevsner, Jonathan</td>\n",
       "      <td>Farber, Gregory</td>\n",
       "      <td>Convergent Neuroscience</td>\n",
       "      <td>GRU</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/aa2bfacc-c28c-4192-960c-b1389cf68516</td>\n",
       "      <td>[TBD]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>44b1f60b-e74c-4430-9378-d4a75e2de72f</td>\n",
       "      <td>Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes</td>\n",
       "      <td>Case-Control</td>\n",
       "      <td>\\nThe goal of this collaborative, interdisciplinary project is to develop powerful, generalizable approaches for discovering how risk variants for psychiatric disorders shape neurobiological processes at multiple levels of analysis, and to identify the processes whose dysregulation underlies disease.\\n\\nInduced pluripotent stem cells (iPSCs) were used towards the development of these new experimental and inferential systems bridging gaps between human genetics and experimental biology. The largest publicly available collection of iPSCs (2607 lines) has been generated from 2184 donors by the California Institute for Regenerative Medicine (CIRM). We wish to share the available SNP data for 2166 CIRM lines and whole genome sequence data generated at the Broad Institute for 299 of the CIRM iPSC donors. These data can be used to identify (for experiments) lines with specific genotypes of interest and lines from donors with high or low polygenic risk scores for phenotypes of interest. The data can also be used to identify acquired mutations in the iPSC lines. The CIRM iPSC lines are available through Fujifilm Cellular Dynamics iPSC Repository [[https://www.fujifilmcdi.com/cirm-ipsc-products/](https://www.fujifilmcdi.com/cirm-ipsc-products/)].\\n\\nAdditional project data registered with the study includes WGS data from an iPSC line derived from an SMA patient (n=1), as well as single-cell RNA sequence data and supplemental processed genomic datasets in support of project publications.\\n\\n**Molecular Datasets**\\n\\n  - **Whole Genome Genotyping**: Illumina HumanCore chip - **Whole Genome Sequencing**: Illumina Novaseq - **Single-Cell RNA-Seq**: 10X Genomics, Illumina Novaseq - **Supplemental \"cell village\" pooled genomic sequence data**: Illumina Nextseq  \\n</td>\n",
       "      <td>['Raw Sequencing data']</td>\n",
       "      <td>CIRM iPSC Repository</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Steve McCarroll</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs002032</td>\n",
       "      <td>Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes</td>\n",
       "      <td>none</td>\n",
       "      <td>National Institute of Mental Health</td>\n",
       "      <td>Pevsner, Jonathan</td>\n",
       "      <td>Farber, Gregory</td>\n",
       "      <td>Convergent Neuroscience</td>\n",
       "      <td>GRU</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/44b1f60b-e74c-4430-9378-d4a75e2de72f</td>\n",
       "      <td>[Single Cell RNAseq, Pooled Genomic Seq]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>5b036d13-e058-4d8d-be91-6fdd070686a7</td>\n",
       "      <td>Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes</td>\n",
       "      <td>Case-Control</td>\n",
       "      <td>\\nThe goal of this collaborative, interdisciplinary project is to develop powerful, generalizable approaches for discovering how risk variants for psychiatric disorders shape neurobiological processes at multiple levels of analysis, and to identify the processes whose dysregulation underlies disease.\\n\\nInduced pluripotent stem cells (iPSCs) were used towards the development of these new experimental and inferential systems bridging gaps between human genetics and experimental biology. The largest publicly available collection of iPSCs (2607 lines) has been generated from 2184 donors by the California Institute for Regenerative Medicine (CIRM). We wish to share the available SNP data for 2166 CIRM lines and whole genome sequence data generated at the Broad Institute for 299 of the CIRM iPSC donors. These data can be used to identify (for experiments) lines with specific genotypes of interest and lines from donors with high or low polygenic risk scores for phenotypes of interest. The data can also be used to identify acquired mutations in the iPSC lines. The CIRM iPSC lines are available through Fujifilm Cellular Dynamics iPSC Repository [[https://www.fujifilmcdi.com/cirm-ipsc-products/](https://www.fujifilmcdi.com/cirm-ipsc-products/)].\\n\\nAdditional project data registered with the study includes WGS data from an iPSC line derived from an SMA patient (n=1), as well as single-cell RNA sequence data and supplemental processed genomic datasets in support of project publications.\\n\\n**Molecular Datasets**\\n\\n  - **Whole Genome Genotyping**: Illumina HumanCore chip - **Whole Genome Sequencing**: Illumina Novaseq - **Single-Cell RNA-Seq**: 10X Genomics, Illumina Novaseq - **Supplemental \"cell village\" pooled genomic sequence data**: Illumina Nextseq  \\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>N/A</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Steve McCarroll</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs002032</td>\n",
       "      <td>Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes</td>\n",
       "      <td>none</td>\n",
       "      <td>National Institute of Mental Health</td>\n",
       "      <td>Pevsner, Jonathan</td>\n",
       "      <td>Farber, Gregory</td>\n",
       "      <td>Convergent Neuroscience</td>\n",
       "      <td>NA</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/5b036d13-e058-4d8d-be91-6fdd070686a7</td>\n",
       "      <td>[Whole Genome]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>0a356156-961d-4829-b9b5-c07fbc73dacc</td>\n",
       "      <td>CSER: North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing 2</td>\n",
       "      <td>Clinical Trial</td>\n",
       "      <td>&lt;p&gt;The &lt;i&gt;North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing, 2 (NCGENES 2)&lt;/i&gt; study is part of a larger consortium project investigating the clinical utility, or net benefit of an intervention on patient and family well-being as well as diagnostic efficacy, management planning, and medical outcomes. A clinical trial will be implemented to compare (1) first-line exome sequencing to usual care and (2) participant pre-visit preparation to no pre-visit preparation. The study will use a randomized controlled design, with 2x2 factorial design, coupled with patient-reported outcomes and comprehensive clinical data collection addressing key outcomes, to determine the net impact of diagnostic results and secondary findings.&lt;/p&gt;</td>\n",
       "      <td>[Simple Nucleotide Variation (SNVs), Raw Sequencing Data, Surveys]</td>\n",
       "      <td>Suspected Genetic Disorder</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Jonathan S. Berg, MD, PhD</td>\n",
       "      <td>None</td>\n",
       "      <td>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs002110</td>\n",
       "      <td>CSER: North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing 2</td>\n",
       "      <td>none</td>\n",
       "      <td>[NHGRI]</td>\n",
       "      <td>Hindorff, Lucia</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>CSER</td>\n",
       "      <td>GRU</td>\n",
       "      <td>45</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/0a356156-961d-4829-b9b5-c07fbc73dacc</td>\n",
       "      <td>[Whole Exome]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>e43974fd-cee1-4d8c-a436-6846d7d24129</td>\n",
       "      <td>CSER: Exome Sequencing in Diverse Populations in Colorado and Oregon</td>\n",
       "      <td>Clinical Trial</td>\n",
       "      <td>&lt;div&gt;The CHARM (Cancer Health Assessment Reaching Many) study, part of the Clinical Sequencing Evidence-Generating Research (CS.ER2) effort, aimed to assess the utility of clinical exome sequencing and how it affects care in diverse populations. The study population included adults at risk for hereditary cancer syndromes. The primary objective was the implementation of a hereditary cancer risk assessment program in healthy 18-49 year-olds in primary care settings within a vertically integrated health delivery system (Kaiser Permanente) and a federal qualified health center (Denver Health). The investigators aimed to assess clinical exome sequencing implementation and interpretation, as well as tailored interactions for low health literacy including a contextualized consent process, and a modified approach to results disclosure and genetic counseling. The investigators were also assessing the clinical utility (healthcare utilization and adherence to recommended care) and personal utility of primary and additional results from clinical exome sequencing, and evaluate the ethical and policy implications of considering personal utility of genomic information decisions for health care coverage.Sequencing and analysis for CHARM was conducted at the Northwest Clinical Genomics Laboratory, University of Washington, Seattle (&lt;a href=\"https://nwgc.gs.washington.edu/\" target=\"_blank\"&gt;https://nwgc.gs.washington.edu/&lt;/a&gt;).&lt;/div&gt;&lt;br&gt;</td>\n",
       "      <td>[Simple Nucleotide Variation (SNVs), Raw Sequencing Data, Surveys]</td>\n",
       "      <td>Hereditary Cancer Risk</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Michael Leo</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs002111</td>\n",
       "      <td>CSER: Exome Sequencing in Diverse Populations in Colorado and Oregon</td>\n",
       "      <td>none</td>\n",
       "      <td>[NHGRI]</td>\n",
       "      <td>Hindorff, Lucia</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>CSER</td>\n",
       "      <td>GRU</td>\n",
       "      <td>880</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/e43974fd-cee1-4d8c-a436-6846d7d24129</td>\n",
       "      <td>[Whole Exome]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>4c8ce027-8094-4f5d-bf62-22b1d51b3c1e</td>\n",
       "      <td>CSER: South-Seq: DNA Sequencing for Newborn Nurseries in the South</td>\n",
       "      <td>Family/Twins/Trios</td>\n",
       "      <td>\\nSouthSeq, part of the Clinical Sequencing Evidence-Generating Research ([CSER2](https://www.genome.gov/Funded-Programs-Projects/Clinical-Sequencing-Evidence-Generating-Research-CSER2)) effort, aims to perform genome sequencing for infants in nurseries at hospitals in Alabama, Mississippi, Louisiana, and Kentucky. SouthSeq aims to sequence 600 newborn babies presenting with congenital anomalies, or other signs of a rare genetic disorder. The primary goals of SouthSeq are to provide early diagnoses to children with rare genetic conditions, to demonstrate the utility of genome sequencing as a frontline test with potential to improve intermediate and long-term clinical outcomes, and to equip non-genetics providers to deliver test results in order to facilitate the conduction of genome sequencing outside of major medical centers where patients may not have access to a genetics provider. SouthSeq also aims to ensure that genomic testing is applied across diverse communities; recruitment efforts focus on patients from rural and minority populations that have been historically under-represented in both medicine and genomics research.&amp;nbsp;\\n\\nSequencing and analysis for SouthSeq are being conducted at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama ([https://www.hudsonalpha.org/](https://www.hudsonalpha.org/)). Enrollment of infants with signs of genetic disease is approved at five clinical sites, including nurseries at the University of Alabama at Birmingham, the University of Mississippi Medical Center, Woman's Hospital in Baton Rouge, Children's Hospital in New Orleans, and the University of Louisville. Both biological parents are enrolled when available so that follow-up testing can be performed to determine inheritance. Further, participant families may choose to opt-into return of secondary findings identified in the proband, which focus on pathogenic and likely pathogenic variation identified within ACMG SFv3.0 genes.\\n\\n</td>\n",
       "      <td>[Simple Nucleotide Variation (SNVs), Raw Sequencing Data, Surveys]</td>\n",
       "      <td>Suspected Genetic Disorder</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Gregory M. Cooper</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs002307</td>\n",
       "      <td>CSER: South-Seq: DNA Sequencing for Newborn Nurseries in the South</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Hindorff, Lucia</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>CSER</td>\n",
       "      <td>GRU</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/4c8ce027-8094-4f5d-bf62-22b1d51b3c1e</td>\n",
       "      <td>[Whole Genome]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>e5ccacfe-1b14-4331-bd8f-a542b5a70d23</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>Prospective Longitudinal Cohort</td>\n",
       "      <td>\\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC):**&lt;br/&gt; Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &amp;#62;261,000 consents that allow return of results to &amp;#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&amp;#39;s Hospital of Philadelphia (CHOP):**&lt;br/&gt; The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&amp;#39;s Hospital of Philadelphia (CHOP), and one of the world&amp;#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&amp;#62;450,000), specifically from &amp;#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&amp;#62;12,000). Center for Applied Genomics, The Children&amp;#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&amp;#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&amp;#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**&lt;br/&gt; The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&amp;#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**&lt;br/&gt; Samples and phenotype data in this study were provided by the Geisinger MyCode&amp;#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**&lt;br/&gt; The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&amp;#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&amp;#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&amp;#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**&lt;br/&gt; KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&amp;#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**&lt;br/&gt; The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &amp;#62;155 or &amp;#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**&lt;br/&gt; Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**&lt;br/&gt; Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**&lt;br/&gt; Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&amp;#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: &lt;table&gt; |42025287|42137441|42412243|42456938|42456946|42672223\\n &lt;/table&gt; \\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>precision medicine</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Josh Peterson</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs001616</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Rowley, Robb</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>eMERGE</td>\n",
       "      <td>GRU</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/e5ccacfe-1b14-4331-bd8f-a542b5a70d23</td>\n",
       "      <td>[Exome Panel]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>2efa7d84-2850-4e6f-bb26-7d13ad147b44</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>Prospective Longitudinal Cohort</td>\n",
       "      <td>\\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC):**&lt;br/&gt; Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &amp;#62;261,000 consents that allow return of results to &amp;#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&amp;#39;s Hospital of Philadelphia (CHOP):**&lt;br/&gt; The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&amp;#39;s Hospital of Philadelphia (CHOP), and one of the world&amp;#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&amp;#62;450,000), specifically from &amp;#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&amp;#62;12,000). Center for Applied Genomics, The Children&amp;#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&amp;#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&amp;#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**&lt;br/&gt; The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&amp;#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**&lt;br/&gt; Samples and phenotype data in this study were provided by the Geisinger MyCode&amp;#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**&lt;br/&gt; The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&amp;#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&amp;#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&amp;#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**&lt;br/&gt; KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&amp;#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**&lt;br/&gt; The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &amp;#62;155 or &amp;#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**&lt;br/&gt; Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**&lt;br/&gt; Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**&lt;br/&gt; Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&amp;#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: &lt;table&gt; |42025287|42137441|42412243|42456938|42456946|42672223\\n &lt;/table&gt; \\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>precision medicine</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Josh Peterson</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs001616</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Rowley, Robb</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>eMERGE</td>\n",
       "      <td>GRU-IRB</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/2efa7d84-2850-4e6f-bb26-7d13ad147b44</td>\n",
       "      <td>[Exome Panel]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>1410a32b-4ee6-4bd3-96d1-4848d38769d8</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>Prospective Longitudinal Cohort</td>\n",
       "      <td>\\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC):**&lt;br/&gt; Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &amp;#62;261,000 consents that allow return of results to &amp;#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&amp;#39;s Hospital of Philadelphia (CHOP):**&lt;br/&gt; The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&amp;#39;s Hospital of Philadelphia (CHOP), and one of the world&amp;#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&amp;#62;450,000), specifically from &amp;#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&amp;#62;12,000). Center for Applied Genomics, The Children&amp;#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&amp;#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&amp;#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**&lt;br/&gt; The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&amp;#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**&lt;br/&gt; Samples and phenotype data in this study were provided by the Geisinger MyCode&amp;#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**&lt;br/&gt; The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&amp;#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&amp;#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&amp;#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**&lt;br/&gt; KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&amp;#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**&lt;br/&gt; The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &amp;#62;155 or &amp;#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**&lt;br/&gt; Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**&lt;br/&gt; Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**&lt;br/&gt; Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&amp;#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: &lt;table&gt; |42025287|42137441|42412243|42456938|42456946|42672223\\n &lt;/table&gt; \\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>precision medicine</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Josh Peterson</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs001616</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Rowley, Robb</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>eMERGE</td>\n",
       "      <td>GRU-IRB-NPU</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/1410a32b-4ee6-4bd3-96d1-4848d38769d8</td>\n",
       "      <td>[Exome Panel]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>b77d83c7-2a8e-4f50-be1a-7848f28dc8cb</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>Prospective Longitudinal Cohort</td>\n",
       "      <td>\\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC):**&lt;br/&gt; Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &amp;#62;261,000 consents that allow return of results to &amp;#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&amp;#39;s Hospital of Philadelphia (CHOP):**&lt;br/&gt; The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&amp;#39;s Hospital of Philadelphia (CHOP), and one of the world&amp;#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&amp;#62;450,000), specifically from &amp;#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&amp;#62;12,000). Center for Applied Genomics, The Children&amp;#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&amp;#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&amp;#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**&lt;br/&gt; The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&amp;#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**&lt;br/&gt; Samples and phenotype data in this study were provided by the Geisinger MyCode&amp;#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**&lt;br/&gt; The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&amp;#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&amp;#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&amp;#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**&lt;br/&gt; KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&amp;#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**&lt;br/&gt; The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &amp;#62;155 or &amp;#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**&lt;br/&gt; Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**&lt;br/&gt; Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**&lt;br/&gt; Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&amp;#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: &lt;table&gt; |42025287|42137441|42412243|42456938|42456946|42672223\\n &lt;/table&gt; \\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>precision medicine</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Josh Peterson</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs001616</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Rowley, Robb</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>eMERGE</td>\n",
       "      <td>GRU-IRB-PUB-NPU</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/b77d83c7-2a8e-4f50-be1a-7848f28dc8cb</td>\n",
       "      <td>[Exome Panel]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>206009c6-cc98-45ab-b504-e6c3a3162a23</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>Prospective Longitudinal Cohort</td>\n",
       "      <td>\\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC):**&lt;br/&gt; Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &amp;#62;261,000 consents that allow return of results to &amp;#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&amp;#39;s Hospital of Philadelphia (CHOP):**&lt;br/&gt; The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&amp;#39;s Hospital of Philadelphia (CHOP), and one of the world&amp;#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&amp;#62;450,000), specifically from &amp;#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&amp;#62;12,000). Center for Applied Genomics, The Children&amp;#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&amp;#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&amp;#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**&lt;br/&gt; The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&amp;#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**&lt;br/&gt; Samples and phenotype data in this study were provided by the Geisinger MyCode&amp;#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**&lt;br/&gt; The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&amp;#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&amp;#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&amp;#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**&lt;br/&gt; KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&amp;#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**&lt;br/&gt; The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &amp;#62;155 or &amp;#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**&lt;br/&gt; Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**&lt;br/&gt; Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**&lt;br/&gt; Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&amp;#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: &lt;table&gt; |42025287|42137441|42412243|42456938|42456946|42672223\\n &lt;/table&gt; \\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>precision medicine</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Josh Peterson</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs001616</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Rowley, Robb</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>eMERGE</td>\n",
       "      <td>GRU-NPU</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/206009c6-cc98-45ab-b504-e6c3a3162a23</td>\n",
       "      <td>[Exome Panel]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>da841552-40bb-4f05-8edf-ad0a76ed13ac</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>Prospective Longitudinal Cohort</td>\n",
       "      <td>\\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC):**&lt;br/&gt; Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &amp;#62;261,000 consents that allow return of results to &amp;#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&amp;#39;s Hospital of Philadelphia (CHOP):**&lt;br/&gt; The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&amp;#39;s Hospital of Philadelphia (CHOP), and one of the world&amp;#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&amp;#62;450,000), specifically from &amp;#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&amp;#62;12,000). Center for Applied Genomics, The Children&amp;#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&amp;#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&amp;#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**&lt;br/&gt; The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&amp;#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**&lt;br/&gt; Samples and phenotype data in this study were provided by the Geisinger MyCode&amp;#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**&lt;br/&gt; The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&amp;#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&amp;#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&amp;#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**&lt;br/&gt; KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&amp;#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**&lt;br/&gt; The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &amp;#62;155 or &amp;#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**&lt;br/&gt; Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**&lt;br/&gt; Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**&lt;br/&gt; Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&amp;#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: &lt;table&gt; |42025287|42137441|42412243|42456938|42456946|42672223\\n &lt;/table&gt; \\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>precision medicine</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Josh Peterson</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs001616</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Rowley, Robb</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>eMERGE</td>\n",
       "      <td>HMB</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/da841552-40bb-4f05-8edf-ad0a76ed13ac</td>\n",
       "      <td>[Exome Panel]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>96874f3e-3e02-400a-96d1-5bd20d4cbc09</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>Prospective Longitudinal Cohort</td>\n",
       "      <td>\\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC):**&lt;br/&gt; Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &amp;#62;261,000 consents that allow return of results to &amp;#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&amp;#39;s Hospital of Philadelphia (CHOP):**&lt;br/&gt; The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&amp;#39;s Hospital of Philadelphia (CHOP), and one of the world&amp;#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&amp;#62;450,000), specifically from &amp;#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&amp;#62;12,000). Center for Applied Genomics, The Children&amp;#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&amp;#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&amp;#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**&lt;br/&gt; The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&amp;#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**&lt;br/&gt; Samples and phenotype data in this study were provided by the Geisinger MyCode&amp;#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**&lt;br/&gt; The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&amp;#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&amp;#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&amp;#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**&lt;br/&gt; KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&amp;#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**&lt;br/&gt; The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &amp;#62;155 or &amp;#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**&lt;br/&gt; Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**&lt;br/&gt; Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**&lt;br/&gt; Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&amp;#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: &lt;table&gt; |42025287|42137441|42412243|42456938|42456946|42672223\\n &lt;/table&gt; \\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>precision medicine</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Josh Peterson</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs001616</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Rowley, Robb</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>eMERGE</td>\n",
       "      <td>HMB-GSO</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/96874f3e-3e02-400a-96d1-5bd20d4cbc09</td>\n",
       "      <td>[Exome Panel]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>651d2fd2-fc96-47b3-909d-0dd46f575dbc</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>Prospective Longitudinal Cohort</td>\n",
       "      <td>\\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC):**&lt;br/&gt; Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &amp;#62;261,000 consents that allow return of results to &amp;#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&amp;#39;s Hospital of Philadelphia (CHOP):**&lt;br/&gt; The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&amp;#39;s Hospital of Philadelphia (CHOP), and one of the world&amp;#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&amp;#62;450,000), specifically from &amp;#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&amp;#62;12,000). Center for Applied Genomics, The Children&amp;#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&amp;#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&amp;#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**&lt;br/&gt; The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&amp;#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**&lt;br/&gt; Samples and phenotype data in this study were provided by the Geisinger MyCode&amp;#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**&lt;br/&gt; The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&amp;#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&amp;#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&amp;#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**&lt;br/&gt; KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&amp;#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**&lt;br/&gt; The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &amp;#62;155 or &amp;#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**&lt;br/&gt; Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**&lt;br/&gt; Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**&lt;br/&gt; Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&amp;#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: &lt;table&gt; |42025287|42137441|42412243|42456938|42456946|42672223\\n &lt;/table&gt; \\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>precision medicine</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Josh Peterson</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs001616</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Rowley, Robb</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>eMERGE</td>\n",
       "      <td>HMB-IRB-PUB</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/651d2fd2-fc96-47b3-909d-0dd46f575dbc</td>\n",
       "      <td>[Exome Panel]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>84cfc3d8-282e-4102-ae43-5513e7a3efd5</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>Prospective Longitudinal Cohort</td>\n",
       "      <td>\\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC):**&lt;br/&gt; Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &amp;#62;261,000 consents that allow return of results to &amp;#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&amp;#39;s Hospital of Philadelphia (CHOP):**&lt;br/&gt; The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&amp;#39;s Hospital of Philadelphia (CHOP), and one of the world&amp;#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&amp;#62;450,000), specifically from &amp;#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&amp;#62;12,000). Center for Applied Genomics, The Children&amp;#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&amp;#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&amp;#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**&lt;br/&gt; The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&amp;#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**&lt;br/&gt; Samples and phenotype data in this study were provided by the Geisinger MyCode&amp;#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**&lt;br/&gt; The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&amp;#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&amp;#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&amp;#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**&lt;br/&gt; KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&amp;#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**&lt;br/&gt; The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &amp;#62;155 or &amp;#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**&lt;br/&gt; Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**&lt;br/&gt; Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**&lt;br/&gt; Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&amp;#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: &lt;table&gt; |42025287|42137441|42412243|42456938|42456946|42672223\\n &lt;/table&gt; \\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>precision medicine</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Josh Peterson</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs001616</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Rowley, Robb</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>eMERGE</td>\n",
       "      <td>HMB-NPU</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/84cfc3d8-282e-4102-ae43-5513e7a3efd5</td>\n",
       "      <td>[Exome Panel]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>40c4297e-d492-4f6a-b651-ee9ee38db14b</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>TBD</td>\n",
       "      <td>\\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC):**&lt;br/&gt; Cincinnati Children&amp;#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &amp;#62;261,000 consents that allow return of results to &amp;#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&amp;#39;s Hospital of Philadelphia (CHOP):**&lt;br/&gt; The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&amp;#39;s Hospital of Philadelphia (CHOP), and one of the world&amp;#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&amp;#62;450,000), specifically from &amp;#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&amp;#62;12,000). Center for Applied Genomics, The Children&amp;#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&amp;#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&amp;#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**&lt;br/&gt; The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&amp;#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**&lt;br/&gt; Samples and phenotype data in this study were provided by the Geisinger MyCode&amp;#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**&lt;br/&gt; The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&amp;#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&amp;#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&amp;#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**&lt;br/&gt; KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&amp;#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**&lt;br/&gt; The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &amp;#62;155 or &amp;#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**&lt;br/&gt; Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**&lt;br/&gt; Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**&lt;br/&gt; Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&amp;#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: &lt;table&gt; |42025287|42137441|42412243|42456938|42456946|42672223\\n &lt;/table&gt; \\n</td>\n",
       "      <td>[]</td>\n",
       "      <td>Unspecified</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs001616</td>\n",
       "      <td>eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Rowley, Robb</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>eMERGE</td>\n",
       "      <td>TBD</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/40c4297e-d492-4f6a-b651-ee9ee38db14b</td>\n",
       "      <td>[TBD]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>8956cc4d-58be-46ae-a81e-74607ffbd9d3</td>\n",
       "      <td></td>\n",
       "      <td>TBD</td>\n",
       "      <td></td>\n",
       "      <td>[]</td>\n",
       "      <td>Unspecified</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>Registration Pending</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>eMERGE</td>\n",
       "      <td>TBD</td>\n",
       "      <td>None</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/8956cc4d-58be-46ae-a81e-74607ffbd9d3</td>\n",
       "      <td>[TBD]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>381737d9-c0ac-4a78-9883-2977516ee64d</td>\n",
       "      <td></td>\n",
       "      <td>TBD</td>\n",
       "      <td>Data Release notes for the workspace\\n\\nUpdate: May 23, 2023\\n\\nFrom March 30, 2023 to May 9, 2023, the following files below were temporarily unavailable. As of May 9, 2023, these files have been restored. \\n\\nassembly_verkko_v1.2_trio.tar\\nm54329U_220829_095708-bc2050.5mc.hifi_reads.bam\\nm54329U_220107_233847-bc1016.5mc.hifi_reads.bam\\nm54329U_211230_014258-bc1010.5mc.hifi_reads.bam\\nm54329U_220117_123334-bc1012.5mc.hifi_reads.bam\\nm64076_220516_221911-bc2018.5mc.hifi_reads.bam\\nm64076_220518_191414-bc2018.5mc.hifi_reads.bam\\nm64076_220826_143529-bc2049.5mc.hifi_reads.bam\\nr54329U_20220901_220229_C01.reads.bam\\nr54329U_20220901_220229_D01.reads.bam\\nHG00621.GRCh38_no_alt.bam\\nHG01106.GRCh38_no_alt.bam\\nHG01109.CHM13Y_EBV.bam\\nHG01109.GRCh38_no_alt.bam\\nHG01978.CHM13Y_EBV.bam\\nHG02080.GRCh38_no_alt.bam\\nHG02486.GRCh38_no_alt.bam\\nHG02559.GRCh38_no_alt.bam\\nNA20129.GRCh38_no_alt.bam\\nNA21309.GRCh38_no_alt.bam\\n01_09_20_R941_GM24631_2.fast5.tar\\n01_09_20_R941_GM24631_3.fast5.tar\\nHG00733_1.fast5.tar.gz\\nHG00733_2.fast5.tar.gz\\nHG00733_3.fast5.tar.gz\\nm54329U_200615_084313.ccs.bam\\n\\n\\n# Human Pangenome Reference Consortium's AnVIL_HPRC Workspace\\n\\n![White Logo](https://s3-us-west-2.amazonaws.com/human-pangenomics/backup/logo-proof-full.png)\\n\\nThis workspace holds sequencing, assembly, and pangenome data submitted to the [Human Pangenome Reference Consortium](https://humanpangenome.org/). Data is stored in this workspace to allow immediate use by researchers participating in the Human Pangenome Project. Data in this workspace is constantly being added and updated and the workspace is under active development as our production pipeline continues. Note that the HPRC Year 1 data is pending publication, currently scheduled for march of 2022. If you would like to publish using this data please contact the HPRC Coordinating Center at hprcadmin@gowustl.onmicrosoft.com.\\n\\n### Data Table Organization\\n**Sequencing Data:** Sample Table &lt;br/&gt;\\n**Participant Information:** Participant Table &lt;br/&gt;\\n**Assemblies:** Assembly_Sample, Assembly_Annotation Tables &lt;br/&gt;\\n**Pangenomes:** Minigraph, Minigraph_CACTUS, PGGB Tables\\n\\n------------------\\n# Sequencing Data\\nProduction information about the HPRC Y1 samples is in the sections below. Note that samples from the HPRC_PLUS cohort had data assembled from other consortia, and the information in the sections below does not apply.\\n\\n## PacBio HiFi Data From UW and WashU\\nPacBio HiFi sequencing was performed on the Sequel2 instrument using v2 chemistry. Samples were sequenced across 3-5 flowcells in order to generate 35-fold coverage or greater. The average coverage for the year1 samples is &gt;40X with a median insert size of 20kb. The following file types are listed in the table:\\n\\n* {flowcell_id}.ccs.bam - consensus called unaligned bam file\\n\\nConsensus sequences were generated with v4.0.0 of the CCS algorithm\\n\\n## Nanopore PromethION Data From UC Santa Cruz\\n\\nThe UCSC Nanopore PromethION HPP data were generated using the a new long read protocol (details to be published on protocols.io shortly). Briefly, this protocol uses Circulomics discs-based UHMW DNA isolation, followed by library preparation using ONT SQK-RAD004 kit and library cleanup using Circulomics discs. Typically, we used 3 RAD004-based sequencing libraries per PromethION flow cell (and 3 flow cells per individual). The observed read N50s (average) are ~80 kb, with 11x coverage in 100kb+ readsa dn 3x coverage in 200kb+ reads for each individual. The following file types are listed in the table:\\n\\n* sample_Guppy_4.0.11_prom.fastq.gz\\n\\n## Hi-C/Omni-C Data From UCSC\\nOmniC is a restriction enzyme-free HiC protocol. DNA is fragmented using an endonuclease that cuts DNA randomly, i.e., not at specific restriction sites. It uses a biotinylated linker to facilitate proximity ligation. This short linker sequence may be present within the read data. The architecture of an OmniC library molecule is:\\n\\nP5adapter:GenomicRegion:Linker:GenomicRegion:P7adapter\\n\\nDepending on the read length, some or all of the Linker sequence may be present in R1, R2, or both. When present, the Linker sequence is: AGGTTCGTCCATCGATCGATGGACGAACCT Note that the linker sequence is a DNA palindrome. Thus, the Linker sequence will be the same whether present in R1 or R2 (forward or reverse read).\\n\\nFor each HPRC sample, two OmniC libraries are generated and sequenced. Duplicates can be identified and removed within each library, but not between libraries as independent sample material goes into each. Libraries are sequenced across several Novaseq lanes, depending on lane availability, with 2x150 paired-end sequencing.\\n\\nThe raw fastq OmniC data can be aligned using bwa mem with flags -5SP In practice, bwa mem (local alignment) will not omit the Linker sequence from the alignment in cases when it is present in the read.\\n\\nThe following file types are available:\\n\\n* {library_name}.R1_001.fastq.gz - forward reads\\n* {library_name}.R2_001.fastq.gz - reverse reads\\n \\n## Bionano Data From Rockefeller\\nThe following file types are available:\\n\\n* {sample_name}_Saphyr_DLE1_3680591.bnx.gz - raw data view of molecule and label information and quality scores\\n* {sample_name}_Saphyr_DLE1_3680616.cmap - location information for label sites\\n\\nFor information about Bionano file specifications or utilization of Bionano files see Bionano's website.\\n\\n## Strand-seq Data From EMBL\\nStrand-seq is a single-cell sequencing technology that resolves individual homologs within a cell by restricting sequence analysis to the DNA template strands used during DNA replication (see Sanders, et al.). Each sample has 192 fastq.gz files available -- from paired-end sequencing of 96 single cells (nuclei).\\n\\n## Trio Illumina Data From NYGC\\nWhen available, we have included high coverage (30X) Illumina datasets produced by NYGC for select 1000G samples. Information about this dataset can be found at [IGSR](https://www.internationalgenome.org/data-portal/data-collection/30x-grch38).\\n\\nNote that the data is stored in CRAM format (aligned to GRCHh38), but is placed in the raw_data area for each sample as the consortium uses the raw reads from the CRAMs. When used in assembly pipelines, the [extract_reads.wdl](https://github.com/human-pangenomics/hpp_production_workflows/blob/master/QC/wdl/tasks/extract_reads.wdl) is used to call samtools fastq to convert the reads to fastq format.\\n\\n\\n------------------\\n# Assemblies\\n\\nThe **assembly_sample** holds assemblies from year 1 data. Assemblies from 47 samples have been uploaded to Genbank and released. Genbank accessions can be found [here](https://github.com/human-pangenomics/HPP_Year1_Assemblies/blob/main/genbank_changes/y1_genbank_assembly_accession_ids.txt). The table has columns for maternal and paternal fastas alongside columns for each assembly aligned to both CHM13 and GRCh38. The **assembly_annotation** table holds annotation files for the assemblies found in the **assembly_sample** table.\\n\\nFor more information about the assembly process see the [Y1 Assembly GitHub repo](https://github.com/human-pangenomics/HPP_Year1_Assemblies)\\n## Assembly Metrics\\n**Select metrics from the [automated assembly QC]() are shown below**\\n\\n### QV\\n![QV](https://github.com/human-pangenomics/HPP_Year1_Assemblies/blob/main/automated_qc_results/Y1_assemblies_v2_genbank_QV.png?raw=true)\\n\\n### N50\\n![N50](https://github.com/human-pangenomics/HPP_Year1_Assemblies/blob/main/automated_qc_results/Y1_assemblies_v2_genbank_N50.png?raw=true)\\n\\n### Hamming Error Rate\\n![Hamming](https://github.com/human-pangenomics/HPP_Year1_Assemblies/blob/main/automated_qc_results/Y1_assemblies_v2_genbank_hamming.png?raw=true)\\n\\n### Switch Error Rate\\n![Switch](https://github.com/human-pangenomics/HPP_Year1_Assemblies/blob/main/automated_qc_results/Y1_assemblies_v2_genbank_switch.png?raw=true)\\n\\n------------------\\n\\n# Pangenomes\\nPangenomes are available from three different strategies summarized in the table (and relevant sections) below:\\n\\n| &lt;sub&gt; &lt;/sub&gt; | &lt;sub&gt;**Minigraph**&lt;/sub&gt; | &lt;sub&gt;**Minigraph-Cactus**&lt;/sub&gt; | &lt;sub&gt;**PGGB**&lt;/sub&gt; |\\n| :-------- | :-------- | :------ | :------ |\\n| &lt;sub&gt; sequence comparison &lt;/sub&gt; | &lt;sub&gt; reference-based, progressive &lt;/sub&gt; | &lt;sub&gt; reference-based, progressive &lt;/sub&gt; | &lt;sub&gt; symmetric, all-vs-all &lt;/sub&gt; |\\n| &lt;sub&gt; resolution &lt;/sub&gt; | &lt;sub&gt; SV only &lt;/sub&gt; | &lt;sub&gt; base-level (via abPOA) &lt;/sub&gt; | &lt;sub&gt; base-level (via abPOA) &lt;/sub&gt; |\\n| &lt;sub&gt; scope &lt;/sub&gt; | &lt;sub&gt; full assemblies &lt;/sub&gt; | &lt;sub&gt; Non-centromeric &lt;/sub&gt; | &lt;sub&gt; full assemblies &lt;/sub&gt; |\\n| &lt;sub&gt; cyclic paths &lt;/sub&gt; | &lt;sub&gt; no &lt;/sub&gt; | &lt;sub&gt; non-reference &lt;/sub&gt; | &lt;sub&gt; all &lt;/sub&gt; |\\n| &lt;sub&gt; short read mapping &lt;/sub&gt; | &lt;sub&gt; untested &lt;/sub&gt; | &lt;sub&gt; yes (fast) &lt;/sub&gt; | &lt;sub&gt; untested &lt;/sub&gt; |\\n| &lt;sub&gt; long read mapping &lt;/sub&gt; | &lt;sub&gt; yes (fastest) &lt;/sub&gt; | &lt;sub&gt; yes &lt;/sub&gt; | &lt;sub&gt; yes (slowest) &lt;/sub&gt; |\\n| &lt;sub&gt; Assembly mapping &lt;/sub&gt; | &lt;sub&gt; yes (direct) &lt;/sub&gt; | &lt;sub&gt; untested &lt;/sub&gt; | &lt;sub&gt; yes (via injection) &lt;/sub&gt; |\\n\\n\\n### Assembly Inputs\\n\\nThe assemblies in the **assembly_sample** table were used as inputs to graph building pipelines. Of the 47 samples assembled (94 assemblies) in year 1, all but three samples were included in graph constructions (HG002, HG005 and NA19240 were excluded for evaluation purposes). GRCh38 and CHM13 were added to make the total number of haplotypes included 90.\\n\\n\\n## Graphs\\n### Minigraph\\n\\n[Minigraph](https://github.com/lh3/minigraph) is a generalization of minimap2 (very fast) which builds the graph with iterative construction. Minigraph aligns with approximate locations and can be used to call structural variants (&gt;50nt). Graphs were built with both GRCh38 and CHM13+Y (found [here](https://s3-us-west-2.amazonaws.com/human-pangenomics/pangenomes/freeze/freeze1/minigraph/CHM13v11Y.fa.gz)) used as reference sequences.\\n\\nGraphs and associated files are available in the **minigraph** table.\\n\\n### Minigraph/CACTUS\\n\\n[The CACTUS pangenome pipeline](https://github.com/ComparativeGenomicsToolkit/cactus/blob/master/doc/pangenome.md) adds base-level alignments to the minigraph graphs above (so both GRCh38- and CHM13-based graphs are available). Centromeric regions are removed during  Minigraph/CACTUS graph creation.\\n\\nGraphs and associated files are available in the **minigraph_cactus** table.\\n\\nThe graphs are available in gfa format alongside other graph and index files. Information about the associated file formats can be found:\\n* graph formats: [xg/gg](https://github.com/vgteam/vg/wiki/Index-Types)\\n* index formats: [gbwt/dist/min](https://github.com/vgteam/vg/wiki/Index-Types)\\n* snarls format: [snarls](https://github.com/vgteam/vg/wiki/Index-Construction)\\n\\n#### Filtered Graphs\\nThe [Giraffe](https://www.biorxiv.org/content/10.1101/2020.12.04.412486v2.abstract) short read mapper relies on the graph's snarl decomposition.  The versions of the Cactus/Minigraph graphs released here contain some spurious large deletion edges that make this decomposition less efficient, which impacts Giraffe *runtime*. Furthermore, we have found that for calling small variants with the Giraffe-[DeepVariant](https://doi.org/10.1038/nbt.4235) pipeline, *accuracy* is improved if all alleles with frequency &lt; 10% are removed from the graph before indexing.  Two filtered versions of each of the two Minigraph/Cactus graphs are available. The graphs with `maxdel.10mb` in the name (recommended to speed up general mapping experiments) were created by removing edges that imply deletions &gt; 10mb, and the graphs with `minaf.0.1` in the name (recommended when using with DeepVariant) were created by removing, in addition to the deletions, nodes that are covered by fewer than 9 haplotypes.\\n\\n### PGGB\\n\\nThe Pangenome Graph Builder pipeline ([PGGB](https://github.com/pangenome/pggb)) creates and all-vs-all graph with base-level alignments and no clipping of mitochondrial or centromeric regions.\\n\\nThe graph files can be found in the **pggb** table\\n\\n\\n\\n\\n\\n\\n\\n\\nTo view currently available sequencing data, navigate to the DATA tab of this workspace to view data stored in the \"sample\" data table. In-progress assembiles can also be found in the \"sample_assembly\" table. These assemblies were generated with Hifiasm v0.14.\\n\\nData can also be accessed from our [S3 Bucket](https://s3-us-west-2.amazonaws.com/human-pangenomics/index.html?prefix=working/) without egress fees. Information about the currently available data can be found on our [GitHub page](https://github.com/human-pangenomics/HPP_Year1_Data_Freeze_v1.0).\\n\\n------------------\\n\\n### Data Use Policy\\n\\nPublication Protocol  V1.0 | April 7, 2020\\n\\nThe goal of the HPRC publication policy is to encourage collaboration and coordination among investigators while ensuring the timely release of research to the scientific community.  The document provides general guidelines and a description of the process for disclosure of planned publications within the consortium through submission.  This policy will be drafted and updated by the HPRC Administration and Coordination Working Group and approved by the HPRC steering committee.\\n\\n**General Guidelines**\\n* This policy applies to all manuscripts resulting from HPRC funded activities.\\n* It is the responsibility of the HPRC members to take steps necessary to protect any intellectual property rights.\\n* Any publication must comply with the NIH Public Access policy and authors should make efforts to publish their work using open access policies when possible.\\n* Individual investigators funded under the HPRC may separately or collaboratively publish the results of their own work.\\n* Investigators within HPRC who have similar work are encouraged to work together on publications.\\n* A manuscript tracking sheet will be used to share information about planned manuscripts.\\n * Entries in the manuscript tracking sheet are the responsibility of the corresponding author.\\n * The Information requested in the manuscript tracking sheet will include the following:  Authors, Title, Status, Potential overlap with other HPRC Publications, Submission Date, Journal, Publication Date, Preprint Submission Link, PMCI Number\\n * The Manuscript Tracking Sheet is available through the HPRC WIKI.\\n\\n**Internal Sharing of Planned Manuscripts**\\n* Investigators shall notify the Steering Committee of any publication using HPRC data or analysis that may impinge on planned integrative data analysis by the consortium, so that the potential impact of the pending publication can be discussed.\\n* Investigators are encouraged to enter information into the tracking system as early in the process as possible to enable collaboration and minimize overlap\\n* Information about manuscripts shared internally within the HPRC will be treated as confidential and may not be shared. \\n* HPRC members are encouraged to sharing information about publications related to the Human Reference even if not directly funded by the HPRC.\\n\\n**External Sharing of Submitted Manuscripts**\\n * When applicable pre-prints of submitted manuscripts must be shared via the appropriate pre-print server prior to or concurrently with the time of submission to a journal.\\n * Pre-prints are considered publications and should be cited like papers. \\n\\n**Resolution of Disagreements**\\n\\nIf questions or disagreements arise between investigators they should work to resolve them together.  If a mutually agreeable solution cannot be attained then the investigators may petition the Steering Committee to help resolve the situation.  The decision of the Steering Committee will be final and all parties agree to abide by their decision.\\n\\n------------------\\n\\n### More Materials\\n\\nGeneral Reference:\\n* Human Pangenome Reference Consortium Homepage: [link](https://humanpangenome.org/).\\n* Wiki (Login Required): [link](http://wiki.humanpangenome.org/index.php/Main_Page)\\n\\nData Storage (Subject To Change):\\n* This Workspace: [link](https://app.terra.bio/#workspaces/anvil-datastorage/AnVIL_HPRC)\\n* S3 Bucket: [link](https://s3-us-west-2.amazonaws.com/human-pangenomics/index.html?prefix=submissions/).\\n\\nGitHub Repositories:\\n* Production Workflows: [link](https://github.com/human-pangenomics/hpp_production_workflows).\\n* Dockstore Site: [link](https://dockstore.org/organizations/HumanPangenome).\\n* Y1 Data Freeze: [link](https://github.com/human-pangenomics/HPP_Year1_Data_Freeze_v1.0)\\n* Y1 Assemblies: [link](https://github.com/human-pangenomics/HPP_Year1_Assemblies)\\n* Pangenome Resources: [link](https://github.com/human-pangenomics/hpp_pangenome_resources)\\n\\n------------------\\n\\nWorkspace contact email: juklucas@ucsc.edu\\n\\nProject Name: Human Pangenome Reference \\n\\nData permissions: Open Access\\n</td>\n",
       "      <td>[]</td>\n",
       "      <td>None</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>HPRC</td>\n",
       "      <td>NRES</td>\n",
       "      <td>None</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/381737d9-c0ac-4a78-9883-2977516ee64d</td>\n",
       "      <td>[Whole Genome]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>6a5b3be6-d1de-4f23-a431-b08e7ab231b8</td>\n",
       "      <td>PAGE: Multiethnic Cohort (MEC)</td>\n",
       "      <td>Case-Control</td>\n",
       "      <td>\\nThe Multiethnic Cohort (MEC) has established a large biorepository of blood and urine (N=67,000) and cryopreserved lymphocytes (N=15,000) linked to extensive, prospectively collected risk factors (e.g., diet, smoking, physical activity), biomarkers and clinical data for five racial/ethnic groups. This cohort study of over 215,000 men and women in Hawaii and California is unique in that it is population-based and includes large representations of older adults (45-75 yrs at baseline) for five US racial/ethnic groups (Japanese Americans, African Americans, European Americans, Latinos and Native Hawaiians) at varying risks of chronic diseases. Within the PAGE investigation, the MEC proposes to study: 1) diseases for which we have DNA available for large numbers of cases and controls (breast, prostate, and colorectal cancer, diabetes, and obesity); 2) important cancers that are less common (e.g., lung, pancreas, endometrial cancers, NHL) but for which we propose to pool our data with other funded groups; 3) common traits that are risk factors for these diseases (e.g., body mass index/weight, waist-to-hip ratio, height) and 4) relevant disease-associated biomarkers (e.g., fasting insulin and lipids, steroid hormones). The specific aims are: 1) To determine the population-based epidemiologic profile (allele frequency, main effect, heterogeneity by disease characteristics) of putative causal variants in the five racial/ethnic groups in the MEC; 2) for variants displaying effect heterogeneity across ethnic/racial groups, we will utilize differences in LD to identify a more complete spectrum of associated variants at these loci; 3) investigate gene x gene and gene x environment interactions to identify modifiers; 4) examine the associations of putative causal variants with already measured intermediate phenotypes (e.g., plasma insulin, lipids, steroid hormones); and 5) for variants that do not fall within known genes, start to investigate their relationships with gene expression and epigenetic patterns in small genomic studies.\\n\\nThis study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study [phs000356](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000356).\\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>population</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Christopher Haiman, ScD</td>\n",
       "      <td>None</td>\n",
       "      <td>University of Southern California, Los Angeles, CA, USA</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs000220</td>\n",
       "      <td>PAGE: Multiethnic Cohort (MEC)</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Hindorff, Lucia</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>PAGE</td>\n",
       "      <td>GRU</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/6a5b3be6-d1de-4f23-a431-b08e7ab231b8</td>\n",
       "      <td>[Whole Genome]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>ffe34538-3ddd-48de-b4a2-94f9b2dad086</td>\n",
       "      <td>PAGE: Women&amp;#39;s Health Initiative (WHI)</td>\n",
       "      <td>Prospective Longitudinal Cohort</td>\n",
       "      <td>\\nThis substudy phs000227 PAGE WHI contains genotypes generated using BeadXpress and Metabochip, produced as part of NHGRI&amp;#39;s PAGE project. Summary level phenotypes for the WHI Cohort study participants can be viewed at the top-level study page [phs000200](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200) WHI Cohort. Individual level phenotype data and molecular data for all WHI top-level study and substudies are available by requesting Authorized Access to the WHI Cohort study [phs000200](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200). \\n\\n**WHI**&lt;br/&gt; The Women&amp;#39;s Health Initiative (WHI) is a long-term national health study that has focused on strategies for preventing heart disease, breast and colorectal cancer and osteoporotic fractures in postmenopausal women. These chronic diseases are the major causes of death, disability and frailty in older women of all races and socioeconomic backgrounds.\\n\\nThis cohort is sponsored by the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), involves 161,808 women aged 50-79, and is one of the most definitive, far-reaching clinical trials of post-menopausal women&amp;#39;s health ever undertaken in the U.S. Women were recruited between 1993 to 1998 at 40 centers across the US and follow up is planned to continue until at least 2015. The WHI Clinical Trial and Observational Study focused on many of the inequities in women&amp;#39;s health research and will continue to provide practical information to women and their physicians about hormone therapy, dietary patterns, calcium/vitamin D supplementation, and their effects on the prevention of heart disease, cancer and osteoporotic fractures.\\n\\nThe WHI has two major parts: a randomized Clinical Trial and an Observational Study. The randomized controlled Clinical Trial (CT) enrolled 68,132 postmenopausal women between the ages of 50-79 into trials testing three prevention strategies. If eligible, women could choose to enroll in one, two, or all three of the trial components. The components are:  - **Hormone Therapy Trials (HT)**: This component examined the effects of combined hormones or estrogen alone on the prevention of coronary heart disease and osteoporotic fractures, and associated risk for breast cancer. Women participating in this component took hormone pills or a placebo (inactive pill) until the Estrogen plus Progestin and Estrogen Alone trials were stopped early in July 2002 and March 2004, respectively. All HT participants continued to be followed without intervention until close-out. - **Dietary Modification Trial (DM)**: The Dietary Modification component evaluated the effect of a low-fat and high fruit, vegetable and grain diet on the prevention of breast and colorectal cancers and coronary heart disease. Study participants followed either their usual eating pattern or a low-fat dietary pattern. - **Calcium/Vitamin D Trial (CaD)**: This component began 1 to 2 years after a woman joined one or both of the other clinical trial components. It evaluated the effect of calcium and vitamin D supplementation on the prevention of osteoporotic fractures and colorectal cancer. Women in this component took calcium and vitamin D pills or a placebo.  \\n\\nThe **Observational Study (OS)** is examining the relationship between lifestyle, health and risk factors and specific disease outcomes. This component involves tracking the medical history and health habits of 93,676 women.\\n\\nTo fully examine the profile of gene and environment interaction, or \"epidemiologic architecture,\" we will comprehensively evaluate such putative genuine variants in the Women&amp;#39;s Health Initiative This large study population not only enables us to examine the population incidence for racial and ethnic subgroups and associated risks of rigorously defined, incident diseases (specific aim 1) but allows us to investigate associated risks given in-depth information on various environmental exposures and disease risk factors as well as three randomized interventions (hormone therapy; low-fat dietary modification; calcium + vitamin D supplements) (specific aim 2). The prospective and longitudinal collection of biospecimens, intermediate outcomes, and phenotypic characteristics, such as bone mineral density, hormone concentrations, breast density, or inflammation will further permit us to link genetic variants to relevant intermediate phenotypes, which will potentially provide important clues to the biological basis of the genuine associations (specific aim 3). For a variety of outcomes we will genotype within this 4-year project 72,000 participants for disease-specific putative genuine variants. Information generated from this study will be critical to determine the health impact of any given undisputable variant. Findings may also provide valuable insights into disease pathways and mechanisms, and targets for disease screening, prevention, and treatment.\\n\\nThis study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study ([phs000356](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000356)).\\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>population</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Kooperberg, Charles</td>\n",
       "      <td>clk@fredhutch.org</td>\n",
       "      <td>FRED HUTCHINSON CANCER RESEARCH CENTERFRED HUTCHINSON CANCER CENTER</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs000227</td>\n",
       "      <td>PAGE: Women&amp;#39;s Health Initiative (WHI)</td>\n",
       "      <td>none</td>\n",
       "      <td>National Heart, Lung, and Blood Institute</td>\n",
       "      <td>Hindorff, Lucia</td>\n",
       "      <td>Ono, Hiromi</td>\n",
       "      <td>PAGE</td>\n",
       "      <td>HMB-IRB</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/ffe34538-3ddd-48de-b4a2-94f9b2dad086</td>\n",
       "      <td>[Whole Genome]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>a4c62d7f-34f0-4e2e-9e46-c762d3ab0ff2</td>\n",
       "      <td>PAGE: IPM BioMe Biobank</td>\n",
       "      <td>Prospective Longitudinal Cohort</td>\n",
       "      <td>\\nThe Institute for Personalized Medicine (IPM) Bio*Me* Biobank is a consented, EMR-linked medical care setting biorepository of the Mount Sinai Medical Center (MSMC) drawing from a population of over 70,000 inpatients and 800,000 outpatient visits annually. MSMC serves diverse local communities of upper Manhattan, including Central Harlem (86% African American), East Harlem (88% Hispanic Latino), and Upper East Side (88% Caucasian/white) with broad health disparities. IPM Bio*Me* Biobank populations include 28% African American, 38% Hispanic Latino predominantly of Caribbean origin, 23% Caucasian/White. IPM BioMe Biobank disease burden is reflective of health disparities with broad public health impact. Biobank operations are fully integrated in clinical care processes, including direct recruitment from clinical sites waiting areas and phlebotomy stations by dedicated Biobank recruiters independent of clinical care providers, prior to or following a clinician standard of care visit. Recruitment currently occurs at a broad spectrum of over 30 clinical care sites.\\n\\nThis study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study ([phs000356](http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bihttps://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000356.v1.p1)). \\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>population</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Ruth Loos, PhD</td>\n",
       "      <td>None</td>\n",
       "      <td>The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs000925</td>\n",
       "      <td>PAGE: IPM BioMe Biobank</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Hindorff, Lucia</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>PAGE</td>\n",
       "      <td>GRU</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/a4c62d7f-34f0-4e2e-9e46-c762d3ab0ff2</td>\n",
       "      <td>[Whole Genome]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>5208772d-21f9-46b0-8167-0b05b57296b8</td>\n",
       "      <td>PAGE: Global Reference Panel</td>\n",
       "      <td>Control Set</td>\n",
       "      <td>\\nStanford contributed samples to the PAGE study that can act as a population reference dataset across the globe. Therefore this dataset includes reference individuals, without phenotypes, chosen to help infer ancestry that will help us understand the diverse samples available in PAGE. The complete dataset comprises individuals of European, African, Asian, Oceanian, and Native American descent, from a total of over 50 populations. A subset of these individuals from Puno, Peru and Easter Island (Rapa Nui), Chile, are included in the PAGE samples that were whole genome sequenced in 2015. Additional details are available in the Study Acknowledgments.\\n\\nThe Global Reference Panel comprises 6 sample sets: - A population sample of Andean individuals primarily of Quechuan/Aymaran ancestry from Puno, Peru - A population sample of Easter Island (Rapa Nui), Chile - Individuals of indigenous origin from Oaxaca, Mexico - Individuals of indigenous origin from Honduras - Individuals of indigenous origin from Colombia - Individuals of indigenous origin from the Nama and Khomani KhoeSan populations of the Northern Cape, South Africa \\n\\nIn addition, we genotyped publicly available samples that will be hosted on the Bustamante lab website ([https://bustamantelab.stanford.edu/](https://bustamantelab.stanford.edu/)). These comprise large public datasets to provide an open reference dataset for the world:\\n\\n - The additional related individuals from the Americas in the Human Genome Diversity Panel (H952) plus all additional samples from the Americas - A subset of the unrelated individuals from the Maasai in Kinyawa, Kenya (MKK) dataset from the International Hapmap Project hosted at Coriell \\n\\nAdditional samples will be available for restricted use with a data access agreement with the Bustamante Lab.\\n\\nThis study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study ([phs000356](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000356)). \\n</td>\n",
       "      <td>[Raw Sequencing data]</td>\n",
       "      <td>population</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td>Carlos Bustamante, PhD</td>\n",
       "      <td>None</td>\n",
       "      <td>Stanford University, Stanford, CA, USA</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>phs001033</td>\n",
       "      <td>PAGE: Global Reference Panel</td>\n",
       "      <td>none</td>\n",
       "      <td>National Human Genome Research Institute</td>\n",
       "      <td>Hindorff, Lucia</td>\n",
       "      <td>Strasburger, Jennifer</td>\n",
       "      <td>PAGE</td>\n",
       "      <td>GRU</td>\n",
       "      <td>1</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/5208772d-21f9-46b0-8167-0b05b57296b8</td>\n",
       "      <td>[Whole Genome]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>b735d811-a7ed-4d82-8b9d-5f23a9f33936</td>\n",
       "      <td></td>\n",
       "      <td>TBD</td>\n",
       "      <td></td>\n",
       "      <td>['Raw Sequencing data']</td>\n",
       "      <td>Unspecified</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>TBD</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>PAGE</td>\n",
       "      <td>HMB</td>\n",
       "      <td>None</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/b735d811-a7ed-4d82-8b9d-5f23a9f33936</td>\n",
       "      <td>[Whole Genome]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>367b7e53-512c-40c2-af8c-53477a79bcb7</td>\n",
       "      <td></td>\n",
       "      <td>Parent-Offspring Trios</td>\n",
       "      <td># Telomere-to-Telomere (T2T) Consortium's AnVIL_T2T Workspace\\n\\n&lt;p align=\"center\"&gt;&lt;img src=\"https://schatz-lab.org/images/t2tlogo.png\" width=\"50%\"&gt;&lt;/p&gt;\\n\\n\\nThe [Telomere-to-Telomere (T2T) consortium](https://sites.google.com/ucsc.edu/t2tworkinggroup) is an open, community-based effort to de novo assemble the first complete reference human genome from the CHM13 hydatidiform mole. Using a combination of PacBio HiFi sequencing and Oxford Nanopore ultra long reads, the recently released CHM13v1 reference genome is nearly perfect, with an estimated sequence accuracy exceeding QV70 and only 5 rRNA arrays left unresolved. The genome includes more than 100 Mbp of novel sequence compared to GRCh38, corrects many structural errors in the GRCh38 reference genome, and unlocks the most complex regions of the genome to clinical and functional study for the first time.\\n\\n### Currently Available Data\\nHere we use the T2T-CHM13 reference genome to investigate how it improves variant calling for individual samples, trios, and population-scale analysis. This includes 17 samples from diverse ethnicities sequenced with long reads that we analyze for SNVs, indels and structural variants using PEPPER-Margin-DeepVariant and Sniffles, along with all 3,202 short-read samples from the recently extended 1000 Genomes Project collection that we analyze using the GATK HaplotypeCaller for SNVs and indels on the NHGRI AnVIL Cloud Platform. We demonstrate that the CHM13 reference improves read mapping and variant calling across all samples in a number of major ways:\\n1. Adds over 80 million base pairs of sequence that can be effectively used for variant calling with long reads\\n2. Eliminates false positive variant calls in functional and medically relevant genes such as MAP2K3 and ZNF717 by adding sequences not present in GRCh38\\n3. Corrects missed variants related to false duplications in GRCh38, including within genes like CBS and KCNE1\\n4. Improves structural variant analysis, especially the balance of large insertion and deletion structural variant calls, by correcting collapsed tandem repeats in GRCh38\\n5. Reduces the rate of false de novo mutations and Mendelian violations found among trios\\n\\nFor more information, see the paper:\\n\\n[A complete reference genome improves analysis of human genetic variation](https://doi.org/10.1101/2021.07.12.452063)&lt;br&gt;\\nAganezov, S*, Yan, SM*, Soto, DC*, Kirsche, M*, Zarate, S*, Avdeyev, P, Taylor, DJ, Shafin, K, Shumate, A, Xiao, C, Wagner, J, McDaniel, J, Olson, ND, Sauria, MEG, Vollger, MR, Rhie, A, Meredith, M, Martin, S, Lee, J, Koren, S, Rosenfeld, J, Paten, B, Layer, R, Chin, CS, Sedlazeck, FJ, Hansen, NF, Miller, DE, Phillippy, AM, Miga, KM, McCoy, RC, Dennis, MY, Zook, JW, Schatz, MC (2021) bioRxiv doi: https://doi.org/10.1101/2021.07.12.452063\\n</td>\n",
       "      <td>['Raw Sequencing data']</td>\n",
       "      <td>None</td>\n",
       "      <td>Homo sapiens</td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>help@lists.anvilproject.org</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>T2T</td>\n",
       "      <td>NRES</td>\n",
       "      <td>None</td>\n",
       "      <td>TDR Location</td>\n",
       "      <td>https://data.terra.bio/snapshots/367b7e53-512c-40c2-af8c-53477a79bcb7</td>\n",
       "      <td>[Whole Genome]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                snapshot_id                                                               studyName                                                              studyType              \\\n",
       "0   fc513b58-cfb7-4871-8694-8dc372fc2e10                                                                                                                                           TBD   \n",
       "1   a1dcd80f-6390-489a-a34a-168f26690a36                                                                                                           NA                         Case Set   \n",
       "2   e91ccc70-2772-46d8-b586-cf3e270a05b5  Center for Common Disease Genomics [CCDG] - Autoimmune: Inflammatory Bowel Disease (IBD) Exomes and Genomes                              TBD   \n",
       "3   6fdea8c7-69d9-466e-9fa2-aca30722ff68                                                                           Autism Sequencing Consortium (ASC)                      Unspecified   \n",
       "4   02d25240-823f-4b1d-8562-95385716a453                                                                              Genomic Answers for Kids (GA4K)        Case only / Trio / Family   \n",
       "5   99b46287-4790-492c-8a12-bea33f0f927c                                                                              Genomic Answers for Kids (GA4K)                              TBD   \n",
       "6   c6ef5822-3929-4ae7-b5bc-dc27528bf226                                                                              Genomic Answers for Kids (GA4K)                              TBD   \n",
       "7   08d19a7e-b868-4766-9f7e-d879d972cbd7                                                                              Genomic Answers for Kids (GA4K)                              TBD   \n",
       "8   1974a21b-c409-4736-a3d7-e195fa96c4eb                                                                              Genomic Answers for Kids (GA4K)        Case only / Trio / Family   \n",
       "9   8fd5b447-77b6-4c33-b66a-a5cc63587220                                  Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes  Prospective Longitudinal Cohort   \n",
       "10  aa2bfacc-c28c-4192-960c-b1389cf68516                                  Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes                              TBD   \n",
       "11  44b1f60b-e74c-4430-9378-d4a75e2de72f                                  Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes                     Case-Control   \n",
       "12  5b036d13-e058-4d8d-be91-6fdd070686a7                                  Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes                     Case-Control   \n",
       "13  0a356156-961d-4829-b9b5-c07fbc73dacc                              CSER: North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing 2                   Clinical Trial   \n",
       "14  e43974fd-cee1-4d8c-a436-6846d7d24129                                         CSER: Exome Sequencing in Diverse Populations in Colorado and Oregon                   Clinical Trial   \n",
       "15  4c8ce027-8094-4f5d-bf62-22b1d51b3c1e                                           CSER: South-Seq: DNA Sequencing for Newborn Nurseries in the South               Family/Twins/Trios   \n",
       "16  e5ccacfe-1b14-4331-bd8f-a542b5a70d23                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel  Prospective Longitudinal Cohort   \n",
       "17  2efa7d84-2850-4e6f-bb26-7d13ad147b44                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel  Prospective Longitudinal Cohort   \n",
       "18  1410a32b-4ee6-4bd3-96d1-4848d38769d8                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel  Prospective Longitudinal Cohort   \n",
       "19  b77d83c7-2a8e-4f50-be1a-7848f28dc8cb                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel  Prospective Longitudinal Cohort   \n",
       "20  206009c6-cc98-45ab-b504-e6c3a3162a23                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel  Prospective Longitudinal Cohort   \n",
       "21  da841552-40bb-4f05-8edf-ad0a76ed13ac                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel  Prospective Longitudinal Cohort   \n",
       "22  96874f3e-3e02-400a-96d1-5bd20d4cbc09                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel  Prospective Longitudinal Cohort   \n",
       "23  651d2fd2-fc96-47b3-909d-0dd46f575dbc                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel  Prospective Longitudinal Cohort   \n",
       "24  84cfc3d8-282e-4102-ae43-5513e7a3efd5                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel  Prospective Longitudinal Cohort   \n",
       "25  40c4297e-d492-4f6a-b651-ee9ee38db14b                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel                              TBD   \n",
       "26  8956cc4d-58be-46ae-a81e-74607ffbd9d3                                                                                                                                           TBD   \n",
       "27  381737d9-c0ac-4a78-9883-2977516ee64d                                                                                                                                           TBD   \n",
       "28  6a5b3be6-d1de-4f23-a431-b08e7ab231b8                                                                               PAGE: Multiethnic Cohort (MEC)                     Case-Control   \n",
       "29  ffe34538-3ddd-48de-b4a2-94f9b2dad086                                                                    PAGE: Women&#39;s Health Initiative (WHI)  Prospective Longitudinal Cohort   \n",
       "30  a4c62d7f-34f0-4e2e-9e46-c762d3ab0ff2                                                                                      PAGE: IPM BioMe Biobank  Prospective Longitudinal Cohort   \n",
       "31  5208772d-21f9-46b0-8167-0b05b57296b8                                                                                 PAGE: Global Reference Panel                      Control Set   \n",
       "32  b735d811-a7ed-4d82-8b9d-5f23a9f33936                                                                                                                                           TBD   \n",
       "33  367b7e53-512c-40c2-af8c-53477a79bcb7                                                                                                                        Parent-Offspring Trios   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          studyDescription                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         \\\n",
       "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AnVIL_CCDG_Broad_NP_Epilepsy_JPNFKA_GRU_WES   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \\nThe National Human Genome Research Institute (NHGRI) has funded a collaborative large-scale genome sequencing effort to comprehensively identify rare risk and protective variants contributing to multiple common disease phenotypes. Called the Centers for Common Disease Genomics (CCDG), this initiative will explore a range of diseases with the ultimate goal of: undertaking variant discovery for enough different examples of disease architectures and study designs to better understand the general principles of the genomic architecture underlying common, complex inherited diseases; understanding how best to design rare variant studies for common disease; developing resources, informatics tools, and innovative approaches and technologies for multiple disease research communities and the wider biomedical research community. The initial focus of the CCDGs will be in cardiovascular disease (early-onset coronary artery disease, atrial fibrillation, hemorrhagic stroke), neuropsychiatric disease (epilepsy, autism), and autoimmune/inflammatory disease (type 1 diabetes, inflammatory bowel disease). The Broad Institute is one of four selected CCDG project centers. The overarching aim of the Inflammatory Bowel Disease (IBD) program is to define the full allelic spectrum of protein-altering variation in genes associated to IBD, and assess their role in both Crohn's Disease (CD) and Ulcerative Colitis (UC) risk. The whole genome sequencing data generated here is comprised of samples from US-based diverse populations including African American, Puerto-Rican, Caribean and Cuban origins. \\n   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \\nThe ARRA Autism Sequencing Collaboration was created in 2010 bringing together expert large-scale sequencing center (at the Baylor College of Medicine, PI Richard Gibbs and the Board Institute of MIT and Harvard, PI Mark J. Daly) and a collaborative network of research labs focused on the genetics of autism (brought together by the Autism Genome Project and the Autism Consortium). These groups worked together to utilize dramatic new advances in DNA sequencing technology to reveal the genetic architecture of autism through comprehensive examination of the exotic sequence of all genes. The Autism Sequencing Consortium (ASC) was founded by Joseph D. Buxbaum and colleagues as an international group of scientists who share autism spectrum disorder (ASD) samples and genetic data. The PIs are Drs. Joseph D. Buxbaum (Icahn School of Medicine at Mount Sinai), Mark J. Daly (Broad Institute of MIT and Harvard), Bernie Devlin (University of Pittsburgh School of Medicine), Kathryn Roeder (Carnegie Mellon University, Matthew State and Stephan Sanders (University of California, San Francisco). The rationale for the ASC is described in [Buxbaum et al. 2012](https://www.ncbi.nlm.nih.gov/pubmed/23259942), and this paper should be cited when referencing the data set. All shared data and analysis is hosted at a single site, which enables joint analysis of large-scale data from many groups. The ASC was first supported by a cooperative agreement grant to four lead sites funded by the National Institute of Mental Health (U01MH100233, U01MH100209, U01MH100229, U01MH100239), with additional support from the National Human Genome Research Institute. The NIMH recently renewed their support with a second grant (U01MH111661, U01MH111660, U01MH111658 and U01MH111662) to expand the project from 29,000 genomes to more than 50,000 exomes over the next 5 years. NHGRI provides ongoing sequencing support for the ASD through the Broad Center for Common Disease Genomics (UM1HG008895, Mark Daly, PI).\\n   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \\nIdentification of complex genetic variants including defects in gene regulatory circuits and uncharacterized genes present challenges for rare disease diagnosis. In Genomic Answers for Kids program we apply the joint interpretation of patient genome sequence with genomic endophenotypes to expand the clinically actionable genome among pediatric cases of suspected genetic disease. Our objective is to examine the role of novel and under-interpreted sequence variation by combining complete DNA sequences, personal epigenetic variations and massively parallel functional screens.\\n\\nTo achieve this we perform augmented whole genome sequence (WGS) interpretation including reanalysis of clinical exomes as well as generating WGS for patients with negative exome results all be subject to family-based semi-automated recall pipeline to discover missed diagnostic variation. We use linked-read and long-read sequencing technologies to focus on putative structural variants missed in short-read genome and exome analysis by the optimized integration of linked and long read technologies that also improve identification of transmission patterns of all variants, as well as resolving genomic regions resistant to standard alignment. We also include tissue DNA sequencing to investigate somatic mosaicism.\\n\\nTo further assist on WGS interpretation for uncommon variation we capture snapshots of patient transcriptomes and epigenomes in individual cells using single-cell RNA (scRNA) and sc open chromatin (scATAC) as well as bulk whole genome bisulphite genome sequencing for methylome interpretation. Alternative splicing is functionally assessed in available patient tissues using RNA-seq, including full length cDNA sequences by IsoSeq (PacBio) methodology.\\n\\nOur overarching goal is an increase rate of diagnostic genomic findings up to two-fold among rare disease, resulting in the majority (>50%) of patient cases resolved by the integrated system developed in our program.\\n   \n",
       "5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \\nIdentification of complex genetic variants including defects in gene regulatory circuits and uncharacterized genes present challenges for rare disease diagnosis. In Genomic Answers for Kids program we apply the joint interpretation of patient genome sequence with genomic endophenotypes to expand the clinically actionable genome among pediatric cases of suspected genetic disease. Our objective is to examine the role of novel and under-interpreted sequence variation by combining complete DNA sequences, personal epigenetic variations and massively parallel functional screens.\\n\\nTo achieve this we perform augmented whole genome sequence (WGS) interpretation including reanalysis of clinical exomes as well as generating WGS for patients with negative exome results all be subject to family-based semi-automated recall pipeline to discover missed diagnostic variation. We use linked-read and long-read sequencing technologies to focus on putative structural variants missed in short-read genome and exome analysis by the optimized integration of linked and long read technologies that also improve identification of transmission patterns of all variants, as well as resolving genomic regions resistant to standard alignment. We also include tissue DNA sequencing to investigate somatic mosaicism.\\n\\nTo further assist on WGS interpretation for uncommon variation we capture snapshots of patient transcriptomes and epigenomes in individual cells using single-cell RNA (scRNA) and sc open chromatin (scATAC) as well as bulk whole genome bisulphite genome sequencing for methylome interpretation. Alternative splicing is functionally assessed in available patient tissues using RNA-seq, including full length cDNA sequences by IsoSeq (PacBio) methodology.\\n\\nOur overarching goal is an increase rate of diagnostic genomic findings up to two-fold among rare disease, resulting in the majority (>50%) of patient cases resolved by the integrated system developed in our program.\\n   \n",
       "6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \\nIdentification of complex genetic variants including defects in gene regulatory circuits and uncharacterized genes present challenges for rare disease diagnosis. In Genomic Answers for Kids program we apply the joint interpretation of patient genome sequence with genomic endophenotypes to expand the clinically actionable genome among pediatric cases of suspected genetic disease. Our objective is to examine the role of novel and under-interpreted sequence variation by combining complete DNA sequences, personal epigenetic variations and massively parallel functional screens.\\n\\nTo achieve this we perform augmented whole genome sequence (WGS) interpretation including reanalysis of clinical exomes as well as generating WGS for patients with negative exome results all be subject to family-based semi-automated recall pipeline to discover missed diagnostic variation. We use linked-read and long-read sequencing technologies to focus on putative structural variants missed in short-read genome and exome analysis by the optimized integration of linked and long read technologies that also improve identification of transmission patterns of all variants, as well as resolving genomic regions resistant to standard alignment. We also include tissue DNA sequencing to investigate somatic mosaicism.\\n\\nTo further assist on WGS interpretation for uncommon variation we capture snapshots of patient transcriptomes and epigenomes in individual cells using single-cell RNA (scRNA) and sc open chromatin (scATAC) as well as bulk whole genome bisulphite genome sequencing for methylome interpretation. Alternative splicing is functionally assessed in available patient tissues using RNA-seq, including full length cDNA sequences by IsoSeq (PacBio) methodology.\\n\\nOur overarching goal is an increase rate of diagnostic genomic findings up to two-fold among rare disease, resulting in the majority (>50%) of patient cases resolved by the integrated system developed in our program.\\n   \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \\nIdentification of complex genetic variants including defects in gene regulatory circuits and uncharacterized genes present challenges for rare disease diagnosis. In Genomic Answers for Kids program we apply the joint interpretation of patient genome sequence with genomic endophenotypes to expand the clinically actionable genome among pediatric cases of suspected genetic disease. Our objective is to examine the role of novel and under-interpreted sequence variation by combining complete DNA sequences, personal epigenetic variations and massively parallel functional screens.\\n\\nTo achieve this we perform augmented whole genome sequence (WGS) interpretation including reanalysis of clinical exomes as well as generating WGS for patients with negative exome results all be subject to family-based semi-automated recall pipeline to discover missed diagnostic variation. We use linked-read and long-read sequencing technologies to focus on putative structural variants missed in short-read genome and exome analysis by the optimized integration of linked and long read technologies that also improve identification of transmission patterns of all variants, as well as resolving genomic regions resistant to standard alignment. We also include tissue DNA sequencing to investigate somatic mosaicism.\\n\\nTo further assist on WGS interpretation for uncommon variation we capture snapshots of patient transcriptomes and epigenomes in individual cells using single-cell RNA (scRNA) and sc open chromatin (scATAC) as well as bulk whole genome bisulphite genome sequencing for methylome interpretation. Alternative splicing is functionally assessed in available patient tissues using RNA-seq, including full length cDNA sequences by IsoSeq (PacBio) methodology.\\n\\nOur overarching goal is an increase rate of diagnostic genomic findings up to two-fold among rare disease, resulting in the majority (>50%) of patient cases resolved by the integrated system developed in our program.\\n   \n",
       "8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \\nIdentification of complex genetic variants including defects in gene regulatory circuits and uncharacterized genes present challenges for rare disease diagnosis. In Genomic Answers for Kids program we apply the joint interpretation of patient genome sequence with genomic endophenotypes to expand the clinically actionable genome among pediatric cases of suspected genetic disease. Our objective is to examine the role of novel and under-interpreted sequence variation by combining complete DNA sequences, personal epigenetic variations and massively parallel functional screens.\\n\\nTo achieve this we perform augmented whole genome sequence (WGS) interpretation including reanalysis of clinical exomes as well as generating WGS for patients with negative exome results all be subject to family-based semi-automated recall pipeline to discover missed diagnostic variation. We use linked-read and long-read sequencing technologies to focus on putative structural variants missed in short-read genome and exome analysis by the optimized integration of linked and long read technologies that also improve identification of transmission patterns of all variants, as well as resolving genomic regions resistant to standard alignment. We also include tissue DNA sequencing to investigate somatic mosaicism.\\n\\nTo further assist on WGS interpretation for uncommon variation we capture snapshots of patient transcriptomes and epigenomes in individual cells using single-cell RNA (scRNA) and sc open chromatin (scATAC) as well as bulk whole genome bisulphite genome sequencing for methylome interpretation. Alternative splicing is functionally assessed in available patient tissues using RNA-seq, including full length cDNA sequences by IsoSeq (PacBio) methodology.\\n\\nOur overarching goal is an increase rate of diagnostic genomic findings up to two-fold among rare disease, resulting in the majority (>50%) of patient cases resolved by the integrated system developed in our program.\\n   \n",
       "9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              \\nThe goal of this collaborative, interdisciplinary project is to develop powerful, generalizable approaches for discovering how risk variants for psychiatric disorders shape neurobiological processes at multiple levels of analysis, and to identify the processes whose dysregulation underlies disease.\\n\\nInduced pluripotent stem cells (iPSCs) were used towards the development of these new experimental and inferential systems bridging gaps between human genetics and experimental biology. The largest publicly available collection of iPSCs (2607 lines) has been generated from 2184 donors by the California Institute for Regenerative Medicine (CIRM). We wish to share the available SNP data for 2166 CIRM lines and whole genome sequence data generated at the Broad Institute for 299 of the CIRM iPSC donors. These data can be used to identify (for experiments) lines with specific genotypes of interest and lines from donors with high or low polygenic risk scores for phenotypes of interest. The data can also be used to identify acquired mutations in the iPSC lines. The CIRM iPSC lines are available through Fujifilm Cellular Dynamics iPSC Repository [[https://www.fujifilmcdi.com/cirm-ipsc-products/](https://www.fujifilmcdi.com/cirm-ipsc-products/)].\\n\\nAdditional project data registered with the study includes WGS data from an iPSC line derived from an SMA patient (n=1), as well as single-cell RNA sequence data and supplemental processed genomic datasets in support of project publications.\\n\\n**Molecular Datasets**\\n\\n  - **Whole Genome Genotyping**: Illumina HumanCore chip - **Whole Genome Sequencing**: Illumina Novaseq - **Single-Cell RNA-Seq**: 10X Genomics, Illumina Novaseq - **Supplemental \"cell village\" pooled genomic sequence data**: Illumina Nextseq  \\n   \n",
       "10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \\nThe goal of this collaborative, interdisciplinary project is to develop powerful, generalizable approaches for discovering how risk variants for psychiatric disorders shape neurobiological processes at multiple levels of analysis, and to identify the processes whose dysregulation underlies disease.\\n\\nInduced pluripotent stem cells (iPSCs) were used towards the development of these new experimental and inferential systems bridging gaps between human genetics and experimental biology. The largest publicly available collection of iPSCs (2607 lines) has been generated from 2184 donors by the California Institute for Regenerative Medicine (CIRM). We wish to share the available SNP data for 2166 CIRM lines and whole genome sequence data generated at the Broad Institute for 299 of the CIRM iPSC donors. These data can be used to identify (for experiments) lines with specific genotypes of interest and lines from donors with high or low polygenic risk scores for phenotypes of interest. The data can also be used to identify acquired mutations in the iPSC lines. The CIRM iPSC lines are available through Fujifilm Cellular Dynamics iPSC Repository [[https://www.fujifilmcdi.com/cirm-ipsc-products/](https://www.fujifilmcdi.com/cirm-ipsc-products/)].\\n\\nAdditional project data registered with the study includes WGS data from an iPSC line derived from an SMA patient (n=1), as well as single-cell RNA sequence data and supplemental processed genomic datasets in support of project publications.\\n\\n**Molecular Datasets**\\n\\n  - **Whole Genome Genotyping**: Illumina HumanCore chip - **Whole Genome Sequencing**: Illumina Novaseq - **Single-Cell RNA-Seq**: 10X Genomics, Illumina Novaseq - **Supplemental \"cell village\" pooled genomic sequence data**: Illumina Nextseq  \\n   \n",
       "11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \\nThe goal of this collaborative, interdisciplinary project is to develop powerful, generalizable approaches for discovering how risk variants for psychiatric disorders shape neurobiological processes at multiple levels of analysis, and to identify the processes whose dysregulation underlies disease.\\n\\nInduced pluripotent stem cells (iPSCs) were used towards the development of these new experimental and inferential systems bridging gaps between human genetics and experimental biology. The largest publicly available collection of iPSCs (2607 lines) has been generated from 2184 donors by the California Institute for Regenerative Medicine (CIRM). We wish to share the available SNP data for 2166 CIRM lines and whole genome sequence data generated at the Broad Institute for 299 of the CIRM iPSC donors. These data can be used to identify (for experiments) lines with specific genotypes of interest and lines from donors with high or low polygenic risk scores for phenotypes of interest. The data can also be used to identify acquired mutations in the iPSC lines. The CIRM iPSC lines are available through Fujifilm Cellular Dynamics iPSC Repository [[https://www.fujifilmcdi.com/cirm-ipsc-products/](https://www.fujifilmcdi.com/cirm-ipsc-products/)].\\n\\nAdditional project data registered with the study includes WGS data from an iPSC line derived from an SMA patient (n=1), as well as single-cell RNA sequence data and supplemental processed genomic datasets in support of project publications.\\n\\n**Molecular Datasets**\\n\\n  - **Whole Genome Genotyping**: Illumina HumanCore chip - **Whole Genome Sequencing**: Illumina Novaseq - **Single-Cell RNA-Seq**: 10X Genomics, Illumina Novaseq - **Supplemental \"cell village\" pooled genomic sequence data**: Illumina Nextseq  \\n   \n",
       "12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \\nThe goal of this collaborative, interdisciplinary project is to develop powerful, generalizable approaches for discovering how risk variants for psychiatric disorders shape neurobiological processes at multiple levels of analysis, and to identify the processes whose dysregulation underlies disease.\\n\\nInduced pluripotent stem cells (iPSCs) were used towards the development of these new experimental and inferential systems bridging gaps between human genetics and experimental biology. The largest publicly available collection of iPSCs (2607 lines) has been generated from 2184 donors by the California Institute for Regenerative Medicine (CIRM). We wish to share the available SNP data for 2166 CIRM lines and whole genome sequence data generated at the Broad Institute for 299 of the CIRM iPSC donors. These data can be used to identify (for experiments) lines with specific genotypes of interest and lines from donors with high or low polygenic risk scores for phenotypes of interest. The data can also be used to identify acquired mutations in the iPSC lines. The CIRM iPSC lines are available through Fujifilm Cellular Dynamics iPSC Repository [[https://www.fujifilmcdi.com/cirm-ipsc-products/](https://www.fujifilmcdi.com/cirm-ipsc-products/)].\\n\\nAdditional project data registered with the study includes WGS data from an iPSC line derived from an SMA patient (n=1), as well as single-cell RNA sequence data and supplemental processed genomic datasets in support of project publications.\\n\\n**Molecular Datasets**\\n\\n  - **Whole Genome Genotyping**: Illumina HumanCore chip - **Whole Genome Sequencing**: Illumina Novaseq - **Single-Cell RNA-Seq**: 10X Genomics, Illumina Novaseq - **Supplemental \"cell village\" pooled genomic sequence data**: Illumina Nextseq  \\n   \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                <p>The <i>North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing, 2 (NCGENES 2)</i> study is part of a larger consortium project investigating the clinical utility, or net benefit of an intervention on patient and family well-being as well as diagnostic efficacy, management planning, and medical outcomes. A clinical trial will be implemented to compare (1) first-line exome sequencing to usual care and (2) participant pre-visit preparation to no pre-visit preparation. The study will use a randomized controlled design, with 2x2 factorial design, coupled with patient-reported outcomes and comprehensive clinical data collection addressing key outcomes, to determine the net impact of diagnostic results and secondary findings.</p>   \n",
       "14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             <div>The CHARM (Cancer Health Assessment Reaching Many) study, part of the Clinical Sequencing Evidence-Generating Research (CS.ER2) effort, aimed to assess the utility of clinical exome sequencing and how it affects care in diverse populations. The study population included adults at risk for hereditary cancer syndromes. The primary objective was the implementation of a hereditary cancer risk assessment program in healthy 18-49 year-olds in primary care settings within a vertically integrated health delivery system (Kaiser Permanente) and a federal qualified health center (Denver Health). The investigators aimed to assess clinical exome sequencing implementation and interpretation, as well as tailored interactions for low health literacy including a contextualized consent process, and a modified approach to results disclosure and genetic counseling. The investigators were also assessing the clinical utility (healthcare utilization and adherence to recommended care) and personal utility of primary and additional results from clinical exome sequencing, and evaluate the ethical and policy implications of considering personal utility of genomic information decisions for health care coverage.Sequencing and analysis for CHARM was conducted at the Northwest Clinical Genomics Laboratory, University of Washington, Seattle (<a href=\"https://nwgc.gs.washington.edu/\" target=\"_blank\">https://nwgc.gs.washington.edu/</a>).</div><br>   \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        \\nSouthSeq, part of the Clinical Sequencing Evidence-Generating Research ([CSER2](https://www.genome.gov/Funded-Programs-Projects/Clinical-Sequencing-Evidence-Generating-Research-CSER2)) effort, aims to perform genome sequencing for infants in nurseries at hospitals in Alabama, Mississippi, Louisiana, and Kentucky. SouthSeq aims to sequence 600 newborn babies presenting with congenital anomalies, or other signs of a rare genetic disorder. The primary goals of SouthSeq are to provide early diagnoses to children with rare genetic conditions, to demonstrate the utility of genome sequencing as a frontline test with potential to improve intermediate and long-term clinical outcomes, and to equip non-genetics providers to deliver test results in order to facilitate the conduction of genome sequencing outside of major medical centers where patients may not have access to a genetics provider. SouthSeq also aims to ensure that genomic testing is applied across diverse communities; recruitment efforts focus on patients from rural and minority populations that have been historically under-represented in both medicine and genomics research.&nbsp;\\n\\nSequencing and analysis for SouthSeq are being conducted at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama ([https://www.hudsonalpha.org/](https://www.hudsonalpha.org/)). Enrollment of infants with signs of genetic disease is approved at five clinical sites, including nurseries at the University of Alabama at Birmingham, the University of Mississippi Medical Center, Woman's Hospital in Baton Rouge, Children's Hospital in New Orleans, and the University of Louisville. Both biological parents are enrolled when available so that follow-up testing can be performed to determine inheritance. Further, participant families may choose to opt-into return of secondary findings identified in the proband, which focus on pathogenic and likely pathogenic variation identified within ACMG SFv3.0 genes.\\n\\n   \n",
       "16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&#39;s Hospital Medical Center (CCHMC):**<br/> Cincinnati Children&#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &#62;261,000 consents that allow return of results to &#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&#39;s Hospital of Philadelphia (CHOP):**<br/> The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&#39;s Hospital of Philadelphia (CHOP), and one of the world&#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&#62;450,000), specifically from &#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&#62;12,000). Center for Applied Genomics, The Children&#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**<br/> The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**<br/> Samples and phenotype data in this study were provided by the Geisinger MyCode&#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**<br/> The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**<br/> KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**<br/> The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &#62;155 or &#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**<br/> Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**<br/> Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**<br/> Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: <table> |42025287|42137441|42412243|42456938|42456946|42672223\\n </table> \\n   \n",
       "17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&#39;s Hospital Medical Center (CCHMC):**<br/> Cincinnati Children&#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &#62;261,000 consents that allow return of results to &#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&#39;s Hospital of Philadelphia (CHOP):**<br/> The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&#39;s Hospital of Philadelphia (CHOP), and one of the world&#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&#62;450,000), specifically from &#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&#62;12,000). Center for Applied Genomics, The Children&#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**<br/> The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**<br/> Samples and phenotype data in this study were provided by the Geisinger MyCode&#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**<br/> The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**<br/> KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**<br/> The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &#62;155 or &#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**<br/> Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**<br/> Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**<br/> Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: <table> |42025287|42137441|42412243|42456938|42456946|42672223\\n </table> \\n   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&#39;s Hospital Medical Center (CCHMC):**<br/> Cincinnati Children&#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &#62;261,000 consents that allow return of results to &#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&#39;s Hospital of Philadelphia (CHOP):**<br/> The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&#39;s Hospital of Philadelphia (CHOP), and one of the world&#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&#62;450,000), specifically from &#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&#62;12,000). Center for Applied Genomics, The Children&#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**<br/> The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**<br/> Samples and phenotype data in this study were provided by the Geisinger MyCode&#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**<br/> The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**<br/> KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**<br/> The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &#62;155 or &#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**<br/> Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**<br/> Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**<br/> Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: <table> |42025287|42137441|42412243|42456938|42456946|42672223\\n </table> \\n   \n",
       "19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&#39;s Hospital Medical Center (CCHMC):**<br/> Cincinnati Children&#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &#62;261,000 consents that allow return of results to &#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&#39;s Hospital of Philadelphia (CHOP):**<br/> The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&#39;s Hospital of Philadelphia (CHOP), and one of the world&#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&#62;450,000), specifically from &#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&#62;12,000). Center for Applied Genomics, The Children&#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**<br/> The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**<br/> Samples and phenotype data in this study were provided by the Geisinger MyCode&#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**<br/> The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**<br/> KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**<br/> The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &#62;155 or &#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**<br/> Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**<br/> Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**<br/> Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: <table> |42025287|42137441|42412243|42456938|42456946|42672223\\n </table> \\n   \n",
       "20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&#39;s Hospital Medical Center (CCHMC):**<br/> Cincinnati Children&#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &#62;261,000 consents that allow return of results to &#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&#39;s Hospital of Philadelphia (CHOP):**<br/> The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&#39;s Hospital of Philadelphia (CHOP), and one of the world&#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&#62;450,000), specifically from &#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&#62;12,000). Center for Applied Genomics, The Children&#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**<br/> The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**<br/> Samples and phenotype data in this study were provided by the Geisinger MyCode&#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**<br/> The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**<br/> KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**<br/> The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &#62;155 or &#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**<br/> Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**<br/> Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**<br/> Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: <table> |42025287|42137441|42412243|42456938|42456946|42672223\\n </table> \\n   \n",
       "21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&#39;s Hospital Medical Center (CCHMC):**<br/> Cincinnati Children&#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &#62;261,000 consents that allow return of results to &#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&#39;s Hospital of Philadelphia (CHOP):**<br/> The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&#39;s Hospital of Philadelphia (CHOP), and one of the world&#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&#62;450,000), specifically from &#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&#62;12,000). Center for Applied Genomics, The Children&#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**<br/> The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**<br/> Samples and phenotype data in this study were provided by the Geisinger MyCode&#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**<br/> The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**<br/> KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**<br/> The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &#62;155 or &#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**<br/> Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**<br/> Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**<br/> Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: <table> |42025287|42137441|42412243|42456938|42456946|42672223\\n </table> \\n   \n",
       "22                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&#39;s Hospital Medical Center (CCHMC):**<br/> Cincinnati Children&#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &#62;261,000 consents that allow return of results to &#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&#39;s Hospital of Philadelphia (CHOP):**<br/> The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&#39;s Hospital of Philadelphia (CHOP), and one of the world&#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&#62;450,000), specifically from &#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&#62;12,000). Center for Applied Genomics, The Children&#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**<br/> The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**<br/> Samples and phenotype data in this study were provided by the Geisinger MyCode&#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**<br/> The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**<br/> KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**<br/> The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &#62;155 or &#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**<br/> Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**<br/> Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**<br/> Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: <table> |42025287|42137441|42412243|42456938|42456946|42672223\\n </table> \\n   \n",
       "23                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&#39;s Hospital Medical Center (CCHMC):**<br/> Cincinnati Children&#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &#62;261,000 consents that allow return of results to &#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&#39;s Hospital of Philadelphia (CHOP):**<br/> The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&#39;s Hospital of Philadelphia (CHOP), and one of the world&#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&#62;450,000), specifically from &#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&#62;12,000). Center for Applied Genomics, The Children&#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**<br/> The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**<br/> Samples and phenotype data in this study were provided by the Geisinger MyCode&#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**<br/> The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**<br/> KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**<br/> The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &#62;155 or &#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**<br/> Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**<br/> Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**<br/> Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: <table> |42025287|42137441|42412243|42456938|42456946|42672223\\n </table> \\n   \n",
       "24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&#39;s Hospital Medical Center (CCHMC):**<br/> Cincinnati Children&#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &#62;261,000 consents that allow return of results to &#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&#39;s Hospital of Philadelphia (CHOP):**<br/> The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&#39;s Hospital of Philadelphia (CHOP), and one of the world&#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&#62;450,000), specifically from &#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&#62;12,000). Center for Applied Genomics, The Children&#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**<br/> The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**<br/> Samples and phenotype data in this study were provided by the Geisinger MyCode&#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**<br/> The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**<br/> KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**<br/> The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &#62;155 or &#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**<br/> Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**<br/> Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**<br/> Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: <table> |42025287|42137441|42412243|42456938|42456946|42672223\\n </table> \\n   \n",
       "25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\nThe Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:  - ~24,000 eMERGE participants from 10 eMERGE III study sites. - Corresponding demographics, body mass index measurements. - Top PheWAS codes generated from a collated list of ICD codes from all study sites.  \\n\\nStudy sites and participants include:\\n\\n**Cincinnati Children&#39;s Hospital Medical Center (CCHMC):**<br/> Cincinnati Children&#39;s Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with &#62;261,000 consents that allow return of results to &#62;84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results. \\n\\n**Children&#39;s Hospital of Philadelphia (CHOP):**<br/> The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children&#39;s Hospital of Philadelphia (CHOP), and one of the world&#39;s largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n&#62;450,000), specifically from &#62;100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n&#62;12,000). Center for Applied Genomics, The Children&#39;s Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children&#39;s Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute&#39;s Electronic Medical Records and Genomics (eMERGE) program (U01HG008684). \\n\\n**Columbia University:**<br/> The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (&#60;1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.\\n\\n**Geisinger:**<br/> Samples and phenotype data in this study were provided by the Geisinger MyCode&#174; Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.\\n\\n**Partners Healthcare (Harvard University):**<br/> The Partners HealthCare Biobank is a large research program designed to help researchers understand how people&#39;s health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women&#39;s Hospital), the Biobank provides:  - Banked samples (plasma, serum, and DNA) collected from consented patients  - Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women&#39;s Hospital and Massachusetts General Hospital Pathology Departments  - Sample handling and preparation services - Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart - Data access through our research portal.  \\n\\nTo date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research. \\n\\n**Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):**<br/> KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA&#39;s integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants. \\n\\n**Mayo Clinic:**<br/> The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level &#62;155 or &#62;120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.\\n\\n**Northwestern University:**<br/> Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.\\n\\n**Vanderbilt University Medical Center:**<br/> Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years. \\n\\n**Meharry Medical College:**<br/> Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients&#39; health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.\\n\\nPlease note that this version of the dataset has a handful of mismatches between genotyped and provided sex. Data with the following IDs should be removed prior to analysis: <table> |42025287|42137441|42412243|42456938|42456946|42672223\\n </table> \\n   \n",
       "26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \n",
       "27  Data Release notes for the workspace\\n\\nUpdate: May 23, 2023\\n\\nFrom March 30, 2023 to May 9, 2023, the following files below were temporarily unavailable. As of May 9, 2023, these files have been restored. \\n\\nassembly_verkko_v1.2_trio.tar\\nm54329U_220829_095708-bc2050.5mc.hifi_reads.bam\\nm54329U_220107_233847-bc1016.5mc.hifi_reads.bam\\nm54329U_211230_014258-bc1010.5mc.hifi_reads.bam\\nm54329U_220117_123334-bc1012.5mc.hifi_reads.bam\\nm64076_220516_221911-bc2018.5mc.hifi_reads.bam\\nm64076_220518_191414-bc2018.5mc.hifi_reads.bam\\nm64076_220826_143529-bc2049.5mc.hifi_reads.bam\\nr54329U_20220901_220229_C01.reads.bam\\nr54329U_20220901_220229_D01.reads.bam\\nHG00621.GRCh38_no_alt.bam\\nHG01106.GRCh38_no_alt.bam\\nHG01109.CHM13Y_EBV.bam\\nHG01109.GRCh38_no_alt.bam\\nHG01978.CHM13Y_EBV.bam\\nHG02080.GRCh38_no_alt.bam\\nHG02486.GRCh38_no_alt.bam\\nHG02559.GRCh38_no_alt.bam\\nNA20129.GRCh38_no_alt.bam\\nNA21309.GRCh38_no_alt.bam\\n01_09_20_R941_GM24631_2.fast5.tar\\n01_09_20_R941_GM24631_3.fast5.tar\\nHG00733_1.fast5.tar.gz\\nHG00733_2.fast5.tar.gz\\nHG00733_3.fast5.tar.gz\\nm54329U_200615_084313.ccs.bam\\n\\n\\n# Human Pangenome Reference Consortium's AnVIL_HPRC Workspace\\n\\n![White Logo](https://s3-us-west-2.amazonaws.com/human-pangenomics/backup/logo-proof-full.png)\\n\\nThis workspace holds sequencing, assembly, and pangenome data submitted to the [Human Pangenome Reference Consortium](https://humanpangenome.org/). Data is stored in this workspace to allow immediate use by researchers participating in the Human Pangenome Project. Data in this workspace is constantly being added and updated and the workspace is under active development as our production pipeline continues. Note that the HPRC Year 1 data is pending publication, currently scheduled for march of 2022. If you would like to publish using this data please contact the HPRC Coordinating Center at hprcadmin@gowustl.onmicrosoft.com.\\n\\n### Data Table Organization\\n**Sequencing Data:** Sample Table <br/>\\n**Participant Information:** Participant Table <br/>\\n**Assemblies:** Assembly_Sample, Assembly_Annotation Tables <br/>\\n**Pangenomes:** Minigraph, Minigraph_CACTUS, PGGB Tables\\n\\n------------------\\n# Sequencing Data\\nProduction information about the HPRC Y1 samples is in the sections below. Note that samples from the HPRC_PLUS cohort had data assembled from other consortia, and the information in the sections below does not apply.\\n\\n## PacBio HiFi Data From UW and WashU\\nPacBio HiFi sequencing was performed on the Sequel2 instrument using v2 chemistry. Samples were sequenced across 3-5 flowcells in order to generate 35-fold coverage or greater. The average coverage for the year1 samples is >40X with a median insert size of 20kb. The following file types are listed in the table:\\n\\n* {flowcell_id}.ccs.bam - consensus called unaligned bam file\\n\\nConsensus sequences were generated with v4.0.0 of the CCS algorithm\\n\\n## Nanopore PromethION Data From UC Santa Cruz\\n\\nThe UCSC Nanopore PromethION HPP data were generated using the a new long read protocol (details to be published on protocols.io shortly). Briefly, this protocol uses Circulomics discs-based UHMW DNA isolation, followed by library preparation using ONT SQK-RAD004 kit and library cleanup using Circulomics discs. Typically, we used 3 RAD004-based sequencing libraries per PromethION flow cell (and 3 flow cells per individual). The observed read N50s (average) are ~80 kb, with 11x coverage in 100kb+ readsa dn 3x coverage in 200kb+ reads for each individual. The following file types are listed in the table:\\n\\n* sample_Guppy_4.0.11_prom.fastq.gz\\n\\n## Hi-C/Omni-C Data From UCSC\\nOmniC is a restriction enzyme-free HiC protocol. DNA is fragmented using an endonuclease that cuts DNA randomly, i.e., not at specific restriction sites. It uses a biotinylated linker to facilitate proximity ligation. This short linker sequence may be present within the read data. The architecture of an OmniC library molecule is:\\n\\nP5adapter:GenomicRegion:Linker:GenomicRegion:P7adapter\\n\\nDepending on the read length, some or all of the Linker sequence may be present in R1, R2, or both. When present, the Linker sequence is: AGGTTCGTCCATCGATCGATGGACGAACCT Note that the linker sequence is a DNA palindrome. Thus, the Linker sequence will be the same whether present in R1 or R2 (forward or reverse read).\\n\\nFor each HPRC sample, two OmniC libraries are generated and sequenced. Duplicates can be identified and removed within each library, but not between libraries as independent sample material goes into each. Libraries are sequenced across several Novaseq lanes, depending on lane availability, with 2x150 paired-end sequencing.\\n\\nThe raw fastq OmniC data can be aligned using bwa mem with flags -5SP In practice, bwa mem (local alignment) will not omit the Linker sequence from the alignment in cases when it is present in the read.\\n\\nThe following file types are available:\\n\\n* {library_name}.R1_001.fastq.gz - forward reads\\n* {library_name}.R2_001.fastq.gz - reverse reads\\n \\n## Bionano Data From Rockefeller\\nThe following file types are available:\\n\\n* {sample_name}_Saphyr_DLE1_3680591.bnx.gz - raw data view of molecule and label information and quality scores\\n* {sample_name}_Saphyr_DLE1_3680616.cmap - location information for label sites\\n\\nFor information about Bionano file specifications or utilization of Bionano files see Bionano's website.\\n\\n## Strand-seq Data From EMBL\\nStrand-seq is a single-cell sequencing technology that resolves individual homologs within a cell by restricting sequence analysis to the DNA template strands used during DNA replication (see Sanders, et al.). Each sample has 192 fastq.gz files available -- from paired-end sequencing of 96 single cells (nuclei).\\n\\n## Trio Illumina Data From NYGC\\nWhen available, we have included high coverage (30X) Illumina datasets produced by NYGC for select 1000G samples. Information about this dataset can be found at [IGSR](https://www.internationalgenome.org/data-portal/data-collection/30x-grch38).\\n\\nNote that the data is stored in CRAM format (aligned to GRCHh38), but is placed in the raw_data area for each sample as the consortium uses the raw reads from the CRAMs. When used in assembly pipelines, the [extract_reads.wdl](https://github.com/human-pangenomics/hpp_production_workflows/blob/master/QC/wdl/tasks/extract_reads.wdl) is used to call samtools fastq to convert the reads to fastq format.\\n\\n\\n------------------\\n# Assemblies\\n\\nThe **assembly_sample** holds assemblies from year 1 data. Assemblies from 47 samples have been uploaded to Genbank and released. Genbank accessions can be found [here](https://github.com/human-pangenomics/HPP_Year1_Assemblies/blob/main/genbank_changes/y1_genbank_assembly_accession_ids.txt). The table has columns for maternal and paternal fastas alongside columns for each assembly aligned to both CHM13 and GRCh38. The **assembly_annotation** table holds annotation files for the assemblies found in the **assembly_sample** table.\\n\\nFor more information about the assembly process see the [Y1 Assembly GitHub repo](https://github.com/human-pangenomics/HPP_Year1_Assemblies)\\n## Assembly Metrics\\n**Select metrics from the [automated assembly QC]() are shown below**\\n\\n### QV\\n![QV](https://github.com/human-pangenomics/HPP_Year1_Assemblies/blob/main/automated_qc_results/Y1_assemblies_v2_genbank_QV.png?raw=true)\\n\\n### N50\\n![N50](https://github.com/human-pangenomics/HPP_Year1_Assemblies/blob/main/automated_qc_results/Y1_assemblies_v2_genbank_N50.png?raw=true)\\n\\n### Hamming Error Rate\\n![Hamming](https://github.com/human-pangenomics/HPP_Year1_Assemblies/blob/main/automated_qc_results/Y1_assemblies_v2_genbank_hamming.png?raw=true)\\n\\n### Switch Error Rate\\n![Switch](https://github.com/human-pangenomics/HPP_Year1_Assemblies/blob/main/automated_qc_results/Y1_assemblies_v2_genbank_switch.png?raw=true)\\n\\n------------------\\n\\n# Pangenomes\\nPangenomes are available from three different strategies summarized in the table (and relevant sections) below:\\n\\n| <sub> </sub> | <sub>**Minigraph**</sub> | <sub>**Minigraph-Cactus**</sub> | <sub>**PGGB**</sub> |\\n| :-------- | :-------- | :------ | :------ |\\n| <sub> sequence comparison </sub> | <sub> reference-based, progressive </sub> | <sub> reference-based, progressive </sub> | <sub> symmetric, all-vs-all </sub> |\\n| <sub> resolution </sub> | <sub> SV only </sub> | <sub> base-level (via abPOA) </sub> | <sub> base-level (via abPOA) </sub> |\\n| <sub> scope </sub> | <sub> full assemblies </sub> | <sub> Non-centromeric </sub> | <sub> full assemblies </sub> |\\n| <sub> cyclic paths </sub> | <sub> no </sub> | <sub> non-reference </sub> | <sub> all </sub> |\\n| <sub> short read mapping </sub> | <sub> untested </sub> | <sub> yes (fast) </sub> | <sub> untested </sub> |\\n| <sub> long read mapping </sub> | <sub> yes (fastest) </sub> | <sub> yes </sub> | <sub> yes (slowest) </sub> |\\n| <sub> Assembly mapping </sub> | <sub> yes (direct) </sub> | <sub> untested </sub> | <sub> yes (via injection) </sub> |\\n\\n\\n### Assembly Inputs\\n\\nThe assemblies in the **assembly_sample** table were used as inputs to graph building pipelines. Of the 47 samples assembled (94 assemblies) in year 1, all but three samples were included in graph constructions (HG002, HG005 and NA19240 were excluded for evaluation purposes). GRCh38 and CHM13 were added to make the total number of haplotypes included 90.\\n\\n\\n## Graphs\\n### Minigraph\\n\\n[Minigraph](https://github.com/lh3/minigraph) is a generalization of minimap2 (very fast) which builds the graph with iterative construction. Minigraph aligns with approximate locations and can be used to call structural variants (>50nt). Graphs were built with both GRCh38 and CHM13+Y (found [here](https://s3-us-west-2.amazonaws.com/human-pangenomics/pangenomes/freeze/freeze1/minigraph/CHM13v11Y.fa.gz)) used as reference sequences.\\n\\nGraphs and associated files are available in the **minigraph** table.\\n\\n### Minigraph/CACTUS\\n\\n[The CACTUS pangenome pipeline](https://github.com/ComparativeGenomicsToolkit/cactus/blob/master/doc/pangenome.md) adds base-level alignments to the minigraph graphs above (so both GRCh38- and CHM13-based graphs are available). Centromeric regions are removed during  Minigraph/CACTUS graph creation.\\n\\nGraphs and associated files are available in the **minigraph_cactus** table.\\n\\nThe graphs are available in gfa format alongside other graph and index files. Information about the associated file formats can be found:\\n* graph formats: [xg/gg](https://github.com/vgteam/vg/wiki/Index-Types)\\n* index formats: [gbwt/dist/min](https://github.com/vgteam/vg/wiki/Index-Types)\\n* snarls format: [snarls](https://github.com/vgteam/vg/wiki/Index-Construction)\\n\\n#### Filtered Graphs\\nThe [Giraffe](https://www.biorxiv.org/content/10.1101/2020.12.04.412486v2.abstract) short read mapper relies on the graph's snarl decomposition.  The versions of the Cactus/Minigraph graphs released here contain some spurious large deletion edges that make this decomposition less efficient, which impacts Giraffe *runtime*. Furthermore, we have found that for calling small variants with the Giraffe-[DeepVariant](https://doi.org/10.1038/nbt.4235) pipeline, *accuracy* is improved if all alleles with frequency < 10% are removed from the graph before indexing.  Two filtered versions of each of the two Minigraph/Cactus graphs are available. The graphs with `maxdel.10mb` in the name (recommended to speed up general mapping experiments) were created by removing edges that imply deletions > 10mb, and the graphs with `minaf.0.1` in the name (recommended when using with DeepVariant) were created by removing, in addition to the deletions, nodes that are covered by fewer than 9 haplotypes.\\n\\n### PGGB\\n\\nThe Pangenome Graph Builder pipeline ([PGGB](https://github.com/pangenome/pggb)) creates and all-vs-all graph with base-level alignments and no clipping of mitochondrial or centromeric regions.\\n\\nThe graph files can be found in the **pggb** table\\n\\n\\n\\n\\n\\n\\n\\n\\nTo view currently available sequencing data, navigate to the DATA tab of this workspace to view data stored in the \"sample\" data table. In-progress assembiles can also be found in the \"sample_assembly\" table. These assemblies were generated with Hifiasm v0.14.\\n\\nData can also be accessed from our [S3 Bucket](https://s3-us-west-2.amazonaws.com/human-pangenomics/index.html?prefix=working/) without egress fees. Information about the currently available data can be found on our [GitHub page](https://github.com/human-pangenomics/HPP_Year1_Data_Freeze_v1.0).\\n\\n------------------\\n\\n### Data Use Policy\\n\\nPublication Protocol  V1.0 | April 7, 2020\\n\\nThe goal of the HPRC publication policy is to encourage collaboration and coordination among investigators while ensuring the timely release of research to the scientific community.  The document provides general guidelines and a description of the process for disclosure of planned publications within the consortium through submission.  This policy will be drafted and updated by the HPRC Administration and Coordination Working Group and approved by the HPRC steering committee.\\n\\n**General Guidelines**\\n* This policy applies to all manuscripts resulting from HPRC funded activities.\\n* It is the responsibility of the HPRC members to take steps necessary to protect any intellectual property rights.\\n* Any publication must comply with the NIH Public Access policy and authors should make efforts to publish their work using open access policies when possible.\\n* Individual investigators funded under the HPRC may separately or collaboratively publish the results of their own work.\\n* Investigators within HPRC who have similar work are encouraged to work together on publications.\\n* A manuscript tracking sheet will be used to share information about planned manuscripts.\\n * Entries in the manuscript tracking sheet are the responsibility of the corresponding author.\\n * The Information requested in the manuscript tracking sheet will include the following:  Authors, Title, Status, Potential overlap with other HPRC Publications, Submission Date, Journal, Publication Date, Preprint Submission Link, PMCI Number\\n * The Manuscript Tracking Sheet is available through the HPRC WIKI.\\n\\n**Internal Sharing of Planned Manuscripts**\\n* Investigators shall notify the Steering Committee of any publication using HPRC data or analysis that may impinge on planned integrative data analysis by the consortium, so that the potential impact of the pending publication can be discussed.\\n* Investigators are encouraged to enter information into the tracking system as early in the process as possible to enable collaboration and minimize overlap\\n* Information about manuscripts shared internally within the HPRC will be treated as confidential and may not be shared. \\n* HPRC members are encouraged to sharing information about publications related to the Human Reference even if not directly funded by the HPRC.\\n\\n**External Sharing of Submitted Manuscripts**\\n * When applicable pre-prints of submitted manuscripts must be shared via the appropriate pre-print server prior to or concurrently with the time of submission to a journal.\\n * Pre-prints are considered publications and should be cited like papers. \\n\\n**Resolution of Disagreements**\\n\\nIf questions or disagreements arise between investigators they should work to resolve them together.  If a mutually agreeable solution cannot be attained then the investigators may petition the Steering Committee to help resolve the situation.  The decision of the Steering Committee will be final and all parties agree to abide by their decision.\\n\\n------------------\\n\\n### More Materials\\n\\nGeneral Reference:\\n* Human Pangenome Reference Consortium Homepage: [link](https://humanpangenome.org/).\\n* Wiki (Login Required): [link](http://wiki.humanpangenome.org/index.php/Main_Page)\\n\\nData Storage (Subject To Change):\\n* This Workspace: [link](https://app.terra.bio/#workspaces/anvil-datastorage/AnVIL_HPRC)\\n* S3 Bucket: [link](https://s3-us-west-2.amazonaws.com/human-pangenomics/index.html?prefix=submissions/).\\n\\nGitHub Repositories:\\n* Production Workflows: [link](https://github.com/human-pangenomics/hpp_production_workflows).\\n* Dockstore Site: [link](https://dockstore.org/organizations/HumanPangenome).\\n* Y1 Data Freeze: [link](https://github.com/human-pangenomics/HPP_Year1_Data_Freeze_v1.0)\\n* Y1 Assemblies: [link](https://github.com/human-pangenomics/HPP_Year1_Assemblies)\\n* Pangenome Resources: [link](https://github.com/human-pangenomics/hpp_pangenome_resources)\\n\\n------------------\\n\\nWorkspace contact email: juklucas@ucsc.edu\\n\\nProject Name: Human Pangenome Reference \\n\\nData permissions: Open Access\\n   \n",
       "28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \\nThe Multiethnic Cohort (MEC) has established a large biorepository of blood and urine (N=67,000) and cryopreserved lymphocytes (N=15,000) linked to extensive, prospectively collected risk factors (e.g., diet, smoking, physical activity), biomarkers and clinical data for five racial/ethnic groups. This cohort study of over 215,000 men and women in Hawaii and California is unique in that it is population-based and includes large representations of older adults (45-75 yrs at baseline) for five US racial/ethnic groups (Japanese Americans, African Americans, European Americans, Latinos and Native Hawaiians) at varying risks of chronic diseases. Within the PAGE investigation, the MEC proposes to study: 1) diseases for which we have DNA available for large numbers of cases and controls (breast, prostate, and colorectal cancer, diabetes, and obesity); 2) important cancers that are less common (e.g., lung, pancreas, endometrial cancers, NHL) but for which we propose to pool our data with other funded groups; 3) common traits that are risk factors for these diseases (e.g., body mass index/weight, waist-to-hip ratio, height) and 4) relevant disease-associated biomarkers (e.g., fasting insulin and lipids, steroid hormones). The specific aims are: 1) To determine the population-based epidemiologic profile (allele frequency, main effect, heterogeneity by disease characteristics) of putative causal variants in the five racial/ethnic groups in the MEC; 2) for variants displaying effect heterogeneity across ethnic/racial groups, we will utilize differences in LD to identify a more complete spectrum of associated variants at these loci; 3) investigate gene x gene and gene x environment interactions to identify modifiers; 4) examine the associations of putative causal variants with already measured intermediate phenotypes (e.g., plasma insulin, lipids, steroid hormones); and 5) for variants that do not fall within known genes, start to investigate their relationships with gene expression and epigenetic patterns in small genomic studies.\\n\\nThis study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study [phs000356](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000356).\\n   \n",
       "29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \\nThis substudy phs000227 PAGE WHI contains genotypes generated using BeadXpress and Metabochip, produced as part of NHGRI&#39;s PAGE project. Summary level phenotypes for the WHI Cohort study participants can be viewed at the top-level study page [phs000200](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200) WHI Cohort. Individual level phenotype data and molecular data for all WHI top-level study and substudies are available by requesting Authorized Access to the WHI Cohort study [phs000200](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200). \\n\\n**WHI**<br/> The Women&#39;s Health Initiative (WHI) is a long-term national health study that has focused on strategies for preventing heart disease, breast and colorectal cancer and osteoporotic fractures in postmenopausal women. These chronic diseases are the major causes of death, disability and frailty in older women of all races and socioeconomic backgrounds.\\n\\nThis cohort is sponsored by the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), involves 161,808 women aged 50-79, and is one of the most definitive, far-reaching clinical trials of post-menopausal women&#39;s health ever undertaken in the U.S. Women were recruited between 1993 to 1998 at 40 centers across the US and follow up is planned to continue until at least 2015. The WHI Clinical Trial and Observational Study focused on many of the inequities in women&#39;s health research and will continue to provide practical information to women and their physicians about hormone therapy, dietary patterns, calcium/vitamin D supplementation, and their effects on the prevention of heart disease, cancer and osteoporotic fractures.\\n\\nThe WHI has two major parts: a randomized Clinical Trial and an Observational Study. The randomized controlled Clinical Trial (CT) enrolled 68,132 postmenopausal women between the ages of 50-79 into trials testing three prevention strategies. If eligible, women could choose to enroll in one, two, or all three of the trial components. The components are:  - **Hormone Therapy Trials (HT)**: This component examined the effects of combined hormones or estrogen alone on the prevention of coronary heart disease and osteoporotic fractures, and associated risk for breast cancer. Women participating in this component took hormone pills or a placebo (inactive pill) until the Estrogen plus Progestin and Estrogen Alone trials were stopped early in July 2002 and March 2004, respectively. All HT participants continued to be followed without intervention until close-out. - **Dietary Modification Trial (DM)**: The Dietary Modification component evaluated the effect of a low-fat and high fruit, vegetable and grain diet on the prevention of breast and colorectal cancers and coronary heart disease. Study participants followed either their usual eating pattern or a low-fat dietary pattern. - **Calcium/Vitamin D Trial (CaD)**: This component began 1 to 2 years after a woman joined one or both of the other clinical trial components. It evaluated the effect of calcium and vitamin D supplementation on the prevention of osteoporotic fractures and colorectal cancer. Women in this component took calcium and vitamin D pills or a placebo.  \\n\\nThe **Observational Study (OS)** is examining the relationship between lifestyle, health and risk factors and specific disease outcomes. This component involves tracking the medical history and health habits of 93,676 women.\\n\\nTo fully examine the profile of gene and environment interaction, or \"epidemiologic architecture,\" we will comprehensively evaluate such putative genuine variants in the Women&#39;s Health Initiative This large study population not only enables us to examine the population incidence for racial and ethnic subgroups and associated risks of rigorously defined, incident diseases (specific aim 1) but allows us to investigate associated risks given in-depth information on various environmental exposures and disease risk factors as well as three randomized interventions (hormone therapy; low-fat dietary modification; calcium + vitamin D supplements) (specific aim 2). The prospective and longitudinal collection of biospecimens, intermediate outcomes, and phenotypic characteristics, such as bone mineral density, hormone concentrations, breast density, or inflammation will further permit us to link genetic variants to relevant intermediate phenotypes, which will potentially provide important clues to the biological basis of the genuine associations (specific aim 3). For a variety of outcomes we will genotype within this 4-year project 72,000 participants for disease-specific putative genuine variants. Information generated from this study will be critical to determine the health impact of any given undisputable variant. Findings may also provide valuable insights into disease pathways and mechanisms, and targets for disease screening, prevention, and treatment.\\n\\nThis study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study ([phs000356](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000356)).\\n   \n",
       "30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \\nThe Institute for Personalized Medicine (IPM) Bio*Me* Biobank is a consented, EMR-linked medical care setting biorepository of the Mount Sinai Medical Center (MSMC) drawing from a population of over 70,000 inpatients and 800,000 outpatient visits annually. MSMC serves diverse local communities of upper Manhattan, including Central Harlem (86% African American), East Harlem (88% Hispanic Latino), and Upper East Side (88% Caucasian/white) with broad health disparities. IPM Bio*Me* Biobank populations include 28% African American, 38% Hispanic Latino predominantly of Caribbean origin, 23% Caucasian/White. IPM BioMe Biobank disease burden is reflective of health disparities with broad public health impact. Biobank operations are fully integrated in clinical care processes, including direct recruitment from clinical sites waiting areas and phlebotomy stations by dedicated Biobank recruiters independent of clinical care providers, prior to or following a clinician standard of care visit. Recruitment currently occurs at a broad spectrum of over 30 clinical care sites.\\n\\nThis study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study ([phs000356](http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bihttps://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000356.v1.p1)). \\n   \n",
       "31                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \\nStanford contributed samples to the PAGE study that can act as a population reference dataset across the globe. Therefore this dataset includes reference individuals, without phenotypes, chosen to help infer ancestry that will help us understand the diverse samples available in PAGE. The complete dataset comprises individuals of European, African, Asian, Oceanian, and Native American descent, from a total of over 50 populations. A subset of these individuals from Puno, Peru and Easter Island (Rapa Nui), Chile, are included in the PAGE samples that were whole genome sequenced in 2015. Additional details are available in the Study Acknowledgments.\\n\\nThe Global Reference Panel comprises 6 sample sets: - A population sample of Andean individuals primarily of Quechuan/Aymaran ancestry from Puno, Peru - A population sample of Easter Island (Rapa Nui), Chile - Individuals of indigenous origin from Oaxaca, Mexico - Individuals of indigenous origin from Honduras - Individuals of indigenous origin from Colombia - Individuals of indigenous origin from the Nama and Khomani KhoeSan populations of the Northern Cape, South Africa \\n\\nIn addition, we genotyped publicly available samples that will be hosted on the Bustamante lab website ([https://bustamantelab.stanford.edu/](https://bustamantelab.stanford.edu/)). These comprise large public datasets to provide an open reference dataset for the world:\\n\\n - The additional related individuals from the Americas in the Human Genome Diversity Panel (H952) plus all additional samples from the Americas - A subset of the unrelated individuals from the Maasai in Kinyawa, Kenya (MKK) dataset from the International Hapmap Project hosted at Coriell \\n\\nAdditional samples will be available for restricted use with a data access agreement with the Bustamante Lab.\\n\\nThis study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study ([phs000356](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000356)). \\n   \n",
       "32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \n",
       "33                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             # Telomere-to-Telomere (T2T) Consortium's AnVIL_T2T Workspace\\n\\n<p align=\"center\"><img src=\"https://schatz-lab.org/images/t2tlogo.png\" width=\"50%\"></p>\\n\\n\\nThe [Telomere-to-Telomere (T2T) consortium](https://sites.google.com/ucsc.edu/t2tworkinggroup) is an open, community-based effort to de novo assemble the first complete reference human genome from the CHM13 hydatidiform mole. Using a combination of PacBio HiFi sequencing and Oxford Nanopore ultra long reads, the recently released CHM13v1 reference genome is nearly perfect, with an estimated sequence accuracy exceeding QV70 and only 5 rRNA arrays left unresolved. The genome includes more than 100 Mbp of novel sequence compared to GRCh38, corrects many structural errors in the GRCh38 reference genome, and unlocks the most complex regions of the genome to clinical and functional study for the first time.\\n\\n### Currently Available Data\\nHere we use the T2T-CHM13 reference genome to investigate how it improves variant calling for individual samples, trios, and population-scale analysis. This includes 17 samples from diverse ethnicities sequenced with long reads that we analyze for SNVs, indels and structural variants using PEPPER-Margin-DeepVariant and Sniffles, along with all 3,202 short-read samples from the recently extended 1000 Genomes Project collection that we analyze using the GATK HaplotypeCaller for SNVs and indels on the NHGRI AnVIL Cloud Platform. We demonstrate that the CHM13 reference improves read mapping and variant calling across all samples in a number of major ways:\\n1. Adds over 80 million base pairs of sequence that can be effectively used for variant calling with long reads\\n2. Eliminates false positive variant calls in functional and medically relevant genes such as MAP2K3 and ZNF717 by adding sequences not present in GRCh38\\n3. Corrects missed variants related to false duplications in GRCh38, including within genes like CBS and KCNE1\\n4. Improves structural variant analysis, especially the balance of large insertion and deletion structural variant calls, by correcting collapsed tandem repeats in GRCh38\\n5. Reduces the rate of false de novo mutations and Mendelian violations found among trios\\n\\nFor more information, see the paper:\\n\\n[A complete reference genome improves analysis of human genetic variation](https://doi.org/10.1101/2021.07.12.452063)<br>\\nAganezov, S*, Yan, SM*, Soto, DC*, Kirsche, M*, Zarate, S*, Avdeyev, P, Taylor, DJ, Shafin, K, Shumate, A, Xiao, C, Wagner, J, McDaniel, J, Olson, ND, Sauria, MEG, Vollger, MR, Rhie, A, Meredith, M, Martin, S, Lee, J, Koren, S, Rosenfeld, J, Paten, B, Layer, R, Chin, CS, Sedlazeck, FJ, Hansen, NF, Miller, DE, Phillippy, AM, Miga, KM, McCoy, RC, Dennis, MY, Zook, JW, Schatz, MC (2021) bioRxiv doi: https://doi.org/10.1101/2021.07.12.452063\\n   \n",
       "\n",
       "                                dataTypes                                  phenotypeIndication        species              piName                    piEmail                                                               piInstitution                                                           dataCustodianEmail            dbGaPPhsID                                               dbGaPStudyRegistrationName                                          embargoReleaseDate           nihICsSupportingStudy            nihProgramOfficerName nihGenomicProgramAdministratorName        consortium        consentGroups.consentCode numberOfParticipants  dataLocation                                  url                                        consentGroups.fileTypes.fileType      \n",
       "0                                                                   []                 Unspecified  Homo sapiens                                                  None                                                                                                                  None   help@lists.anvilproject.org                   TBD                                                                                                         None        None                                              None                 None                          None                           CCDG                   TBD             None          TDR Location  https://data.terra.bio/snapshots/fc513b58-cfb7-4871-8694-8dc372fc2e10                                     [TBD]  \n",
       "1                                                [Raw Sequencing data]                    epilepsy  Homo sapiens                         NA                       None                                                                                                                  None    ccusick@broadinstitute.org                  None                                                                                                         None        None                                              None                 None                          None                           CCDG                   GRU             None          TDR Location  https://data.terra.bio/snapshots/a1dcd80f-6390-489a-a34a-168f26690a36                                   [Exome]  \n",
       "2                                              [Genotyping Array data]  inflammatory bowel disease  Homo sapiens             Mark Daly, PhD                       None                                                                               The Broad Institute, Cambridge, MA, USA     curley@broadinstitute.org             phs001642  Center for Common Disease Genomics [CCDG] - Autoimmune: Inflammatory Bowel Disease (IBD) Exomes and Genomes        none          National Human Genome Research Institute     Felsenfeld, Adam         Strasburger, Jennifer                           CCDG                   TBD                1          TDR Location  https://data.terra.bio/snapshots/e91ccc70-2772-46d8-b586-cf3e270a05b5                        [Genotyping Array]  \n",
       "3                                       [SNP/CNV Genotypes (NGS), WXS]           Autistic Disorder  Homo sapiens                 Daly, Mark  mjdaly@broadinstitute.org                              MASSACHUSETTS INSTITUTE OF TECHNOLOGYBROAD INSTITUTE, INC.MASSACHUSETTS GENERAL HOSPITAL                          None             phs000298                                                                           Autism Sequencing Consortium (ASC)        none               National Institute of Mental Health      Senthil, Geetha               Farber, Gregory                           CCDG                  None                1          TDR Location  https://data.terra.bio/snapshots/6fdea8c7-69d9-466e-9fa2-aca30722ff68                                      None  \n",
       "4                                                                   []           pediatric disease  Homo sapiens      Tomi Pastinen MD, PhD                       None                                                                       Children's Mercy Hospital, Kansas City, MO, USA             tpastinen@cmh.edu             phs002206                                                                              Genomic Answers for Kids (GA4K)        none          National Human Genome Research Institute                 None         Strasburger, Jennifer                            CMH           DS-PEDD-IRB                1          TDR Location  https://data.terra.bio/snapshots/02d25240-823f-4b1d-8562-95385716a453                            [Whole Genome]  \n",
       "5                                                                   []           pediatric disease  Homo sapiens      Tomi Pastinen MD, PhD                       None                                                                       Children's Mercy Hospital, Kansas City, MO, USA   help@lists.anvilproject.org             phs002206                                                                              Genomic Answers for Kids (GA4K)        none          National Human Genome Research Institute                 None         Strasburger, Jennifer                            CMH           DS-PEDD-IRB                1          TDR Location  https://data.terra.bio/snapshots/99b46287-4790-492c-8a12-bea33f0f927c                                     [TBD]  \n",
       "6                                                                   []           pediatric disease  Homo sapiens      Tomi Pastinen MD, PhD                       None                                                                       Children's Mercy Hospital, Kansas City, MO, USA   help@lists.anvilproject.org             phs002206                                                                              Genomic Answers for Kids (GA4K)        none          National Human Genome Research Institute                 None         Strasburger, Jennifer                            CMH           DS-PEDD-IRB                1          TDR Location  https://data.terra.bio/snapshots/c6ef5822-3929-4ae7-b5bc-dc27528bf226                                     [TBD]  \n",
       "7                                                                   []           pediatric disease  Homo sapiens      Tomi Pastinen MD, PhD                       None                                                                       Children's Mercy Hospital, Kansas City, MO, USA   help@lists.anvilproject.org             phs002206                                                                              Genomic Answers for Kids (GA4K)        none          National Human Genome Research Institute                 None         Strasburger, Jennifer                            CMH           DS-PEDD-IRB                1          TDR Location  https://data.terra.bio/snapshots/08d19a7e-b868-4766-9f7e-d879d972cbd7                                     [TBD]  \n",
       "8                                                                   []    Genetic Diseases, Inborn  Homo sapiens      Tomi Pastinen MD, PhD                       None                                                                       Children's Mercy Hospital, Kansas City, MO, USA             tpastinen@cmh.edu             phs002206                                                                              Genomic Answers for Kids (GA4K)        none          National Human Genome Research Institute                 None         Strasburger, Jennifer                            CMH                  None                1          TDR Location  https://data.terra.bio/snapshots/1974a21b-c409-4736-a3d7-e195fa96c4eb                  [Whole Long-read Genome]  \n",
       "9                                                [Raw Sequencing data]     spinal muscular atrophy  Homo sapiens            Steve McCarroll                       None                                                                                                                  None   help@lists.anvilproject.org             phs002032                                  Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes        none               National Institute of Mental Health    Pevsner, Jonathan               Farber, Gregory        Convergent Neuroscience            DS-SMA-MDS                1          TDR Location  https://data.terra.bio/snapshots/8fd5b447-77b6-4c33-b66a-a5cc63587220                            [Whole Genome]  \n",
       "10                                                                  []                 Unspecified  Homo sapiens                                                  None                                                                                                                  None   help@lists.anvilproject.org             phs002032                                  Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes        none               National Institute of Mental Health    Pevsner, Jonathan               Farber, Gregory        Convergent Neuroscience                   GRU                1          TDR Location  https://data.terra.bio/snapshots/aa2bfacc-c28c-4192-960c-b1389cf68516                                     [TBD]  \n",
       "11                                             ['Raw Sequencing data']        CIRM iPSC Repository  Homo sapiens            Steve McCarroll                       None                                                                                                                  None   help@lists.anvilproject.org             phs002032                                  Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes        none               National Institute of Mental Health    Pevsner, Jonathan               Farber, Gregory        Convergent Neuroscience                   GRU                1          TDR Location  https://data.terra.bio/snapshots/44b1f60b-e74c-4430-9378-d4a75e2de72f  [Single Cell RNAseq, Pooled Genomic Seq]  \n",
       "12                                               [Raw Sequencing data]                         N/A  Homo sapiens            Steve McCarroll                       None                                                                                                                  None   help@lists.anvilproject.org             phs002032                                  Genetic Neuroscience: How Human Genes and Alleles Shape Neuronal Phenotypes        none               National Institute of Mental Health    Pevsner, Jonathan               Farber, Gregory        Convergent Neuroscience                    NA                1          TDR Location  https://data.terra.bio/snapshots/5b036d13-e058-4d8d-be91-6fdd070686a7                            [Whole Genome]  \n",
       "13  [Simple Nucleotide Variation (SNVs), Raw Sequencing Data, Surveys]  Suspected Genetic Disorder  Homo sapiens  Jonathan S. Berg, MD, PhD                       None                                                     University of North Carolina at Chapel Hill, Chapel Hill, NC, USA   help@lists.anvilproject.org             phs002110                              CSER: North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing 2        none                                           [NHGRI]      Hindorff, Lucia         Strasburger, Jennifer                           CSER                   GRU               45          TDR Location  https://data.terra.bio/snapshots/0a356156-961d-4829-b9b5-c07fbc73dacc                             [Whole Exome]  \n",
       "14  [Simple Nucleotide Variation (SNVs), Raw Sequencing Data, Surveys]      Hereditary Cancer Risk  Homo sapiens                Michael Leo                       None                                                                                                                  None   help@lists.anvilproject.org             phs002111                                         CSER: Exome Sequencing in Diverse Populations in Colorado and Oregon        none                                           [NHGRI]      Hindorff, Lucia         Strasburger, Jennifer                           CSER                   GRU              880          TDR Location  https://data.terra.bio/snapshots/e43974fd-cee1-4d8c-a436-6846d7d24129                             [Whole Exome]  \n",
       "15  [Simple Nucleotide Variation (SNVs), Raw Sequencing Data, Surveys]  Suspected Genetic Disorder  Homo sapiens          Gregory M. Cooper                       None                                                                                                                  None   help@lists.anvilproject.org             phs002307                                           CSER: South-Seq: DNA Sequencing for Newborn Nurseries in the South        none          National Human Genome Research Institute      Hindorff, Lucia         Strasburger, Jennifer                           CSER                   GRU                1          TDR Location  https://data.terra.bio/snapshots/4c8ce027-8094-4f5d-bf62-22b1d51b3c1e                            [Whole Genome]  \n",
       "16                                               [Raw Sequencing data]          precision medicine  Homo sapiens              Josh Peterson                       None                                                                                                                  None  help@lists.anvilproject.org              phs001616                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel        none          National Human Genome Research Institute         Rowley, Robb         Strasburger, Jennifer                         eMERGE                   GRU                1          TDR Location  https://data.terra.bio/snapshots/e5ccacfe-1b14-4331-bd8f-a542b5a70d23                             [Exome Panel]  \n",
       "17                                               [Raw Sequencing data]          precision medicine  Homo sapiens              Josh Peterson                       None                                                                                                                  None  help@lists.anvilproject.org              phs001616                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel        none          National Human Genome Research Institute         Rowley, Robb         Strasburger, Jennifer                         eMERGE               GRU-IRB                1          TDR Location  https://data.terra.bio/snapshots/2efa7d84-2850-4e6f-bb26-7d13ad147b44                             [Exome Panel]  \n",
       "18                                               [Raw Sequencing data]          precision medicine  Homo sapiens              Josh Peterson                       None                                                                                                                  None  help@lists.anvilproject.org              phs001616                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel        none          National Human Genome Research Institute         Rowley, Robb         Strasburger, Jennifer                         eMERGE           GRU-IRB-NPU                1          TDR Location  https://data.terra.bio/snapshots/1410a32b-4ee6-4bd3-96d1-4848d38769d8                             [Exome Panel]  \n",
       "19                                               [Raw Sequencing data]          precision medicine  Homo sapiens              Josh Peterson                       None                                                                                                                  None  help@lists.anvilproject.org              phs001616                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel        none          National Human Genome Research Institute         Rowley, Robb         Strasburger, Jennifer                         eMERGE       GRU-IRB-PUB-NPU                1          TDR Location  https://data.terra.bio/snapshots/b77d83c7-2a8e-4f50-be1a-7848f28dc8cb                             [Exome Panel]  \n",
       "20                                               [Raw Sequencing data]          precision medicine  Homo sapiens              Josh Peterson                       None                                                                                                                  None  help@lists.anvilproject.org              phs001616                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel        none          National Human Genome Research Institute         Rowley, Robb         Strasburger, Jennifer                         eMERGE               GRU-NPU                1          TDR Location  https://data.terra.bio/snapshots/206009c6-cc98-45ab-b504-e6c3a3162a23                             [Exome Panel]  \n",
       "21                                               [Raw Sequencing data]          precision medicine  Homo sapiens              Josh Peterson                       None                                                                                                                  None  help@lists.anvilproject.org              phs001616                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel        none          National Human Genome Research Institute         Rowley, Robb         Strasburger, Jennifer                         eMERGE                   HMB                1          TDR Location  https://data.terra.bio/snapshots/da841552-40bb-4f05-8edf-ad0a76ed13ac                             [Exome Panel]  \n",
       "22                                               [Raw Sequencing data]          precision medicine  Homo sapiens              Josh Peterson                       None                                                                                                                  None  help@lists.anvilproject.org              phs001616                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel        none          National Human Genome Research Institute         Rowley, Robb         Strasburger, Jennifer                         eMERGE               HMB-GSO                1          TDR Location  https://data.terra.bio/snapshots/96874f3e-3e02-400a-96d1-5bd20d4cbc09                             [Exome Panel]  \n",
       "23                                               [Raw Sequencing data]          precision medicine  Homo sapiens              Josh Peterson                       None                                                                                                                  None  help@lists.anvilproject.org              phs001616                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel        none          National Human Genome Research Institute         Rowley, Robb         Strasburger, Jennifer                         eMERGE           HMB-IRB-PUB                1          TDR Location  https://data.terra.bio/snapshots/651d2fd2-fc96-47b3-909d-0dd46f575dbc                             [Exome Panel]  \n",
       "24                                               [Raw Sequencing data]          precision medicine  Homo sapiens              Josh Peterson                       None                                                                                                                  None  help@lists.anvilproject.org              phs001616                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel        none          National Human Genome Research Institute         Rowley, Robb         Strasburger, Jennifer                         eMERGE               HMB-NPU                1          TDR Location  https://data.terra.bio/snapshots/84cfc3d8-282e-4102-ae43-5513e7a3efd5                             [Exome Panel]  \n",
       "25                                                                  []                 Unspecified  Homo sapiens                                                  None                                                                                                                  None   help@lists.anvilproject.org             phs001616                                                eMERGE Network Phase III Clinical Sequencing: eMERGEseq Panel        none          National Human Genome Research Institute         Rowley, Robb         Strasburger, Jennifer                         eMERGE                   TBD                1          TDR Location  https://data.terra.bio/snapshots/40c4297e-d492-4f6a-b651-ee9ee38db14b                                     [TBD]  \n",
       "26                                                                  []                 Unspecified  Homo sapiens                                                  None                                                                                                                  None   help@lists.anvilproject.org  Registration Pending                                                                                                         None        None                                              None                 None                          None                         eMERGE                   TBD             None          TDR Location  https://data.terra.bio/snapshots/8956cc4d-58be-46ae-a81e-74607ffbd9d3                                     [TBD]  \n",
       "27                                                                  []                        None  Homo sapiens                                                  None                                                                                                                  None   help@lists.anvilproject.org                  None                                                                                                         None        None                                              None                 None                          None                           HPRC                  NRES             None          TDR Location  https://data.terra.bio/snapshots/381737d9-c0ac-4a78-9883-2977516ee64d                            [Whole Genome]  \n",
       "28                                               [Raw Sequencing data]                  population  Homo sapiens    Christopher Haiman, ScD                       None                                                               University of Southern California, Los Angeles, CA, USA   help@lists.anvilproject.org             phs000220                                                                               PAGE: Multiethnic Cohort (MEC)        none          National Human Genome Research Institute      Hindorff, Lucia         Strasburger, Jennifer                           PAGE                   GRU                1          TDR Location  https://data.terra.bio/snapshots/6a5b3be6-d1de-4f23-a431-b08e7ab231b8                            [Whole Genome]  \n",
       "29                                               [Raw Sequencing data]                  population  Homo sapiens        Kooperberg, Charles          clk@fredhutch.org                                                   FRED HUTCHINSON CANCER RESEARCH CENTERFRED HUTCHINSON CANCER CENTER   help@lists.anvilproject.org             phs000227                                                                    PAGE: Women&#39;s Health Initiative (WHI)        none         National Heart, Lung, and Blood Institute      Hindorff, Lucia                   Ono, Hiromi                           PAGE               HMB-IRB                1          TDR Location  https://data.terra.bio/snapshots/ffe34538-3ddd-48de-b4a2-94f9b2dad086                            [Whole Genome]  \n",
       "30                                               [Raw Sequencing data]                  population  Homo sapiens             Ruth Loos, PhD                       None  The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA   help@lists.anvilproject.org             phs000925                                                                                      PAGE: IPM BioMe Biobank        none          National Human Genome Research Institute      Hindorff, Lucia         Strasburger, Jennifer                           PAGE                   GRU                1          TDR Location  https://data.terra.bio/snapshots/a4c62d7f-34f0-4e2e-9e46-c762d3ab0ff2                            [Whole Genome]  \n",
       "31                                               [Raw Sequencing data]                  population  Homo sapiens     Carlos Bustamante, PhD                       None                                                                                Stanford University, Stanford, CA, USA   help@lists.anvilproject.org             phs001033                                                                                 PAGE: Global Reference Panel        none          National Human Genome Research Institute      Hindorff, Lucia         Strasburger, Jennifer                           PAGE                   GRU                1          TDR Location  https://data.terra.bio/snapshots/5208772d-21f9-46b0-8167-0b05b57296b8                            [Whole Genome]  \n",
       "32                                             ['Raw Sequencing data']                 Unspecified  Homo sapiens                                                  None                                                                                                                  None   help@lists.anvilproject.org                   TBD                                                                                                         None        None                                              None                 None                          None                           PAGE                   HMB             None          TDR Location  https://data.terra.bio/snapshots/b735d811-a7ed-4d82-8b9d-5f23a9f33936                            [Whole Genome]  \n",
       "33                                             ['Raw Sequencing data']                        None  Homo sapiens                                                  None                                                                                                                  None   help@lists.anvilproject.org                  None                                                                                                         None        None                                              None                 None                          None                            T2T                  NRES             None          TDR Location  https://data.terra.bio/snapshots/367b7e53-512c-40c2-af8c-53477a79bcb7                            [Whole Genome]  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#############################################\n",
    "## Functions\n",
    "#############################################\n",
    "\n",
    "def coalesce(*arg): \n",
    "    return next((a for a in arg if a is not None), None)\n",
    "\n",
    "def format_description(input_string):\n",
    "    output_string = input_string if input_string else \"\"\n",
    "    output_string = re.sub(\"\\n\\n\\t\", \" \", output_string)\n",
    "    output_string = re.sub(\"\\t\", \" \", output_string)\n",
    "    output_string = re.sub(\"study.cgi\\?study_id=|.\\/study.cgi\\?study_id=\", \"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=\", output_string)\n",
    "    return output_string\n",
    "\n",
    "def fetch_dataset_details(snapshot_id):\n",
    "    \n",
    "    # Initialize variables\n",
    "    terra_dict = {}\n",
    "    dbgap_xml_dict = {}\n",
    "    dbgap_study_api_dict = {}\n",
    "    dbgap_fhir_dict = {}\n",
    "    final_results_dict = {}\n",
    "    \n",
    "    # Retrieve snapshot details\n",
    "    api_client = refresh_tdr_api_client()\n",
    "    datasets_api = data_repo_client.DatasetsApi(api_client=api_client)\n",
    "    snapshots_api = data_repo_client.SnapshotsApi(api_client=api_client)\n",
    "    snapshot_details = snapshots_api.retrieve_snapshot(id=snapshot_id).to_dict()\n",
    "    dataset_id = snapshot_details[\"source\"][0][\"dataset\"][\"id\"]\n",
    "    phs_id = snapshot_details[\"source\"][0][\"dataset\"][\"phs_id\"]\n",
    "    dataset_details = datasets_api.retrieve_dataset(id=dataset_id, include=[\"PROPERTIES\"]).to_dict()\n",
    "    if dataset_details[\"properties\"].get(\"source_workspaces\"):\n",
    "        source_workspace = dataset_details[\"properties\"][\"source_workspaces\"][0]\n",
    "    else:\n",
    "        source_workspace = None\n",
    "    print(\"Snapshot PHS_ID: \" + phs_id)\n",
    "    print(\"Source Workspace: \" + source_workspace)\n",
    "    \n",
    "    # Pull information from original workspace (if listed)\n",
    "    if source_workspace:\n",
    "        # Establish credentials\n",
    "        creds, project = google.auth.default()\n",
    "        auth_req = google.auth.transport.requests.Request()\n",
    "        creds.refresh(auth_req)\n",
    "\n",
    "        # Pull workspace attributes\n",
    "        ws_attributes = requests.get(\n",
    "            url=f\"https://api.firecloud.org/api/workspaces/anvil-datastorage/{source_workspace}?fields=workspace.attributes,workspace.authorizationDomain,workspace.googleProject,workspace.bucketName\",\n",
    "            headers={\"Authorization\": f\"Bearer {creds.token}\"}\n",
    "        ).json()\n",
    "\n",
    "        # Map to schema\n",
    "        terra_dict[\"studyName\"] = ws_attributes[\"workspace\"][\"attributes\"].get(\"library:projectName\")\n",
    "        terra_dict[\"studyType\"] = ws_attributes[\"workspace\"][\"attributes\"].get(\"library:studyDesign\")\n",
    "        terra_dict[\"studyDescription\"] = ws_attributes[\"workspace\"][\"attributes\"].get(\"description\")\n",
    "        if ws_attributes[\"workspace\"][\"attributes\"].get(\"library:dataCategory\"):\n",
    "            terra_dict[\"dataTypes\"] = ws_attributes[\"workspace\"][\"attributes\"][\"library:dataCategory\"][\"items\"]\n",
    "        terra_dict[\"phenotypeIndication\"] = ws_attributes[\"workspace\"][\"attributes\"].get(\"library:indication\")\n",
    "        terra_dict[\"species\"] = \"Homo sapiens\"\n",
    "        terra_dict[\"piName\"] = ws_attributes[\"workspace\"][\"attributes\"].get(\"library:datasetOwner\")\n",
    "        terra_dict[\"dataCustodianEmail\"] = ws_attributes[\"workspace\"][\"attributes\"].get(\"library:contactEmail\")\n",
    "        if ws_attributes[\"workspace\"][\"attributes\"].get(\"tag:tags\"):\n",
    "            for tag in ws_attributes[\"workspace\"][\"attributes\"].get(\"tag:tags\")[\"items\"]:\n",
    "                if \"Consortium:\" in tag:\n",
    "                    terra_dict[\"consortium\"] = tag.split(\":\")[1].strip()\n",
    "                elif \"dbGaP:\" in tag:\n",
    "                    terra_dict[\"dbGaPPhsID\"] = tag.split(\":\")[1].strip()\n",
    "                    if not phs_id:\n",
    "                        phs_id = tag.split(\":\")[1].strip() \n",
    "        terra_dict[\"consentGroups.consentCode\"] = ws_attributes[\"workspace\"][\"attributes\"].get(\"library:dataUseRestriction\")\n",
    "        if ws_attributes[\"workspace\"][\"attributes\"].get(\"library:datatype\"):\n",
    "            terra_dict[\"consentGroups.fileTypes.fileType\"] = ws_attributes[\"workspace\"][\"attributes\"][\"library:datatype\"][\"items\"]\n",
    "#         print(\"------------------------------------------------------\")\n",
    "#         print(\"terra_dict\")\n",
    "#         print(terra_dict)\n",
    "        \n",
    "    # Pull information from dbGaP (if phs_id listed)\n",
    "    print(\"PHS ID for dbGaP: \" + phs_id)\n",
    "    if phs_id:\n",
    "        # Pull and parse XML\n",
    "        phs_short = phs_id.replace(\"phs\", \"\")\n",
    "        dbgap_url = \"https://dbgap.ncbi.nlm.nih.gov/ss/dbgapssws.cgi?request=Study&phs=\" + phs_short\n",
    "        response = requests.get(url=dbgap_url)\n",
    "        xml_data = xmltodict.parse(response.text)\n",
    "        study_uid = \"\"\n",
    "\n",
    "        # Map to schema\n",
    "        if xml_data[\"dbgapss\"].get(\"Study\"):\n",
    "            if isinstance(xml_data[\"dbgapss\"][\"Study\"], list):\n",
    "                study_data = xml_data[\"dbgapss\"][\"Study\"][0]\n",
    "            else:\n",
    "                study_data = xml_data[\"dbgapss\"][\"Study\"] \n",
    "            study_uid = study_data.get(\"@uid\")\n",
    "            dbgap_xml_dict[\"studyName\"] = study_data[\"StudyInfo\"].get(\"StudyNameEntrez\")\n",
    "            dbgap_xml_dict[\"studyDescription\"] = study_data[\"StudyInfo\"].get(\"Description\")\n",
    "            dbgap_xml_dict[\"dbGaPPhsID\"] = phs_id\n",
    "            dbgap_xml_dict[\"dbGaPStudyRegistrationName\"] = study_data[\"StudyInfo\"].get(\"StudyNameEntrez\")\n",
    "            if study_data[\"Authority\"][\"Persons\"].get(\"Person\"):\n",
    "                for ap_entry in study_data[\"Authority\"][\"Persons\"][\"Person\"]:\n",
    "                    if ap_entry[\"Role\"] == \"PI\":\n",
    "                        dbgap_xml_dict[\"piName\"] = ap_entry[\"@lname\"] + \", \" + ap_entry[\"@fname\"]\n",
    "                        dbgap_xml_dict[\"piEmail\"] = ap_entry[\"@email\"]\n",
    "                        dbgap_xml_dict[\"piInstitution\"] = ap_entry[\"Organization\"]\n",
    "                    elif ap_entry[\"Role\"] == \"PO\" and ap_entry[\"Organization\"] == \"NIH\":\n",
    "                        dbgap_xml_dict[\"nihProgramOfficerName\"] = ap_entry[\"@lname\"] + \", \" + ap_entry[\"@fname\"]\n",
    "                    elif ap_entry[\"Role\"] == \"GPA\" and ap_entry[\"Organization\"] == \"NIH\":\n",
    "                        dbgap_xml_dict[\"nihGenomicProgramAdministratorName\"] = ap_entry[\"@lname\"] + \", \" + ap_entry[\"@fname\"]\n",
    "            ic_list = []\n",
    "            if isinstance(study_data[\"Authority\"][\"ICs\"][\"IC\"], list):\n",
    "                for ic_entry in study_data[\"Authority\"][\"ICs\"][\"IC\"]:\n",
    "                    ic_list.append(ic_entry[\"@name\"])\n",
    "            else:\n",
    "                ic_list.append(study_data[\"Authority\"][\"ICs\"][\"IC\"][\"@name\"])\n",
    "            dbgap_xml_dict[\"nihICsSupportingStudy\"] = ic_list\n",
    "            dbgap_xml_dict[\"numberOfParticipants\"] = study_data.get(\"@num_participants\")\n",
    "            dbgap_xml_dict[\"embargoReleaseDate\"] = study_data[\"Policy\"].get(\"@pub-embargo\")\n",
    "#             print(\"------------------------------------------------------\")\n",
    "#             print(\"dbgap_xml_dict\")\n",
    "#             print(dbgap_xml_dict)\n",
    "        \n",
    "        # Pull and parse Study API JSON\n",
    "        if study_uid:\n",
    "            dbgap_study_url = \"https://submit.ncbi.nlm.nih.gov/dbgap/api/v1/study_config/\" + str(study_uid)\n",
    "            response = requests.get(url=dbgap_study_url)\n",
    "            study_api_data = json.loads(response.text)\n",
    "\n",
    "            # Map to schema\n",
    "            if study_api_data.get(\"error\") == None:\n",
    "                dbgap_study_api_dict[\"studyName\"] = study_api_data[\"data\"].get(\"report_name\")\n",
    "                dbgap_study_api_dict[\"studyDescription\"] = study_api_data[\"data\"].get(\"description\")\n",
    "                dbgap_study_api_dict[\"phenotypeIndication\"] = study_api_data[\"data\"].get(\"primary_disease\")\n",
    "                dbgap_study_api_dict[\"studyType\"] = study_api_data[\"data\"].get(\"study_design\")\n",
    "                dbgap_study_api_dict[\"dbGaPPhsID\"] = phs_id\n",
    "                dbgap_study_api_dict[\"dbGaPStudyRegistrationName\"] = study_api_data[\"data\"].get(\"report_name\")\n",
    "                for attr_entry in study_api_data[\"data\"].get(\"attribution\"):\n",
    "                    if attr_entry.get(\"title\") == \"Principal Investigator\":\n",
    "                        dbgap_study_api_dict[\"piName\"] = attr_entry.get(\"name\")\n",
    "                        dbgap_study_api_dict[\"piInstitution\"] = attr_entry.get(\"institute\")\n",
    "                        break\n",
    "#             print(\"------------------------------------------------------\")\n",
    "#             print(\"dbgap_study_api_dict\")\n",
    "#             print(dbgap_study_api_dict)\n",
    "        \n",
    "        # Pull and parse FHIR API JSON\n",
    "        dbgap_fhir_url = \"https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/ResearchStudy?_format=json&_id=\" + phs_id\n",
    "        response = requests.get(url=dbgap_fhir_url)\n",
    "        fhir_data = json.loads(response.text)\n",
    "\n",
    "        # Map to schema\n",
    "        if fhir_data.get(\"entry\"):\n",
    "            dbgap_fhir_dict[\"studyName\"] = fhir_data[\"entry\"][0][\"resource\"].get(\"title\")\n",
    "            dbgap_fhir_dict[\"studyDescription\"] = fhir_data[\"entry\"][0][\"resource\"].get(\"description\")\n",
    "            dbgap_fhir_dict[\"dbGaPPhsID\"] = phs_id\n",
    "            dbgap_fhir_dict[\"dbGaPStudyRegistrationName\"] = fhir_data[\"entry\"][0][\"resource\"].get(\"title\")\n",
    "            dbgap_fhir_dict[\"nihICsSupportingStudy\"] = fhir_data[\"entry\"][0][\"resource\"][\"sponsor\"].get(\"display\")\n",
    "            # studyType\n",
    "            if fhir_data[\"entry\"][0][\"resource\"].get(\"category\"):\n",
    "                for cat_entry in fhir_data[\"entry\"][0][\"resource\"].get(\"category\"):\n",
    "                    for coding_entry in cat_entry.get(\"coding\"):\n",
    "                        if coding_entry.get(\"system\") == \"https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyDesign\":\n",
    "                            value = coding_entry.get(\"display\") if coding_entry.get(\"display\") else coding_entry.get(\"code\")\n",
    "                            if dbgap_fhir_dict.get(\"studyType\") and value:\n",
    "                                dbgap_fhir_dict[\"studyType\"] += f\", {value}\"\n",
    "                            elif value:\n",
    "                                dbgap_fhir_dict[\"studyType\"] = value\n",
    "            # dataTypes\n",
    "            dt_list = []\n",
    "            if fhir_data[\"entry\"][0][\"resource\"].get(\"extension\"): \n",
    "                for ext_entry in fhir_data[\"entry\"][0][\"resource\"].get(\"extension\"):\n",
    "                    if ext_entry.get(\"url\") == \"https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-MolecularDataTypes\":\n",
    "                        for inner_ext_entry in ext_entry.get(\"extension\"):\n",
    "                            if inner_ext_entry.get(\"url\") == \"https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-MolecularDataTypes-MolecularDataType\":\n",
    "                                for coding_entry in inner_ext_entry[\"valueCodeableConcept\"].get(\"coding\"):\n",
    "                                    dt_list.append(coding_entry.get(\"code\"))\n",
    "            dbgap_fhir_dict[\"dataTypes\"] = dt_list\n",
    "            # phenotypeIndication\n",
    "            if fhir_data[\"entry\"][0][\"resource\"].get(\"focus\"):\n",
    "                for focus_entry in fhir_data[\"entry\"][0][\"resource\"].get(\"focus\"):\n",
    "                    for coding_entry in focus_entry.get(\"coding\"):\n",
    "                        value = coding_entry.get(\"display\") if coding_entry.get(\"display\") else coding_entry.get(\"code\")\n",
    "                        if dbgap_fhir_dict.get(\"phenotypeIndication\") and value:\n",
    "                            dbgap_fhir_dict[\"phenotypeIndication\"] += f\", {value}\"\n",
    "                        elif value:\n",
    "                            dbgap_fhir_dict[\"phenotypeIndication\"] = value\n",
    "            # numberOfParticipants\n",
    "            if fhir_data[\"entry\"][0][\"resource\"].get(\"extension\"):\n",
    "                for ext_entry in fhir_data[\"entry\"][0][\"resource\"].get(\"extension\"):\n",
    "                    if ext_entry.get(\"url\") == \"https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-Content\":\n",
    "                        for inner_ext_entry in ext_entry.get(\"extension\"):\n",
    "                            if inner_ext_entry.get(\"url\") == \"https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-Content-NumSubjects\":\n",
    "                                dbgap_fhir_dict[\"numberOfParticipants\"] = inner_ext_entry[\"valueCount\"].get(\"code\")\n",
    "#         print(\"------------------------------------------------------\")\n",
    "#         print(\"dbgap_fhir_dict\")\n",
    "#         print(dbgap_fhir_dict)\n",
    "    \n",
    "    # Reconcile information and create final results\n",
    "    final_results_dict[\"snapshot_id\"] = snapshot_id\n",
    "    final_results_dict[\"studyName\"] = coalesce(dbgap_fhir_dict.get(\"studyName\"), dbgap_xml_dict.get(\"studyName\"), dbgap_study_api_dict.get(\"studyName\"), terra_dict.get(\"studyName\"))\n",
    "    final_results_dict[\"studyType\"] = coalesce(terra_dict.get(\"studyType\"), dbgap_fhir_dict.get(\"studyType\"), dbgap_xml_dict.get(\"studyType\"), dbgap_study_api_dict.get(\"studyType\"))\n",
    "    final_results_dict[\"studyDescription\"] = format_description(coalesce(dbgap_fhir_dict.get(\"studyDescription\"), dbgap_xml_dict.get(\"studyDescription\"), dbgap_study_api_dict.get(\"studyDescription\"), terra_dict.get(\"studyDescription\")))\n",
    "    final_results_dict[\"dataTypes\"] = coalesce(terra_dict.get(\"dataTypes\"), dbgap_fhir_dict.get(\"dataTypes\"), dbgap_xml_dict.get(\"dataTypes\"), dbgap_study_api_dict.get(\"dataTypes\"))\n",
    "    final_results_dict[\"phenotypeIndication\"] = coalesce(terra_dict.get(\"phenotypeIndication\"), dbgap_fhir_dict.get(\"phenotypeIndication\"), dbgap_xml_dict.get(\"phenotypeIndication\"), dbgap_study_api_dict.get(\"phenotypeIndication\"))\n",
    "    final_results_dict[\"species\"] = \"Homo sapiens\"\n",
    "    final_results_dict[\"piName\"] = coalesce(dbgap_fhir_dict.get(\"piName\"), dbgap_xml_dict.get(\"piName\"), dbgap_study_api_dict.get(\"piName\"), terra_dict.get(\"piName\"))\n",
    "    final_results_dict[\"piEmail\"] = coalesce(dbgap_fhir_dict.get(\"piEmail\"), dbgap_xml_dict.get(\"piEmail\"), dbgap_study_api_dict.get(\"piEmail\"), terra_dict.get(\"piEmail\"))\n",
    "    final_results_dict[\"piInstitution\"] = coalesce(dbgap_fhir_dict.get(\"piInstitution\"), dbgap_xml_dict.get(\"piInstitution\"), dbgap_study_api_dict.get(\"piInstitution\"), terra_dict.get(\"piInstitution\"))\n",
    "    final_results_dict[\"dataCustodianEmail\"] = coalesce(terra_dict.get(\"dataCustodianEmail\"), dbgap_fhir_dict.get(\"dataCustodianEmail\"), dbgap_xml_dict.get(\"dataCustodianEmail\"), dbgap_study_api_dict.get(\"dataCustodianEmail\"))\n",
    "    final_results_dict[\"dbGaPPhsID\"] = coalesce(dbgap_fhir_dict.get(\"dbGaPPhsID\"), dbgap_xml_dict.get(\"dbGaPPhsID\"), dbgap_study_api_dict.get(\"dbGaPPhsID\"), terra_dict.get(\"dbGaPPhsID\"))\n",
    "    final_results_dict[\"dbGaPStudyRegistrationName\"] = coalesce(dbgap_fhir_dict.get(\"dbGaPStudyRegistrationName\"), dbgap_xml_dict.get(\"dbGaPStudyRegistrationName\"), dbgap_study_api_dict.get(\"dbGaPStudyRegistrationName\"), terra_dict.get(\"dbGaPStudyRegistrationName\"))\n",
    "    final_results_dict[\"embargoReleaseDate\"] = coalesce(dbgap_fhir_dict.get(\"embargoReleaseDate\"), dbgap_xml_dict.get(\"embargoReleaseDate\"), dbgap_study_api_dict.get(\"embargoReleaseDate\"), terra_dict.get(\"embargoReleaseDate\"))\n",
    "    final_results_dict[\"nihICsSupportingStudy\"] = coalesce(dbgap_fhir_dict.get(\"nihICsSupportingStudy\"), dbgap_xml_dict.get(\"nihICsSupportingStudy\"), dbgap_study_api_dict.get(\"nihICsSupportingStudy\"), terra_dict.get(\"nihICsSupportingStudy\"))\n",
    "    final_results_dict[\"nihProgramOfficerName\"] = coalesce(dbgap_fhir_dict.get(\"nihProgramOfficerName\"), dbgap_xml_dict.get(\"nihProgramOfficerName\"), dbgap_study_api_dict.get(\"nihProgramOfficerName\"), terra_dict.get(\"nihProgramOfficerName\"))\n",
    "    final_results_dict[\"nihGenomicProgramAdministratorName\"] = coalesce(dbgap_fhir_dict.get(\"nihGenomicProgramAdministratorName\"), dbgap_xml_dict.get(\"nihGenomicProgramAdministratorName\"), dbgap_study_api_dict.get(\"nihGenomicProgramAdministratorName\"), terra_dict.get(\"nihGenomicProgramAdministratorName\"))\n",
    "    final_results_dict[\"consortium\"] = coalesce(terra_dict.get(\"consortium\"), dbgap_fhir_dict.get(\"consortium\"), dbgap_xml_dict.get(\"consortium\"), dbgap_study_api_dict.get(\"consortium\"))\n",
    "    final_results_dict[\"consentGroups.consentCode\"] = coalesce(terra_dict.get(\"consentGroups.consentCode\"), dbgap_fhir_dict.get(\"consentGroups.consentCode\"), dbgap_xml_dict.get(\"consentGroups.consentCode\"), dbgap_study_api_dict.get(\"consentGroups.consentCode\"))\n",
    "    final_results_dict[\"numberOfParticipants\"] = coalesce(terra_dict.get(\"numberOfParticipants\"), dbgap_fhir_dict.get(\"numberOfParticipants\"), dbgap_xml_dict.get(\"numberOfParticipants\"), dbgap_study_api_dict.get(\"numberOfParticipants\"))\n",
    "    final_results_dict[\"dataLocation\"] = \"TDR Location\"\n",
    "    final_results_dict[\"url\"] = \"https://data.terra.bio/snapshots/\" + snapshot_id\n",
    "    final_results_dict[\"consentGroups.fileTypes.fileType\"] = coalesce(terra_dict.get(\"consentGroups.fileTypes.fileType\"), dbgap_fhir_dict.get(\"consentGroups.fileTypes.fileType\"), dbgap_xml_dict.get(\"consentGroups.fileTypes.fileType\"), dbgap_study_api_dict.get(\"consentGroups.fileTypes.fileType\"))\n",
    "    \n",
    "    # Return results\n",
    "    return final_results_dict\n",
    "\n",
    "\n",
    "#############################################\n",
    "## Input Parameters\n",
    "#############################################\n",
    "\n",
    "# Specify the users to manage access for and the role they should have:\n",
    "snapshot_id_list = [\n",
    "'fc513b58-cfb7-4871-8694-8dc372fc2e10',\n",
    "'a1dcd80f-6390-489a-a34a-168f26690a36',\n",
    "'e91ccc70-2772-46d8-b586-cf3e270a05b5',\n",
    "'6fdea8c7-69d9-466e-9fa2-aca30722ff68',\n",
    "'02d25240-823f-4b1d-8562-95385716a453',\n",
    "'99b46287-4790-492c-8a12-bea33f0f927c',\n",
    "'c6ef5822-3929-4ae7-b5bc-dc27528bf226',\n",
    "'08d19a7e-b868-4766-9f7e-d879d972cbd7',\n",
    "'1974a21b-c409-4736-a3d7-e195fa96c4eb',\n",
    "'8fd5b447-77b6-4c33-b66a-a5cc63587220',\n",
    "'aa2bfacc-c28c-4192-960c-b1389cf68516',\n",
    "'44b1f60b-e74c-4430-9378-d4a75e2de72f',\n",
    "'5b036d13-e058-4d8d-be91-6fdd070686a7',\n",
    "'0a356156-961d-4829-b9b5-c07fbc73dacc',\n",
    "'e43974fd-cee1-4d8c-a436-6846d7d24129',\n",
    "'4c8ce027-8094-4f5d-bf62-22b1d51b3c1e',\n",
    "'e5ccacfe-1b14-4331-bd8f-a542b5a70d23',\n",
    "'2efa7d84-2850-4e6f-bb26-7d13ad147b44',\n",
    "'1410a32b-4ee6-4bd3-96d1-4848d38769d8',\n",
    "'b77d83c7-2a8e-4f50-be1a-7848f28dc8cb',\n",
    "'206009c6-cc98-45ab-b504-e6c3a3162a23',\n",
    "'da841552-40bb-4f05-8edf-ad0a76ed13ac',\n",
    "'96874f3e-3e02-400a-96d1-5bd20d4cbc09',\n",
    "'651d2fd2-fc96-47b3-909d-0dd46f575dbc',\n",
    "'84cfc3d8-282e-4102-ae43-5513e7a3efd5',\n",
    "'40c4297e-d492-4f6a-b651-ee9ee38db14b',\n",
    "'8956cc4d-58be-46ae-a81e-74607ffbd9d3',\n",
    "'381737d9-c0ac-4a78-9883-2977516ee64d',\n",
    "'6a5b3be6-d1de-4f23-a431-b08e7ab231b8',\n",
    "'ffe34538-3ddd-48de-b4a2-94f9b2dad086',\n",
    "'a4c62d7f-34f0-4e2e-9e46-c762d3ab0ff2',\n",
    "'5208772d-21f9-46b0-8167-0b05b57296b8',\n",
    "'b735d811-a7ed-4d82-8b9d-5f23a9f33936',\n",
    "'367b7e53-512c-40c2-af8c-53477a79bcb7',\n",
    "]\n",
    "\n",
    "#############################################\n",
    "## Execution\n",
    "#############################################\n",
    "dataset_details_records = []\n",
    "for snapshot_id in snapshot_id_list:\n",
    "    dataset_details = fetch_dataset_details(snapshot_id)\n",
    "    dataset_details_records.append(dataset_details)\n",
    "output = pd.DataFrame(dataset_details_records)\n",
    "display(output)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true
   },
   "source": [
    "# Fetch parameters from snapshot/dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "phs000693\n",
      "AnVIL_CMG_UWash_GRU\n"
     ]
    }
   ],
   "source": [
    "# Parameters\n",
    "snapshot_id = \"099d2585-1379-4333-b3b1-ffc0d26d95c5\"\n",
    "\n",
    "# Retrieve snapshot details\n",
    "api_client = refresh_tdr_api_client()\n",
    "datasets_api = data_repo_client.DatasetsApi(api_client=api_client)\n",
    "snapshots_api = data_repo_client.SnapshotsApi(api_client=api_client)\n",
    "snapshot_details = snapshots_api.retrieve_snapshot(id=snapshot_id).to_dict()\n",
    "dataset_id = snapshot_details[\"source\"][0][\"dataset\"][\"id\"]\n",
    "phs_id = snapshot_details[\"source\"][0][\"dataset\"][\"phs_id\"]\n",
    "\n",
    "# Retrieve dataset details\n",
    "dataset_details = datasets_api.retrieve_dataset(id=dataset_id, include=[\"PROPERTIES\"]).to_dict()\n",
    "if dataset_details[\"properties\"].get(\"auth_domains\"):\n",
    "    auth_domain = dataset_details[\"properties\"][\"auth_domains\"][0]\n",
    "if dataset_details[\"properties\"].get(\"source_workspaces\"):\n",
    "    source_workspace = dataset_details[\"properties\"][\"source_workspaces\"][0]\n",
    "\n",
    "# Print output\n",
    "print(phs_id)\n",
    "print(source_workspace)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true
   },
   "source": [
    "# Pulling Workspace Attributes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'studyName': 'GREGoR', 'studyType': 'Case/Control, Cohort, Parent-Offspring Trios, Case Set', 'dataTypes': ['Aligned DNA short read sequencing data, Variant call format (VCFs) files for SNVs and Indels, Data tables with subject, family, clinical phenotype and experimental information'], 'phenotypeIndication': 'Mendelian Disorders', 'species': 'Homo sapiens', 'piName': 'Susanne May', 'dataCustodianEmail': 'gregorconsortium@uw.edu', 'consortium': 'GREGoR', 'dbGaPPhsID': 'phs003047', 'consentGroups.consentCode': 'HMB', 'consentGroups.fileTypes.fileType': ['Whole Exome, Whole Genome']}\n"
     ]
    }
   ],
   "source": [
    "# Parameters\n",
    "ws_project = \"anvil-datastorage\"\n",
    "ws_name = \"AnVIL_GREGOR_RELEASE_01_HMB\"\n",
    "\n",
    "# Establish credentials\n",
    "creds, project = google.auth.default()\n",
    "auth_req = google.auth.transport.requests.Request()\n",
    "creds.refresh(auth_req)\n",
    "\n",
    "# Pull workspace attributes\n",
    "ws_attributes = requests.get(\n",
    "    url=f\"https://api.firecloud.org/api/workspaces/{ws_project}/{ws_name}?fields=workspace.attributes,workspace.authorizationDomain,workspace.googleProject,workspace.bucketName\",\n",
    "    headers={\"Authorization\": f\"Bearer {creds.token}\"}\n",
    ").json()\n",
    "\n",
    "# Map to schema\n",
    "terra_dict = {}\n",
    "terra_dict[\"studyName\"] = ws_attributes[\"workspace\"][\"attributes\"].get(\"library:projectName\")\n",
    "terra_dict[\"studyType\"] = ws_attributes[\"workspace\"][\"attributes\"].get(\"library:studyDesign\")\n",
    "#terra_dict[\"studyDescription\"] = ws_attributes[\"workspace\"][\"attributes\"].get(\"description\")\n",
    "terra_dict[\"dataTypes\"] = ws_attributes[\"workspace\"][\"attributes\"].get(\"library:dataCategory\")[\"items\"]\n",
    "terra_dict[\"phenotypeIndication\"] = ws_attributes[\"workspace\"][\"attributes\"].get(\"library:indication\")\n",
    "terra_dict[\"species\"] = \"Homo sapiens\"\n",
    "terra_dict[\"piName\"] = ws_attributes[\"workspace\"][\"attributes\"].get(\"library:datasetOwner\")\n",
    "terra_dict[\"dataCustodianEmail\"] = ws_attributes[\"workspace\"][\"attributes\"].get(\"library:contactEmail\")\n",
    "if ws_attributes[\"workspace\"][\"attributes\"].get(\"tag:tags\"):\n",
    "    for tag in ws_attributes[\"workspace\"][\"attributes\"].get(\"tag:tags\")[\"items\"]:\n",
    "        if \"Consortium:\" in tag:\n",
    "            terra_dict[\"consortium\"] = tag.split(\":\")[1].strip()\n",
    "        elif \"dbGaP:\" in tag:\n",
    "            terra_dict[\"dbGaPPhsID\"] = tag.split(\":\")[1].strip()\n",
    "terra_dict[\"consentGroups.consentCode\"] = ws_attributes[\"workspace\"][\"attributes\"][\"library:dataUseRestriction\"] \n",
    "terra_dict[\"consentGroups.fileTypes.fileType\"] = ws_attributes[\"workspace\"][\"attributes\"][\"library:datatype\"][\"items\"]\n",
    "\n",
    "# View schema\n",
    "print(terra_dict)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'workspace': {'attributes': {'library:dulvn': 4,\n",
       "   'library:studyDesign': 'Case/Control, Cohort, Parent-Offspring Trios, Case Set',\n",
       "   'library:cohortCountry': 'United States',\n",
       "   'description': \"The NHGRI GREGoR (Genomics Research to Elucidate the Genetics of Rare Disease, https://gregorconsortium.org) Consortium was established in June 2021 with the goal of developing novel tools and approaches to advance the discovery of the genetic basis of rare conditions. Participant information and numerous types of molecular data are collected and generated by the  GREGoR Consortium.  This data is available on the NHGRI Analysis Visualization and Informatics Lab-space ([AnVIL](https://anvilproject.org/)) cloud platform via dbGaP application to [phs003047](http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003047.v1.p1).\\n\\nThe GREGoR Data Set conforms to the GREGoR Consortium [Data Model](https://github.com/UW-GAC/gregor_data_models), which is designed to support comprehensive data analysis and to expand to support the addition of new data types. The Current Data Release (R01) includes family, clinical and phenotype information as well as short-read DNA (whole exome and whole genome sequencing) and RNA sequencing data. We anticipate that future releases will include long-read DNA sequencing, methylomics, proteomics and other molecular data.\\n\\nThe Current Data Release (R01)  contains data for 2,512 participants and 990 families across two consent groups ([GRU and HMB](https://sharing.nih.gov/genomic-data-sharing-policy/institutional-certifications/completing-an-institutional-certification-form#step-5)). Family and participant information includes de-identified clinical phenotype data described using standardized ontologies. Molecular data in this release includes: 2,438 aligned DNA short read sequencing files, and 231 aligned RNA short read sequencing files.\\n\\nIn this release, molecular data was generated and independently processed by GREGoR Consortium Research Centers.  The sample preparation and bioinformatics pipelines for each of the GREGoR Consortium Research Centers are summarized in the Methods section below . Future releases will include harmonized aligned sequencing files, single sample variant files and jointly processed variant callsets.\\n\\n# Methods\\n##  Baylor College of Medicine Research Center (BCM-GREGoR)\\n\\n### Exome and Genome Sequencing Methods using the Illumina Platform\\n\\nExome and genome sequencing were performed at the Human Genome Sequencing Center (HGSC) at Baylor College of Medicine through the BCM-GREGoR initiative.\\n\\n### Sample Quality Control\\n\\nUpon receipt of samples, two independent methods were used to determine the quantity and quality of the DNA before library construction including (1) Picogreen assays and (2) E-Gels. Picogreen assays were used for DNA quantification and was based on use of Quant-iT PicoGreen dsDNA reagent. Semi-quantitative and qualitative yield gels were used to estimate DNA sample integrity. Once DNA quality was assessed, samples moved forward for the appropriate sequencing application.\\n\\n### Exome Sequencing\\n\\nUsing 500ng of DNA, dual-indexed pre-capture libraries were prepared using KAPA reagents as described in the [BCM-HGSC protocol](https://www.hgsc.bcm.edu/content/protocols-sequencing-library-construction).  Libraries were pooled into 10-plex pools and capture was performed using a custom HSGC exome capture reagent (36.8Mb, custom TWIST).  Paired-end sequencing was performed in a format of multiplexed pools using the Illumina NovaSeq 6000 instrument.  Passing criteria for exomes included 90X average coverage and 90% of bases covered to a depth of 20X or greater.\\n\\n### Genome Sequencing\\n\\nUsing 750ng of DNA, libraries were prepared with KAPA Hyper PCR-free reagents as described in the BCM-HGSC protocol.  The HGSC Illumina NovaSeq 6000 instrument fleet was employed to generate 150 bp, dual indexed and paired-end sequence reads for all samples in a format of multiplexed pools.  Passing criteria included 30X average coverage and 90% of bases covered to a depth of 20X or greater.\\n\\n### Primary Data Processing\\n\\nPost-sequencing data analysis was performed using the HGSC HgV analysis pipeline which executed base calling, mapping, merging, variant calling, post-processing, and QC metric collection for all sequencing events.  Finally, annotation data was added to the VCF using a suite of annotation tools Cassandra that brings together frequency, function, and other relevant information using AnnoVar with UCSC and RefSeq gene models, as well as a host of other internal and external data resources.  \\n\\n### Sequence Data Quality Control\\n\\nQuality control (QC) criteria were reviewed at each procedural step in the sequencing workflows.  A series of QC metrics were calculated after the mapping step. Daily quality criteria included >60% Pass Filter, >90% aligned bases, <3.0% error rate, >85% unique reads and >75% Q30 bases to achieve the application-specific metrics. Additional metrics such as library insert size (mode and mean) per sample, duplicate reads, read 1 and read 2 error rates, % pair reads and mean quality scores were also monitored.  To ensure sample identity and integrity the Fluidigm SNPtrace method for rapidly genotyping 96 SNP sites was employed to verify gender prior to sequencing and to detect contamination using the Error Rate In Sequencing (ERIS) software developed at the HGSC.  Sample concordance was measured by comparing SNP Trace genotype calls for a given sample to alignment-based genotype calls from that sample. Self-concordance was reported as a fraction of genotype matches, weighted by each SNPtrace sites MAF. The concordance report includes both self-concordance and the top six next best concordant samples. Samples whose self-concordance is less than 90% or whose self-concordance is not the highest match were further evaluated for a sample-swap.\\n\\n\\n## Broad Institute (Broad)\\n\\n### Human Whole Genome Sequencing PCR-Free (v1.1-v1.3)\\n\\n#### Preparation of libraries for cluster amplification and sequencing\\n\\nAn aliquot of genomic DNA (350ng in 50L) is used as the input into DNA fragmentation (also known as shearing). Shearing is performed acoustically using a Covaris focused-ultrasonicator, targeting 385bp fragments. Following fragmentation, additional size selection is performed using a SPRI cleanup. Library preparation is performed using a commercially available kit provided by KAPA Biosystems (KAPA Hyper Prep without amplification module, product KK8505), and with palindromic forked adapters with unique 8-base index sequences embedded within the adapter (purchased from Roche). Following sample preparation, libraries are quantified using quantitative PCR (kit purchased from KAPA Biosystems), with probes specific to the ends of the adapters. This assay is automated using Agilents Bravo liquid handling platform. Based on qPCR quantification, libraries are normalized to 2.2nM and pooled into 24-plexes.\\n\\n#### Cluster amplification and sequencing (HiSeq X)\\n\\nSample pools are combined with HiSeqX Cluster Amp Regents EPX1, EPX2 and EPX3 into single wells on a strip tube using the Hamilton Starlet Liquid Handling system. Cluster amplification of the templates is performed according to the manufacturers protocol (Illumina) with the Illumina cBot. Flowcells are sequenced on HiSeqX utilizing sequencing-by-synthesis kits to produce 151bp paired-end reads. Output from Illumina software is processed by the Picard data-processing pipeline to yield CRAM or BAM files containing demultiplexed, aggregated aligned reads. All sample information tracking is performed by automated LIMS messaging.\\n\\nCluster amplification and sequencing (NovaSeq 6000) Sample pools are combined with NovaSeq Cluster Amp Reagents DPX1, DPX2 and DPX3 and loaded into single lanes of a NovaSeq 6000 S4 flowcell cell using the Hamilton Starlet Liquid Handling system. Cluster amplification and sequencing occur on NovaSeq 6000 Instruments utilizing sequencing-by-synthesis kits to produce 151bp paired-end reads. Output from Illumina software is processed by the Picard data-processing pipeline to yield CRAM or BAM files containing demultiplexed, aggregated aligned reads. All sample information tracking is performed by automated LIMS messaging.\\n\\n### Broad Stranded RNA-Seq Method\\n\\n#### cDNA Library Construction\\n\\nTotal RNA was quantified using the Quant-iT RiboGreen RNA Assay Kit and normalized to 5ng/ul. Following plating, 2 uL of ERCC controls (using a 1:1000 dilution) were spiked into each sample. An aliquot of 325 ng for each sample was transferred into library preparation which uses automated variant of the Illumina TruSeq Stranded mRNA Sample Preparation Kit. This method preserves strand orientation of the RNA transcript. It uses oligo dT beads to select mRNA from the total RNA sample. It is followed by heat fragmentation and cDNA synthesis from the RNA template. The resultant 400bp cDNA then goes through dual-indexed library preparation: A base addition, adapter ligation using P7 adapters, and PCR enrichment using P5 adapters. After enrichment the libraries were quantified using Quant-iT PicoGreen (1:200 dilution). After normalizing samples to 5 ng/uL, the set was pooled and quantified using the KAPA Library Quantification Kit for Illumina Sequencing Platforms. The entire process is in 96-well format and all pipetting is done by either Agilent Bravo or Hamilton Starlet.\\n\\n#### Illumina Sequencing\\n\\nPooled libraries were normalized to 2nM and denatured using 0.1 N NaOH prior to sequencing. Flowcell cluster amplification and sequencing were performed according to the manufacturers protocols using the NovaSeq. Each run was a 151bp paired-end with an eight-base index barcode read. Data was analyzed using the Broad Picard Pipeline which includes de-multiplexing and data aggregation.\\n\\n\\n## Children's National Hospital / Invitae - Pediatric Mendelian Genomics (CNH/Invitae)\\n\\n### Short Read WGS Methods Summary\\n\\n#### Input Read Quality Control\\n\\nFastqs were processed by [fastqc](https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) 0.12.1 with default parameters. Fastqs were concurrently processed by [fastp](https://github.com/OpenGene/fastp) 0.23.2 with the following relevant parameter settings: `-q 10 --trim_poly_g --overrepresentation_analysis --overrepresentation_sampling 100 -5 -3`. Paired, passing reads are passed through fastqc as above for inspection (as post-trimmed reads) in [multiqc](https://multiqc.info/).\\n\\n#### Read Alignment\\n\\nTrimmed reads are aligned to human reference genome [GRCh38](ftp://ftp.ncbi.nlm.nih.gov/genomes/all/GCA/000/001/405/GCA_000001405.15_GRCh38/seqs_for_alignment_pipelines.ucsc_ids/GCA_000001405.15_GRCh38_no_alt_analysis_set.fna.gz) with [bwa](https://bio-bwa.sourceforge.net/). Aside from standard defaults, softclipping of alts (`-Y`) and a fixed `-K` are provided to stabilize output across repeated runs. Reads trimmed for residual Illumina adapter content are used for alignment. Duplicate reads are annotated and removed with [GATK](https://github.com/broadinstitute/gatk) 4.4.0.0 MarkDuplicates. Quality scores are recalibrated with GATK 4.4.0.0 BaseRecalibrator/ApplyBQSR.\\n\\nFollowing BQSR, aligned reads are analyzed with GATK 4.4.0.0 CollectMultipleMetrics, CollectGcBiasMetrics, and CollectWgsMetrics; [alignstats](https://github.com/jfarek/alignstats) 0.10; [VerifyBamID](https://github.com/Griffan/VerifyBamID) 2.0.1 for sample contamination; and [somalier](https://github.com/brentp/somalier) 0.2.15 for relatedness and sex check.\\n\\nAligned bam files are mapped to generic sample IDs and converted to lossless crams. For recordkeeping, the sites pipeline's version and reference fasta URL used for alignment are added to the bam header as a comment (@CO) tag.\\n\\n### RNA-sequencing (RNAseq) library preparation and data processing\\n\\nRNA samples were isolated from whole blood collected in PAXgene tubes.  RNA isolation was performed using either the Qiagen PAX Gene kit (Qiagen) or the MagMAX for Stabilized Blood Tubes RNA Isolation Kit (Invitrogen) on a KingFisher system. Total RNA was quantitated by Qubit. Ribosomal/globin-depleted, stranded libraries were prepared from 250 ng total RNA using the Watchmaker RNA Library Prep Kit with Polaris depletion (Watchmaker Genomics). Sequencing was performed on the Illumina NovaSeq platform, generating paired-end 150bp reads on S4 flowcells, using standard loading of the flow cell. Targeted coverage was 100-200 million reads per sample.  We aligned RNAseq reads to the human reference genome, GRCh38, using STAR1 ([PMC3530905](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530905/), v2.7.10a) and gene annotation, GENCODEv41. with the basic two-pass protocol, allowing up to 3 mismatches and a minimum aligned length of 100bp. All other parameters were set to default. Quality control was performed using QoRTs ([PMC4506620](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506620/)) to check for any failed samples. We checked for the following:\\n \\n1.\\tTotal alignment rate (unique+multi-map) >80%.\\n2.\\tCorrect strandedness: fr-firststrand.\\n3.\\tSamples with fewer than 100 million reads were flagged as low read count.\\n4.\\tRIN< 6 was flagged as poor RIN value.\\n\\n\\n## GREGoR Stanford Site (GSS)\\n\\nThe majority of GSS participants have their WGS performed at Stanford Clinical Genomics Lab (CGL). However, a small proportion of participants have WGS already sequenced from different external labs at the time of enrollment to GSS. The details about their sequencing and analysis can be found in the experiment_dna_short_read and aligned_dna_short_read data tables in AnVIL.\\n\\nPeripheral blood samples were collected in EDTA vacutainer tubes using standard practices and DNA was isolated using the Maxwell RSC Buffy Coat DNA Kit (Promega Corporation, Madison, WI) according to manufacturer instructions.\\n \\n### Library Preparation and Short-Read Sequencing\\n\\nGenome sequencing library preparation was performed using the KAPA Hyper Prep Kit (Roche Sequencing and Life Science, Indianapolis, IN) and KAPA Unique-Dual Indexed (UDI) adapters (Roche Sequencing and Life Science) according to manufacturer instructions. In brief, 500 ng of genomic DNA was fragmented to ~400-450 bp and subjected to end repair and A-tailing, followed by adapter ligation, bead-based purification, and size selection. Adaptor-ligated libraries were quantified by qPCR and pooled for sequencing, which was performed on the NovaSeq 6000 (Illumina, San Diego, CA) using either S2 or S4 flow cells and 150 bp paired-end sequencing according to manufacturer instructions. Genome sequencing depth of coverage was targeted to 40X, consistent with the quality metrics defined by the Stanford Medicine Clinical Genomics Laboratory (see table below).\\n \\n### Bioinformatics Pipeline and Variant Calling\\n\\nSequencing data was analyzed using the Stanford Clinical Genomics Laboratory genome pipeline. Demultiplexed FASTQ files were generated from binary base call (BCL) files using bcl2fastq (Illumina), and sequencing reads were mapped to Genome Reference Consortium Human Build 38 (GRCh38). Variant calling was performed using the Illumina DRAGEN Germline Pipeline v3.10.4 (currently), which employs a Germline Small Variant Caller for SNVs/indels, and both the Structural Variant (SV) caller (Manta) and CNV Caller for structural variants. Secondary analysis data was transferred to Stanford Health Cares Google Cloud project instance for archival storage, additional custom processing, and quality control (QC) monitoring for selected sequencing, alignment, and variant metrics.\\n \\n### Quality Control (QC) and Quality Monitoring (QM)\\n\\nThe Stanford Clinical Genomics Laboratory bioinformatics quality control (QC) and quality monitoring (QM) metrics are detailed in the table below, which are monitored for overall performance and to detect any deviations from expected results over time. Any deviations from the clinical QC/QM metrics among the GREGoR Stanford Site (GSS) specimens are reviewed by a Laboratory Director and either released for downstream processing (if deviations are considered minor), or the specimen is subjected to resequencing as appropriate.\\n\\nQuality Control (QC) Metric\\t| Short Read Genome QC Thresholds (Blood)\\n--- | ---\\nestimated_sample_contamination |\\t<5%\\ninsert_length_mean |\\t300-600\\nnumber_of_duplicate_marked_reads_pct |\\t<30%\\npct_of_genome_with_coverage_20x_inf |\\t>92%\\nproperly_paired_reads_pct |\\t>90%\\nq30_bases_pct |\\t>85%\\ntotal_input_reads |\\t>800M\\naverage_autosomal_coverage_over_genome |\\t40X\\nmapped_reads |\\t>800M\\nmismatched_bases_r1_pct |\\t<1.5%\\nmismatched_bases_r2_pct |\\t<1.5%\\nreads_with_mapq_40inf_pct |\\t>85%\\nvariants_snps_pass |\\t3.5-5.5M\\nvariants_ti_to_tv_ratio_pass |\\t1.9-2.0\\n\\n\\n## University of Washington Center for Rare Disease Research (UW-CRDR)\\n\\nRelevant methods are described at https://uwmendelian.org/#/instruction.\\n\\n\\nTerra Data Repository Snapshot | Import timestamp\\n--- | ---\\nca23b03e-182d-4dff-8b0c-a27039d2ef61 | 2023-09-11T13:51:42\",\n",
       "   'library:indication': 'Mendelian Disorders',\n",
       "   'library:datasetOwner': 'Susanne May',\n",
       "   'library:datatype': {'itemsType': 'AttributeValue',\n",
       "    'items': ['Whole Exome, Whole Genome']},\n",
       "   'library:datasetCustodian': 'GREGoR Data Coordinating Center',\n",
       "   'library:projectName': 'GREGoR',\n",
       "   'library:institute': {'itemsType': 'AttributeValue',\n",
       "    'items': ['Baylor College of Medicine Research Center; Broad Institute; Childrens National Hospital / Invitae - Pediatric Mendelian Genomics, GREGoR Stanford Site; University of Washington Ceter for Rare Disease Research;']},\n",
       "   'library:technology': {'itemsType': 'AttributeValue',\n",
       "    'items': ['Illumina HiSeq, Illumina NovaSeq']},\n",
       "   'tag:tags': {'itemsType': 'AttributeValue',\n",
       "    'items': ['consent_code: HMB', 'Consortium: GREGoR', 'dbGaP: phs003047']},\n",
       "   'library:datasetDescription': 'The NHGRI GREGoR (Genomics Research to Elucidate the Genetics of Rare Disease) Consortium was established in June 2021 with the goal of developing novel tools and approaches to advance the discovery of the genetic basis of rare conditions. Numerous types of molecular data are generated in GREGoR and available on the AnVIL cloud platform via dbGaP application, including short- and long-read genome and exome sequencing, transcriptomics, metabolomics, methylomics, and proteomics. De-identified clinical and demographic data is obtained, with a focus on standardized ontologies. The Consortium comprises five Research Centers (RCs - see below), a Data Coordinating Center (DCC), and various partner members and external collaborators. Most participants are members of family trios consisting of the proband and parents.',\n",
       "   'library:contactEmail': 'gregorconsortium@uw.edu',\n",
       "   'library:numSubjects': 285,\n",
       "   'library:dataUseRestriction': 'HMB',\n",
       "   'library:datasetDepositor': 'GREGoR Data Coordinating Center',\n",
       "   'library:reference': 'GRCh38',\n",
       "   'library:datasetName': 'GREGoR Release R01 HMB',\n",
       "   'library:ethnicity': {'itemsType': 'AttributeValue',\n",
       "    'items': ['American indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, White']},\n",
       "   'library:dataCategory': {'itemsType': 'AttributeValue',\n",
       "    'items': ['Aligned DNA short read sequencing data, Variant call format (VCFs) files for SNVs and Indels, Data tables with subject, family, clinical phenotype and experimental information']},\n",
       "   'library:dataFileFormats': {'itemsType': 'AttributeValue',\n",
       "    'items': ['CRAM, BAM, VCF, BED, PED, TSV']}},\n",
       "  'authorizationDomain': [{'membersGroupName': 'AUTH_AnVIL_GREGOR_RELEASE_01_HMB'}],\n",
       "  'bucketName': 'fc-secure-8fc2057e-2be9-43d8-b8a0-36c493d4b546',\n",
       "  'googleProject': 'terra-8d5f958a'}}"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ws_attributes"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# dbGaP XML Parse"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'studyName': 'NHGRI GREGoR Consortium: Genomics Research to Elucidate the Genetics of Rare Disease', 'studyDescription': None, 'dbGaPPhsID': 'phs003047', 'dbGaPStudyRegistrationName': 'NHGRI GREGoR Consortium: Genomics Research to Elucidate the Genetics of Rare Disease', 'nihProgramOfficerName': 'Wellington, Christopher', 'nihGenomicProgramAdministratorName': 'Strasburger, Jennifer', 'nihICsSupportingStudy': ['NHGRI'], 'numberOfParticipants': '1000', 'embargoReleaseDate': 'none'}\n"
     ]
    }
   ],
   "source": [
    "# Parameters\n",
    "phs_id = \"phs003047\"\n",
    "#phs_id = \"phs000693\"\n",
    "\n",
    "# Pull and parse XML\n",
    "phs_short = phs_id.replace(\"phs\", \"\")\n",
    "dbgap_url = \"https://dbgap.ncbi.nlm.nih.gov/ss/dbgapssws.cgi?request=Study&phs=\" + phs_short\n",
    "response = requests.get(url=dbgap_url)\n",
    "xml_data = xmltodict.parse(response.text)\n",
    "\n",
    "# Map to schema\n",
    "dbgap_xml_dict = {}\n",
    "if isinstance(xml_data[\"dbgapss\"][\"Study\"], list):\n",
    "    study_data = xml_data[\"dbgapss\"][\"Study\"][0]\n",
    "else:\n",
    "    study_data = xml_data[\"dbgapss\"][\"Study\"] \n",
    "dbgap_xml_dict[\"studyName\"] = study_data[\"StudyInfo\"].get(\"StudyNameEntrez\")\n",
    "dbgap_xml_dict[\"studyDescription\"] = study_data[\"StudyInfo\"].get(\"Description\")\n",
    "dbgap_xml_dict[\"dbGaPPhsID\"] = phs_id\n",
    "dbgap_xml_dict[\"dbGaPStudyRegistrationName\"] = study_data[\"StudyInfo\"].get(\"StudyNameEntrez\")\n",
    "for ap_entry in study_data[\"Authority\"][\"Persons\"][\"Person\"]:\n",
    "    if ap_entry[\"Role\"] == \"PI\":\n",
    "        dbgap_xml_dict[\"piName\"] = ap_entry[\"@lname\"] + \", \" + ap_entry[\"@fname\"]\n",
    "        dbgap_xml_dict[\"piEmail\"] = ap_entry[\"@email\"]\n",
    "        dbgap_xml_dict[\"piInstitution\"] = ap_entry[\"Organization\"]\n",
    "    elif ap_entry[\"Role\"] == \"PO\" and ap_entry[\"Organization\"] == \"NIH\":\n",
    "        dbgap_xml_dict[\"nihProgramOfficerName\"] = ap_entry[\"@lname\"] + \", \" + ap_entry[\"@fname\"]\n",
    "    elif ap_entry[\"Role\"] == \"GPA\" and ap_entry[\"Organization\"] == \"NIH\":\n",
    "        dbgap_xml_dict[\"nihGenomicProgramAdministratorName\"] = ap_entry[\"@lname\"] + \", \" + ap_entry[\"@fname\"]\n",
    "ic_list = []\n",
    "if isinstance(study_data[\"Authority\"][\"ICs\"][\"IC\"], list):\n",
    "    for ic_entry in study_data[\"Authority\"][\"ICs\"][\"IC\"]:\n",
    "        ic_list.append(ic_entry[\"@name\"])\n",
    "else:\n",
    "    ic_list.append(study_data[\"Authority\"][\"ICs\"][\"IC\"][\"@name\"])\n",
    "dbgap_xml_dict[\"nihICsSupportingStudy\"] = ic_list\n",
    "dbgap_xml_dict[\"numberOfParticipants\"] = study_data.get(\"@num_participants\")\n",
    "dbgap_xml_dict[\"embargoReleaseDate\"] = study_data[\"Policy\"].get(\"@pub-embargo\")\n",
    "\n",
    "# View schema\n",
    "print(dbgap_xml_dict)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'@uid': '52672',\n",
       " '@whole_study_id': '8807',\n",
       " '@phs': '000693',\n",
       " '@v': '7',\n",
       " '@createDate': '2023-08-11T15:26:30-05:00',\n",
       " '@modDate': '2023-08-11T15:26:32-05:00',\n",
       " '@maxParentChildStudyModDate': '2023-08-11T15:26:32-05:00',\n",
       " '@handle': 'MendelianGenomics_UW',\n",
       " '@num_participants': '5000',\n",
       " 'StudyInfo': {'@accession': 'phs000693.v7',\n",
       "  '@parentAccession': 'phs000693.v7',\n",
       "  'BioProject': [{'@id': 'PRJNA233538',\n",
       "    '@entrez_id': '233538',\n",
       "    '@type': 'bp_admin_access'},\n",
       "   {'@id': 'PRJNA233539',\n",
       "    '@entrez_id': '233539',\n",
       "    '@type': 'bp_data_submission'}],\n",
       "  'StudyNameEntrez': 'Center for Mendelian Genomics [CMG] - University of Washington Center for Mendelian Genomics',\n",
       "  'StudyTypes': None,\n",
       "  'StudyTypes2': {'@calculated': 'No',\n",
       "   'StudyType21': [{'@name': 'phenotype_data', '@chosen': 'No'},\n",
       "    {'@name': 'analysis', '@chosen': 'No'},\n",
       "    {'@name': 'individual_sequencing', '@chosen': 'No'},\n",
       "    {'@name': 'supporting_documents', '@chosen': 'No'},\n",
       "    {'@name': 'images', '@chosen': 'No'},\n",
       "    {'@name': 'molecular', '@chosen': 'No'},\n",
       "    {'@name': 'subject_samples', '@chosen': 'No'},\n",
       "    {'@name': 'links_to_ncbi_dbs', '@chosen': 'No'},\n",
       "    {'@name': 'other_general', '@chosen': 'No', '@other_value': ''}]},\n",
       "  'Funding': 'U54 HG006493'},\n",
       " 'Authority': {'ICs': {'IC': [{'@id': '12',\n",
       "     '@name': 'NHLBI',\n",
       "     '@is_funding_ic': 'false',\n",
       "     '@is_admin_ic': 'false'},\n",
       "    {'@id': '15',\n",
       "     '@name': 'NHGRI',\n",
       "     '@is_funding_ic': 'false',\n",
       "     '@is_admin_ic': 'false',\n",
       "     '@primary': 'true'},\n",
       "    {'@id': '4',\n",
       "     '@name': 'NCI',\n",
       "     '@is_funding_ic': 'false',\n",
       "     '@is_admin_ic': 'false'}]},\n",
       "  'Persons': {'Person': [{'@nedid': 'DEBNICK',\n",
       "     '@aid': '2',\n",
       "     '@auth': 'eRA',\n",
       "     '@login': 'DEBNICK',\n",
       "     '@fname': 'DEBORAH',\n",
       "     '@mname': 'A',\n",
       "     '@lname': 'NICKERSON',\n",
       "     '@email': 'debnick@u.washington.edu',\n",
       "     'Role': 'PI',\n",
       "     'Organization': 'UNIVERSITY OF WASHINGTON'},\n",
       "    {'@nedid': '0012271892',\n",
       "     '@aid': '1',\n",
       "     '@auth': 'cit',\n",
       "     '@login': 'chadwickl',\n",
       "     '@fname': 'Lisa',\n",
       "     '@mname': 'Helbling',\n",
       "     '@lname': 'Chadwick',\n",
       "     '@email': 'lisa.chadwick@nih.gov',\n",
       "     'Role': 'PO',\n",
       "     'Organization': 'NIH'},\n",
       "    {'@aid': '8',\n",
       "     '@auth': 'virtual',\n",
       "     '@fname': 'Colleen',\n",
       "     '@lname': 'Davis',\n",
       "     '@email': 'codavis@u.washington.edu',\n",
       "     'Role': 'PI_ASSIST',\n",
       "     'Organization': None},\n",
       "    {'@nedid': '0010579723',\n",
       "     '@aid': '1',\n",
       "     '@auth': 'cit',\n",
       "     '@login': 'wewu',\n",
       "     '@fname': 'Wenyu',\n",
       "     '@mname': '',\n",
       "     '@lname': 'Wu',\n",
       "     '@email': 'wwu@ncbi.nlm.nih.gov',\n",
       "     'Role': 'PHENO_CURATOR',\n",
       "     'Organization': 'NIH'},\n",
       "    {'@nedid': '0011552437',\n",
       "     '@aid': '1',\n",
       "     '@auth': 'cit',\n",
       "     '@login': 'jawang',\n",
       "     '@fname': 'Zhen',\n",
       "     '@mname': 'Yuan',\n",
       "     '@lname': 'Wang',\n",
       "     '@email': 'zhen.wang@nih.gov',\n",
       "     'Role': 'GENO_CURATOR',\n",
       "     'Organization': 'NIH'},\n",
       "    {'@nedid': '0010170421',\n",
       "     '@aid': '1',\n",
       "     '@auth': 'cit',\n",
       "     '@login': 'strasbuj',\n",
       "     '@fname': 'Jennifer',\n",
       "     '@mname': 'A',\n",
       "     '@lname': 'Strasburger',\n",
       "     '@email': 'strasbuj@mail.nih.gov',\n",
       "     'Role': 'GPA',\n",
       "     'Organization': 'NIH'}]}},\n",
       " 'Policy': {'@display-research-statement': 'true',\n",
       "  '@display-public-summary': 'true',\n",
       "  '@years-until-renewal': '1',\n",
       "  '@weeks-to-cancel-request': '8',\n",
       "  '@pub-embargo': 'none',\n",
       "  'acknowledgement_statement': 'National Institutes of Health (NIH) support was provided in part by a grant from the National Human Genome Research Institute and the National Heart, Lung, and Blood Institute (2UM1HG006493) to Drs. Debbie Nickerson, Michael Bamshad, and Suzanne Leal for the UW Center for Mendelian Genomics program, which generated the sequence data. The dataset(s) used for the analyses described in this manuscript was obtained from the database of Genotype and Phenotype (dbGaP) found at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number phs000693.',\n",
       "  'ic_specific_access_term': None,\n",
       "  'DUC': {'@universal_duc': 'Yes',\n",
       "   'File': {'@full_url': 'https://dbgap.ncbi.nlm.nih.gov/aa/docs/Universal_DUC_20190319-01102023.pdf',\n",
       "    '@filename': 'Universal_DUC_20190319-01102023.pdf',\n",
       "    '@content-type': 'application/pdf'}},\n",
       "  'DUC_PDF': {'@universal_duc': 'Yes',\n",
       "   'File': {'@full_url': 'https://dbgap.ncbi.nlm.nih.gov/aa/docs/Universal_DUC_20190319-01102023.pdf',\n",
       "    '@filename': 'Universal_DUC_20190319-01102023.pdf',\n",
       "    '@content-type': 'application/pdf'}},\n",
       "  'GSR_Access': {'@gsr_mode': 'unrest_access_new_cert',\n",
       "   '@gsr_mode_label': 'Unrestricted access (according to a new Institutional Certification)'},\n",
       "  'ConsentGroup': [{'@uid': '897',\n",
       "    '@CGType': 'cg_class_GRU',\n",
       "    '@title': 'General Research Use',\n",
       "    '@name': 'GRU',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data is limited only by the terms of the model Data Use Certification.'},\n",
       "   {'@uid': '4221',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Epilepsy)',\n",
       "    '@name': 'DS-EP',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Epilepsy.'},\n",
       "   {'@uid': '4222',\n",
       "    '@CGType': 'cg_class_HMB',\n",
       "    '@title': 'Health/Medical/Biomedical (GSO)',\n",
       "    '@name': 'HMB-GSO',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.\\nUse of the data is limited to genetic studies only.'},\n",
       "   {'@uid': '4223',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Skin Laxity or Arterial Narrowing, NPU)',\n",
       "    '@name': 'DS-SL_AN-NPU',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Skin Laxity or Arterial Narrowing.\\nUse of the data is limited to not-for-profit organizations.'},\n",
       "   {'@uid': '4224',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Supravalvular Aortic Stenosis or Cutix Laxa)',\n",
       "    '@name': 'DS-SASC',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Supravalvular Aortic Stenosis or Cutix Laxa.'},\n",
       "   {'@uid': '4225',\n",
       "    '@CGType': 'cg_class_HMB',\n",
       "    '@title': 'Health/Medical/Biomedical (NPU)',\n",
       "    '@name': 'HMB-NPU',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.\\nUse of the data is limited to not-for-profit organizations.'},\n",
       "   {'@uid': '4226',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Skeletal Dysplasias)',\n",
       "    '@name': 'DS-SKDYS',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Skeletal Dysplasias.'},\n",
       "   {'@uid': '4227',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Bicuspid Aortic Valve, IRB, PUB, RD)',\n",
       "    '@name': 'DS-BAV-IRB-PUB-RD',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'Yes',\n",
       "    'Use-Restriction': 'Use of the data must be related to Bicuspid Aortic Valve and related disorders.\\nRequestor must provide documentation of local IRB approval.\\nRequestor agrees to make results of studies using the data available to the larger scientific community.'},\n",
       "   {'@uid': '4228',\n",
       "    '@CGType': 'cg_class_HMB',\n",
       "    '@title': 'Health/Medical/Biomedical',\n",
       "    '@name': 'HMB',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.'},\n",
       "   {'@uid': '4229',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Brain Abnormalities)',\n",
       "    '@name': 'DS-BAB',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Brain Abnormalities.'},\n",
       "   {'@uid': '4230',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Skeletal Dysplasias, RD)',\n",
       "    '@name': 'DS-SKDYS-RD',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Skeletal Dysplasias and related disorders.'},\n",
       "   {'@uid': '4233',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Hallervorden-Spatz Syndrome)',\n",
       "    '@name': 'DS-HSS',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Hallervorden-Spatz Syndrome.'},\n",
       "   {'@uid': '4234',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Neurological and Related Disorders)',\n",
       "    '@name': 'DS-NDRD',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Neurological and Related Disorders.'},\n",
       "   {'@uid': '4235',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Progeria)',\n",
       "    '@name': 'DS-PRO',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Progeria.'},\n",
       "   {'@uid': '4236',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Genetic and Inherited Disorders)',\n",
       "    '@name': 'DS-GIDIS',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Genetic and Inherited Disorders.'},\n",
       "   {'@uid': '4237',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Rare Disorders Involving Malformations of Head and Neck)',\n",
       "    '@name': 'DS-RCTD',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Rare Disorders Involving Malformations of Head and Neck.'},\n",
       "   {'@uid': '4238',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Epilepsy and Disorders of Human Cognition)',\n",
       "    '@name': 'DS-HECD',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Epilepsy and Disorders of Human Cognition.'},\n",
       "   {'@uid': '4239',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Lipodystrophy, Premature Aging, or Related Syndromes, IRB)',\n",
       "    '@name': 'DS-LPARS-IRB',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'Yes',\n",
       "    'Use-Restriction': 'Use of the data must be related to Lipodystrophy, Premature Aging, or Related Syndromes.\\nRequestor must provide documentation of local IRB approval.'},\n",
       "   {'@uid': '4240',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Idiopathic Pulmonary Fibrosis)',\n",
       "    '@name': 'DS-IPF',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Idiopathic Pulmonary Fibrosis.'},\n",
       "   {'@uid': '4241',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Liver Disease)',\n",
       "    '@name': 'DS-LIVD',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Liver Disease.'},\n",
       "   {'@uid': '4242',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Head and Face)',\n",
       "    '@name': 'DS-HFA',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Head and Face.'},\n",
       "   {'@uid': '4243',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Idiopathic Fibrosis)',\n",
       "    '@name': 'DS-IF',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Idiopathic Fibrosis.'},\n",
       "   {'@uid': '4244',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Thyroid Cancer, IRB)',\n",
       "    '@name': 'DS-TC-IRB',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'Yes',\n",
       "    'Use-Restriction': 'Use of the data must be related to Thyroid Cancer.\\nRequestor must provide documentation of local IRB approval.'},\n",
       "   {'@uid': '4245',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Pediatric Liver or Gut Disease, NPU)',\n",
       "    '@name': 'DS-PLGD-NPU',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Pediatric Liver or Gut Disease.\\nUse of the data is limited to not-for-profit organizations.'},\n",
       "   {'@uid': '4246',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Lung Diseases)',\n",
       "    '@name': 'DS-LD',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Lung Diseases.'},\n",
       "   {'@uid': '4247',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Trichelemmel Cysts)',\n",
       "    '@name': 'DS-TRIC',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Trichelemmel Cysts.'},\n",
       "   {'@uid': '4248',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Neurodegeneration with Brain Iron Accumulation)',\n",
       "    '@name': 'DS-NBIA',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Neurodegeneration with Brain Iron Accumulation.'},\n",
       "   {'@uid': '4249',\n",
       "    '@CGType': 'cg_class_HMB',\n",
       "    '@title': 'Health/Medical/Biomedical (IRB)',\n",
       "    '@name': 'HMB-IRB',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'Yes',\n",
       "    'Use-Restriction': 'Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.\\nRequestor must provide documentation of local IRB approval.'},\n",
       "   {'@uid': '4250',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Congenital Heart Disease, IRB)',\n",
       "    '@name': 'DS-CHD-IRB',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'Yes',\n",
       "    'Use-Restriction': 'Use of the data must be related to Congenital Heart Disease.\\nRequestor must provide documentation of local IRB approval.'},\n",
       "   {'@uid': '4251',\n",
       "    '@CGType': 'cg_class_GRU',\n",
       "    '@title': 'General Research Use (IRB)',\n",
       "    '@name': 'GRU-IRB',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'Yes',\n",
       "    'Use-Restriction': 'Use of the data is limited only by the terms of the model Data Use Certification.\\nRequestor must provide documentation of local IRB approval.'},\n",
       "   {'@uid': '4252',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Hereditary Condition Causes)',\n",
       "    '@name': 'DS-CHC',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Hereditary Condition Causes.'},\n",
       "   {'@uid': '4253',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Split Hand Foot Malformations and Related Disorders)',\n",
       "    '@name': 'DS-SHFM',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Split Hand Foot Malformations and Related Disorders.'},\n",
       "   {'@uid': '4254',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Causes or Etiology of Rare Diseases)',\n",
       "    '@name': 'DS-CERD',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Causes or Etiology of Rare Diseases.'},\n",
       "   {'@uid': '4255',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Brain Disorders)',\n",
       "    '@name': 'DS-BDIS',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Brain Disorders.'},\n",
       "   {'@uid': '4256',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Congenital Heart Defects)',\n",
       "    '@name': 'DS-CHDEF',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Congenital Heart Defects.'},\n",
       "   {'@uid': '4257',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Lymphatic Disease)',\n",
       "    '@name': 'DS-LYD',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Lymphatic Disease.'}],\n",
       "  'ConsentGroupLinks': {'ConsentGroupLink': {'@cg_uid_from': '897',\n",
       "    'StudyTo': {'@study_uid': '10253',\n",
       "     '@name': 'dbGaP Collection: Compilation of Individual-Level Genomic Data for General Research Use',\n",
       "     '@accession': 'phs000688.v1',\n",
       "     'ConsentGroupTo': {'@uid': '1115', '@name': 'GRU'}}}},\n",
       "  'TrustedPartners': {'TrustedPartner': {'@trp_id': '7',\n",
       "    '@trp_db_name': 'AnVIL',\n",
       "    '@trp_download_url': 'https://anvilproject.org/',\n",
       "    '@trp_help_url': 'help@lists.anvilproject.org',\n",
       "    'StudyFlags': {'@sam_with_min_meta': 'No',\n",
       "     '@seq_data_to_ncbi': 'No',\n",
       "     '@gen_phen_to_ncbi': 'No',\n",
       "     '@has_out_ncbi_data': 'Yes'}}}},\n",
       " 'SRA': None,\n",
       " 'Documents': None,\n",
       " 'Status': {'@uid': '2',\n",
       "  '@name': 'complete',\n",
       "  '@title': \"Awaiting GPA's Approval\"}}"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "study_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'@uid': '41868',\n",
       " '@whole_study_id': '26521',\n",
       " '@phs': '001642',\n",
       " '@v': '2',\n",
       " '@p': '1',\n",
       " '@createDate': '2021-05-11T09:57:32-05:00',\n",
       " '@completedByGPADate': '2022-04-27T14:24:32-05:00',\n",
       " '@modDate': '2023-05-05T22:04:26-05:00',\n",
       " '@maxParentChildStudyModDate': '2023-05-05T22:04:26-05:00',\n",
       " '@handle': 'CCDG_IBD',\n",
       " '@num_participants': '8000',\n",
       " 'StudyInfo': {'@accession': 'phs001642.v2.p1',\n",
       "  '@parentAccession': 'phs001642.v2.p1',\n",
       "  'BioProject': [{'@id': 'PRJNA477898',\n",
       "    '@entrez_id': '477898',\n",
       "    '@type': 'bp_admin_access'},\n",
       "   {'@id': 'PRJNA477899',\n",
       "    '@entrez_id': '477899',\n",
       "    '@type': 'bp_data_submission'}],\n",
       "  'StudyNameEntrez': 'Center for Common Disease Genomics [CCDG] - Inflammatory Bowel Disease (IBD) Genomes',\n",
       "  'StudyTypes': None,\n",
       "  'StudyTypes2': {'@calculated': 'No',\n",
       "   'StudyType21': [{'@name': 'phenotype_data', '@chosen': 'No'},\n",
       "    {'@name': 'analysis', '@chosen': 'No'},\n",
       "    {'@name': 'individual_sequencing', '@chosen': 'No'},\n",
       "    {'@name': 'supporting_documents', '@chosen': 'No'},\n",
       "    {'@name': 'images', '@chosen': 'No'},\n",
       "    {'@name': 'molecular', '@chosen': 'No'},\n",
       "    {'@name': 'subject_samples', '@chosen': 'No'},\n",
       "    {'@name': 'links_to_ncbi_dbs', '@chosen': 'No'},\n",
       "    {'@name': 'other_general', '@chosen': 'No', '@other_value': ''}]},\n",
       "  'Funding': 'HG008895'},\n",
       " 'Authority': {'ICs': {'IC': {'@id': '15',\n",
       "    '@name': 'NHGRI',\n",
       "    '@is_funding_ic': 'false',\n",
       "    '@is_admin_ic': 'false',\n",
       "    '@primary': 'true'}},\n",
       "  'Persons': {'Person': [{'@nedid': 'MJDALY',\n",
       "     '@aid': '2',\n",
       "     '@auth': 'eRA',\n",
       "     '@login': 'MJDALY',\n",
       "     '@fname': 'Mark',\n",
       "     '@mname': 'J',\n",
       "     '@lname': 'Daly',\n",
       "     '@email': 'mjdaly@broadinstitute.org',\n",
       "     'Role': {'@allow_direct_access': 'true', '#text': 'PI'},\n",
       "     'Organization': 'MASSACHUSETTS INSTITUTE OF TECHNOLOGYBROAD INSTITUTE, INC.MASSACHUSETTS GENERAL HOSPITAL'},\n",
       "    {'@nedid': '0010085947',\n",
       "     '@aid': '1',\n",
       "     '@auth': 'cit',\n",
       "     '@login': 'felsenfa',\n",
       "     '@fname': 'Adam',\n",
       "     '@mname': 'Lewis',\n",
       "     '@lname': 'Felsenfeld',\n",
       "     '@email': 'felsenfa@exchange.nih.gov',\n",
       "     'Role': 'PO',\n",
       "     'Organization': 'NIH'},\n",
       "    {'@nedid': 'CHRISTINESTEVENS',\n",
       "     '@aid': '2',\n",
       "     '@auth': 'eRA',\n",
       "     '@login': 'CHRISTINESTEVENS',\n",
       "     '@fname': 'Christine',\n",
       "     '@mname': '',\n",
       "     '@lname': 'Stevens',\n",
       "     '@email': 'stevens@broadinstitute.org',\n",
       "     'Role': 'PI_ASSIST',\n",
       "     'Organization': 'BROAD INSTITUTE, INC.'},\n",
       "    {'@nedid': '0010579723',\n",
       "     '@aid': '1',\n",
       "     '@auth': 'cit',\n",
       "     '@login': 'wewu',\n",
       "     '@fname': 'Wenyu',\n",
       "     '@mname': '',\n",
       "     '@lname': 'Wu',\n",
       "     '@email': 'wwu@ncbi.nlm.nih.gov',\n",
       "     'Role': 'PHENO_CURATOR',\n",
       "     'Organization': 'NIH'},\n",
       "    {'@nedid': '0011559580',\n",
       "     '@aid': '1',\n",
       "     '@auth': 'cit',\n",
       "     '@login': 'stefanov',\n",
       "     '@fname': 'Stefan',\n",
       "     '@mname': 'Alexandrov',\n",
       "     '@lname': 'Stefanov',\n",
       "     '@email': 'stefanov@mail.nih.gov',\n",
       "     'Role': 'GENO_CURATOR',\n",
       "     'Organization': 'NIH'},\n",
       "    {'@nedid': '0010170421',\n",
       "     '@aid': '1',\n",
       "     '@auth': 'cit',\n",
       "     '@login': 'strasbuj',\n",
       "     '@fname': 'Jennifer',\n",
       "     '@mname': 'A',\n",
       "     '@lname': 'Strasburger',\n",
       "     '@email': 'strasbuj@mail.nih.gov',\n",
       "     'Role': 'GPA',\n",
       "     'Organization': 'NIH'}]}},\n",
       " 'Policy': {'@display-research-statement': 'true',\n",
       "  '@display-public-summary': 'true',\n",
       "  '@years-until-renewal': '1',\n",
       "  '@weeks-to-cancel-request': '8',\n",
       "  '@pub-embargo': 'none',\n",
       "  'acknowledgement_statement': 'Sequencing at Broad Institute was supported by NHGRI grant UM1HG008895.  We acknowledge the clinicians and organizations that contributed to samples used in this study. Finally, we are grateful to the many families whose participation made this study possible.',\n",
       "  'ic_specific_access_term': None,\n",
       "  'DUC': {'@universal_duc': 'Yes',\n",
       "   'File': {'@full_url': 'https://dbgap.ncbi.nlm.nih.gov/aa/docs/Universal_DUC_20190319-01102023.pdf',\n",
       "    '@filename': 'Universal_DUC_20190319-01102023.pdf',\n",
       "    '@content-type': 'application/pdf'}},\n",
       "  'DUC_PDF': {'@universal_duc': 'Yes',\n",
       "   'File': {'@full_url': 'https://dbgap.ncbi.nlm.nih.gov/aa/docs/Universal_DUC_20190319-01102023.pdf',\n",
       "    '@filename': 'Universal_DUC_20190319-01102023.pdf',\n",
       "    '@content-type': 'application/pdf'}},\n",
       "  'GSR_Access': {'@gsr_mode': 'unrest_access_by_timeout',\n",
       "   '@gsr_mode_label': 'Unrestricted access (institution did not respond within six months)'},\n",
       "  'ConsentGroup': [{'@uid': '2725',\n",
       "    '@CGType': 'cg_class_GRU',\n",
       "    '@title': 'General Research Use',\n",
       "    '@name': 'GRU',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data is limited only by the terms of the model Data Use Certification.'},\n",
       "   {'@uid': '2726',\n",
       "    '@CGType': 'cg_class_HMB',\n",
       "    '@title': 'Health/Medical/Biomedical',\n",
       "    '@name': 'HMB',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.'},\n",
       "   {'@uid': '2727',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Inflammatory Bowel Disease)',\n",
       "    '@name': 'DS-IBD',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Inflammatory Bowel Disease.'},\n",
       "   {'@uid': '2728',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Gastrointestinal Diseases)',\n",
       "    '@name': 'DS-GID',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Gastrointestinal Diseases.'},\n",
       "   {'@uid': '5838',\n",
       "    '@CGType': 'cg_class_HMB',\n",
       "    '@title': 'Health/Medical/Biomedical (IRB, MDS)',\n",
       "    '@name': 'HMB-IRB-MDS',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'Yes',\n",
       "    'Use-Restriction': 'Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.\\nRequestor must provide documentation of local IRB approval.\\nUse of the data includes methods development research (e.g., development of software or algorithms).'},\n",
       "   {'@uid': '5839',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Inflammatory Bowel Disease, MDS)',\n",
       "    '@name': 'DS-IBD-MDS',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Inflammatory Bowel Disease.\\nUse of the data includes methods development research (e.g., development of software or algorithms).'},\n",
       "   {'@uid': '5840',\n",
       "    '@CGType': 'cg_class_HMB',\n",
       "    '@title': 'Health/Medical/Biomedical (MDS)',\n",
       "    '@name': 'HMB-MDS',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.\\nUse of the data includes methods development research (e.g., development of software or algorithms).'},\n",
       "   {'@uid': '5841',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Digestive System Diseases, MDS)',\n",
       "    '@name': 'DS-DSDI-MDS',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'No',\n",
       "    'Use-Restriction': 'Use of the data must be related to Digestive System Diseases.\\nUse of the data includes methods development research (e.g., development of software or algorithms).\\n\\nResearch only in adults over 18 YO.'},\n",
       "   {'@uid': '5842',\n",
       "    '@CGType': 'cg_class_DS',\n",
       "    '@title': 'Disease-Specific (Gastroenterology, IRB, MDS)',\n",
       "    '@name': 'DS-GR-IRB-MDS',\n",
       "    '@dac_uid': '54',\n",
       "    '@dac_name': 'NHGRI',\n",
       "    '@irb-approval-required': 'Yes',\n",
       "    'Use-Restriction': 'Use of the data must be related to Gastroenterology.\\nRequestor must provide documentation of local IRB approval.\\nUse of the data includes methods development research (e.g., development of software or algorithms).'}],\n",
       "  'TrustedPartners': {'TrustedPartner': {'@trp_id': '7',\n",
       "    '@trp_db_name': 'AnVIL',\n",
       "    '@trp_download_url': 'https://anvilproject.org/',\n",
       "    '@trp_help_url': 'help@lists.anvilproject.org',\n",
       "    'StudyFlags': {'@sam_with_min_meta': 'No',\n",
       "     '@seq_data_to_ncbi': 'No',\n",
       "     '@gen_phen_to_ncbi': 'No',\n",
       "     '@has_out_ncbi_data': 'Yes'}}}},\n",
       " 'SRA': None,\n",
       " 'Documents': None,\n",
       " 'Status': {'@uid': '1', '@name': 'released', '@title': 'Released'}}"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "study_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# dbGaP Study API"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{}\n"
     ]
    }
   ],
   "source": [
    "# Parameters\n",
    "study_uid = 483191234\n",
    "\n",
    "# Pull and parse JSON\n",
    "dbgap_study_url = \"https://submit.ncbi.nlm.nih.gov/dbgap/api/v1/study_config/\" + str(study_uid)\n",
    "response = requests.get(url=dbgap_study_url)\n",
    "study_api_data = json.loads(response.text)\n",
    "\n",
    "# Map to schema\n",
    "dbgap_study_api_dict = {}\n",
    "if study_api_data.get(\"error\") == None:\n",
    "    dbgap_study_api_dict[\"studyName\"] = study_api_data[\"data\"].get(\"report_name\")\n",
    "    dbgap_study_api_dict[\"studyDescription\"] = study_api_data[\"data\"].get(\"description\")\n",
    "    dbgap_study_api_dict[\"phenotypeIndication\"] = study_api_data[\"data\"].get(\"primary_disease\")\n",
    "    dbgap_study_api_dict[\"studyType\"] = study_api_data[\"data\"].get(\"study_design\")\n",
    "    for attr_entry in study_api_data[\"data\"].get(\"attribution\"):\n",
    "        if attr_entry.get(\"title\") == \"Principal Investigator\":\n",
    "            dbgap_study_api_dict[\"piName\"] = attr_entry.get(\"name\")\n",
    "            dbgap_study_api_dict[\"piInstitution\"] = attr_entry.get(\"institute\")\n",
    "            break\n",
    "\n",
    "# View schema\n",
    "print(dbgap_study_api_dict)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'error': {'message': 'Invalid or non-existent study with study uid 483191234',\n",
       "  'code': 1}}"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "study_api_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# dbGaP FHIR API"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'studyName': 'University of Washington Center for Mendelian Genomics (UW-CMG)', 'studyDescription': '\\nThe Centers for Mendelian Genomics project uses next-generation sequencing and computational approaches to discover the genes and variants that underlie Mendelian conditions. By discovering genes that cause Mendelian conditions, we will expand our understanding of their biology to facilitate diagnosis and new treatments.\\n', 'dbGaPPhsID': 'phs000693', 'dbGaPStudyRegistrationName': 'University of Washington Center for Mendelian Genomics (UW-CMG)', 'nihICsSupportingStudy': 'National Human Genome Research Institute', 'studyType': 'Mendelian', 'dataTypes': ['SNP Genotypes (NGS)', 'SNP/CNV Genotypes (NGS)'], 'phenotypeIndication': 'Rare Diseases', 'numberOfParticipants': '1'}\n"
     ]
    }
   ],
   "source": [
    "# Parameters\n",
    "#phs_id = \"phs003047\"\n",
    "phs_id = \"phs000693\"\n",
    "\n",
    "# Pull and parse JSON\n",
    "dbgap_fhir_url = \"https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/ResearchStudy?_format=json&_id=\" + phs_id\n",
    "response = requests.get(url=dbgap_fhir_url)\n",
    "fhir_data = json.loads(response.text)\n",
    "\n",
    "# Map to schema\n",
    "dbgap_fhir_dict = {}\n",
    "dbgap_fhir_dict[\"studyName\"] = fhir_data[\"entry\"][0][\"resource\"].get(\"title\")\n",
    "dbgap_fhir_dict[\"studyDescription\"] = fhir_data[\"entry\"][0][\"resource\"].get(\"description\")\n",
    "dbgap_fhir_dict[\"dbGaPPhsID\"] = phs_id\n",
    "dbgap_fhir_dict[\"dbGaPStudyRegistrationName\"] = fhir_data[\"entry\"][0][\"resource\"].get(\"title\")\n",
    "dbgap_fhir_dict[\"nihICsSupportingStudy\"] = fhir_data[\"entry\"][0][\"resource\"][\"sponsor\"].get(\"display\")\n",
    "# studyType\n",
    "for cat_entry in fhir_data[\"entry\"][0][\"resource\"].get(\"category\"):\n",
    "    for coding_entry in cat_entry.get(\"coding\"):\n",
    "        if coding_entry.get(\"system\") == \"https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyDesign\":\n",
    "            value = coding_entry.get(\"display\") if coding_entry.get(\"display\") else coding_entry.get(\"code\")\n",
    "            if dbgap_fhir_dict.get(\"studyType\") and value:\n",
    "                dbgap_fhir_dict[\"studyType\"] += f\", {value}\"\n",
    "            elif value:\n",
    "                dbgap_fhir_dict[\"studyType\"] = value\n",
    "# dataTypes\n",
    "dt_list = []\n",
    "for ext_entry in fhir_data[\"entry\"][0][\"resource\"].get(\"extension\"):\n",
    "    if ext_entry.get(\"url\") == \"https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-MolecularDataTypes\":\n",
    "        for inner_ext_entry in ext_entry.get(\"extension\"):\n",
    "            if inner_ext_entry.get(\"url\") == \"https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-MolecularDataTypes-MolecularDataType\":\n",
    "                for coding_entry in inner_ext_entry[\"valueCodeableConcept\"].get(\"coding\"):\n",
    "                    dt_list.append(coding_entry.get(\"code\"))\n",
    "dbgap_fhir_dict[\"dataTypes\"] = dt_list\n",
    "# phenotypeIndication\n",
    "for focus_entry in fhir_data[\"entry\"][0][\"resource\"].get(\"focus\"):\n",
    "    for coding_entry in focus_entry.get(\"coding\"):\n",
    "        value = coding_entry.get(\"display\") if coding_entry.get(\"display\") else coding_entry.get(\"code\")\n",
    "        if dbgap_fhir_dict.get(\"phenotypeIndication\") and value:\n",
    "            dbgap_fhir_dict[\"phenotypeIndication\"] += f\", {value}\"\n",
    "        elif value:\n",
    "            dbgap_fhir_dict[\"phenotypeIndication\"] = value\n",
    "# numberOfParticipants\n",
    "for ext_entry in fhir_data[\"entry\"][0][\"resource\"].get(\"extension\"):\n",
    "    if ext_entry.get(\"url\") == \"https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-Content\":\n",
    "        for inner_ext_entry in ext_entry.get(\"extension\"):\n",
    "            if inner_ext_entry.get(\"url\") == \"https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-Content-NumSubjects\":\n",
    "                dbgap_fhir_dict[\"numberOfParticipants\"] = inner_ext_entry[\"valueCount\"].get(\"code\")\n",
    "\n",
    "# View schema\n",
    "print(dbgap_fhir_dict)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'resourceType': 'Bundle',\n",
       " 'id': '37fafb4c-88e7-4afc-8a1c-e2229ba94055',\n",
       " 'meta': {'lastUpdated': '2023-10-10T10:00:06.464-04:00'},\n",
       " 'type': 'searchset',\n",
       " 'total': 1,\n",
       " 'link': [{'relation': 'self',\n",
       "   'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/ResearchStudy?_format=json&_id=phs000693'}],\n",
       " 'entry': [{'fullUrl': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/ResearchStudy/phs000693',\n",
       "   'resource': {'resourceType': 'ResearchStudy',\n",
       "    'id': 'phs000693',\n",
       "    'meta': {'versionId': '1',\n",
       "     'lastUpdated': '2022-02-14T02:01:18.881-05:00',\n",
       "     'source': '#z4zdXYRpgdryBD2q',\n",
       "     'security': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/DbGaPConcept-SecurityStudyConsent',\n",
       "       'code': 'public',\n",
       "       'display': 'public'}]},\n",
       "    'extension': [{'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyOverviewUrl',\n",
       "      'valueUrl': 'https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000693.v6.p2'},\n",
       "     {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-ReleaseDate',\n",
       "      'valueDate': '2021-05-04'},\n",
       "     {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents',\n",
       "      'extension': [{'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 1',\n",
       "         'display': 'GRU'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 2',\n",
       "         'display': 'DS-EP'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 3',\n",
       "         'display': 'HMB-GSO'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 4',\n",
       "         'display': 'DS-SL_AN-NPU'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 5',\n",
       "         'display': 'DS-SASC'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 6',\n",
       "         'display': 'HMB-NPU'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 7',\n",
       "         'display': 'DS-SKDYS'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 8',\n",
       "         'display': 'DS-BAV-IRB-PUB-RD'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 9',\n",
       "         'display': 'HMB'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 10',\n",
       "         'display': 'DS-BAB'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 11',\n",
       "         'display': 'DS-SKDYS-RD'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 12',\n",
       "         'display': 'DS-HSS'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 13',\n",
       "         'display': 'DS-NDRD'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 14',\n",
       "         'display': 'DS-PRO'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 15',\n",
       "         'display': 'DS-GIDIS'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 16',\n",
       "         'display': 'DS-RCTD'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 17',\n",
       "         'display': 'DS-HECD'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 18',\n",
       "         'display': 'DS-LPARS-IRB'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 19',\n",
       "         'display': 'DS-IPF'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 20',\n",
       "         'display': 'DS-LIVD'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 21',\n",
       "         'display': 'DS-HFA'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 22',\n",
       "         'display': 'DS-IF'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 23',\n",
       "         'display': 'DS-TC-IRB'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 24',\n",
       "         'display': 'DS-PLGD-NPU'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 25',\n",
       "         'display': 'DS-LD'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 26',\n",
       "         'display': 'DS-TRIC'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 27',\n",
       "         'display': 'DS-NBIA'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 28',\n",
       "         'display': 'HMB-IRB'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 29',\n",
       "         'display': 'DS-CHD-IRB'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 30',\n",
       "         'display': 'GRU-IRB'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 31',\n",
       "         'display': 'DS-CHC'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 32',\n",
       "         'display': 'DS-SHFM'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 33',\n",
       "         'display': 'DS-CERD'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 34',\n",
       "         'display': 'DS-BDIS'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 35',\n",
       "         'display': 'DS-CHDEF'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-StudyConsents-StudyConsent',\n",
       "        'valueCoding': {'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyConsents-StudyConsent',\n",
       "         'code': 'phs000693.v6.p2 - 36',\n",
       "         'display': 'DS-LYD'}}]},\n",
       "     {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-Content',\n",
       "      'extension': [{'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-Content-NumMolecularDatasets',\n",
       "        'valueCount': {'system': 'http://unitsofmeasure.org', 'code': '1'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-Content-NumSubjects',\n",
       "        'valueCount': {'system': 'http://unitsofmeasure.org', 'code': '1'}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-Content-NumSubStudies',\n",
       "        'valueCount': {'system': 'http://unitsofmeasure.org', 'code': '1'}}]},\n",
       "     {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-MolecularDataTypes',\n",
       "      'extension': [{'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-MolecularDataTypes-MolecularDataType',\n",
       "        'valueCodeableConcept': {'coding': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-MolecularDataTypes-MolecularDataType',\n",
       "           'code': 'SNP Genotypes (NGS)'}]}},\n",
       "       {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-MolecularDataTypes-MolecularDataType',\n",
       "        'valueCodeableConcept': {'coding': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-MolecularDataTypes-MolecularDataType',\n",
       "           'code': 'SNP/CNV Genotypes (NGS)'}]}}]},\n",
       "     {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-Citers',\n",
       "      'extension': [{'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-Citers-Citer',\n",
       "        'extension': [{'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-Citers-Citer-Title',\n",
       "          'valueString': 'Comprehensive Genomic Characterization of Parathyroid Cancer Identifies Novel Candidate Driver Mutations and Core Pathways'},\n",
       "         {'url': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/StructureDefinition/ResearchStudy-Citers-Citer-Url',\n",
       "          'valueUrl': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372985'}]}]}],\n",
       "    'identifier': [{'type': {'coding': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/DbGaPConcept-DbGaPStudyIdentifier',\n",
       "         'code': 'dbgap_study_id',\n",
       "         'display': 'dbgap_study_id'}]},\n",
       "      'value': 'phs000693.v6.p2'}],\n",
       "    'title': 'University of Washington Center for Mendelian Genomics (UW-CMG)',\n",
       "    'status': 'completed',\n",
       "    'category': [{'coding': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/CodeSystem/ResearchStudy-StudyDesign',\n",
       "        'code': 'Mendelian',\n",
       "        'display': 'Mendelian'}],\n",
       "      'text': 'Mendelian'}],\n",
       "    'focus': [{'coding': [{'system': 'urn:oid:2.16.840.1.113883.6.177',\n",
       "        'code': 'D035583',\n",
       "        'display': 'Rare Diseases'}],\n",
       "      'text': 'Rare Diseases'}],\n",
       "    'condition': [{'coding': [{'system': 'urn:oid:2.16.840.1.113883.6.177',\n",
       "        'code': 'D035583',\n",
       "        'display': 'Rare Diseases'}],\n",
       "      'text': 'Rare Diseases'},\n",
       "     {'coding': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/NamingSystem/MeshEntryTerm',\n",
       "        'code': 'D035583 entry term: Disease, Orphan',\n",
       "        'display': 'Disease, Orphan'}],\n",
       "      'text': 'Disease, Orphan'},\n",
       "     {'coding': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/NamingSystem/MeshEntryTerm',\n",
       "        'code': 'D035583 entry term: Disease, Rare',\n",
       "        'display': 'Disease, Rare'}],\n",
       "      'text': 'Disease, Rare'},\n",
       "     {'coding': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/NamingSystem/MeshEntryTerm',\n",
       "        'code': 'D035583 entry term: Orphan Disease',\n",
       "        'display': 'Orphan Disease'}],\n",
       "      'text': 'Orphan Disease'},\n",
       "     {'coding': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/NamingSystem/MeshEntryTerm',\n",
       "        'code': 'D035583 entry term: Orphan Diseases',\n",
       "        'display': 'Orphan Diseases'}],\n",
       "      'text': 'Orphan Diseases'},\n",
       "     {'coding': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/NamingSystem/MeshEntryTerm',\n",
       "        'code': 'D035583 entry term: Rare Diseases',\n",
       "        'display': 'Rare Diseases'}],\n",
       "      'text': 'Rare Diseases'},\n",
       "     {'coding': [{'system': 'https://uts.nlm.nih.gov/metathesaurus.html',\n",
       "        'code': 'C0678236',\n",
       "        'display': 'Rare Diseases'}],\n",
       "      'text': 'Rare Diseases'}],\n",
       "    'keyword': [{'coding': [{'system': 'urn:oid:2.16.840.1.113883.6.177',\n",
       "        'code': 'D035583',\n",
       "        'display': 'Rare Diseases'}],\n",
       "      'text': 'Rare Diseases'},\n",
       "     {'coding': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/NamingSystem/MeshEntryTerm',\n",
       "        'code': 'D035583 entry term: Disease, Orphan',\n",
       "        'display': 'Disease, Orphan'}],\n",
       "      'text': 'Disease, Orphan'},\n",
       "     {'coding': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/NamingSystem/MeshEntryTerm',\n",
       "        'code': 'D035583 entry term: Disease, Rare',\n",
       "        'display': 'Disease, Rare'}],\n",
       "      'text': 'Disease, Rare'},\n",
       "     {'coding': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/NamingSystem/MeshEntryTerm',\n",
       "        'code': 'D035583 entry term: Orphan Disease',\n",
       "        'display': 'Orphan Disease'}],\n",
       "      'text': 'Orphan Disease'},\n",
       "     {'coding': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/NamingSystem/MeshEntryTerm',\n",
       "        'code': 'D035583 entry term: Orphan Diseases',\n",
       "        'display': 'Orphan Diseases'}],\n",
       "      'text': 'Orphan Diseases'},\n",
       "     {'coding': [{'system': 'https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/NamingSystem/MeshEntryTerm',\n",
       "        'code': 'D035583 entry term: Rare Diseases',\n",
       "        'display': 'Rare Diseases'}],\n",
       "      'text': 'Rare Diseases'},\n",
       "     {'coding': [{'system': 'https://uts.nlm.nih.gov/metathesaurus.html',\n",
       "        'code': 'C0678236',\n",
       "        'display': 'Rare Diseases'}],\n",
       "      'text': 'Rare Diseases'}],\n",
       "    'description': '\\nThe Centers for Mendelian Genomics project uses next-generation sequencing and computational approaches to discover the genes and variants that underlie Mendelian conditions. By discovering genes that cause Mendelian conditions, we will expand our understanding of their biology to facilitate diagnosis and new treatments.\\n',\n",
       "    'enrollment': [{'reference': 'Group/phs000693.v6.p2-all-subjects'}],\n",
       "    'sponsor': {'reference': 'Organization/NHGRI',\n",
       "     'type': 'Organization',\n",
       "     'display': 'National Human Genome Research Institute'}},\n",
       "   'search': {'mode': 'match'}}]}"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "fhir_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Scratch"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Description clean-up from Dave\n",
    "function getStudyDescription(resource: ResearchStudy): string {\n",
    "  if (resource) {\n",
    "    const rawDescription = resource.description;\n",
    "    if (rawDescription) {\n",
    "      /* Replace any `\\n\\n\\t` with space to avoid unwanted line breaks\n",
    "      /* Replace any `\\t` (tab) with a space - avoids markdown processing tab as <pre/>. */\n",
    "      /* Replace any dbGap internal links with an external link to the dbGap study. */\n",
    "      const parsedDescription = rawDescription\n",
    "        .replace(/\\n\\n\\t/g, \" \")\n",
    "        .replace(/\\t/g, \" \")\n",
    "        .replace(\n",
    "          /study.cgi\\?study_id=|.\\/study.cgi\\?study_id=/g,\n",
    "          \"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=\"\n",
    "        );\n",
    "      return markdownToHTML(parsedDescription);\n",
    "    }\n",
    "  }\n",
    "  return \"\";\n",
    "}"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.11"
  },
  "toc": {
   "base_numbering": 1,
   "nav_menu": {},
   "number_sections": true,
   "sideBar": true,
   "skip_h1_title": false,
   "title_cell": "Table of Contents",
   "title_sidebar": "Contents",
   "toc_cell": false,
   "toc_position": {},
   "toc_section_display": true,
   "toc_window_display": false
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
